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Abstract 
 
 The effect of environmental factors in cellular processes has been an area of 
interest for decades. Within this research field, emerging research niches appear 
concominantly with advances in molecular biology and genetics. One such field is the 
one of molecular toxicology, which investigates the molecular and cellular events that 
certain chemicals trigger. Chemicals that present genotoxic properties are of particular 
interest based on the potential contribution to the aetiology of cancer that the 
discoveries of their effects might provide. A group of chemicals that belong to this 
category are heterocyclic amines, organic compounds that are formed during the 
cooking of red meat from the pyrolysis of aminoacids. Research into heterocyclic 
amines has created a well established description for their ability to create DNA 
adducts that lead to mutations. Recent reports from our laboratory however, indicated 
that certain heterocyclic amines, and in particular 2-amino-1-methyl-6-phenylimidazo 
[4,5-b] pyridine (PhIP), present with molecular effects that are non genotoxic but 
nevertheless carcinogenic and are very similar to those induce by the natural hormone 
estradiol in breast cancer cells. Based on these findings this thesis set out to 
investigate whether these non-genotoxic effects of PhIP also extend to   epigenetic 
mechanisms of gene expression control, and more specifically microRNA expression 
regulation. MicroRNAs are a class of small non-coding RNA molecules that post-
trasncriptionally regulate gene expression and are involved in an array of process 
including carcinogenesis. Our results showed that PhIP, as well as estradiol, drive 
differential regulation of microRNAs and that these effects are very similar amongst 
the two compounds. This deregulation of microRNAs could be an attributing factor to 
the cancer promoting characteristics of both estradiol and PhIP and they extend the 
estrogenic character of this heterocyclic amine to the area of epigenetic regulation, 
and microRNAs in particular.   
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CHAPTER 1: General Introduction 
 
 It has long been established that cancer is heavily affected by environmental 
influences and it is nowadays common knowledge that factors such as smoking, 
pollution and dietary concerns constitute major factors in the formation of neoplasias 
(Casey et al., 2015). The mode of action of cancer causing agents can be categorized 
in two major groups: one that entails the direct effects of these factors on the genetic 
information, by altering the sequence of genetic material giving rise to mutations 
(termed genotoxicity); and another that includes alterations that do not change the  
sequence of DNA, but do nevertheless contribute to the formation and progression of 
cancerous behaviour in cells and tissues (epigenetic effects). The importance of both 
categories of cancer-causing agents is equally significant, however the former had 
overshadowed the latter for a long period. With cancer being such a multifactorial 
disease, the early emphasis of cancer research was heavily directed towards the 
genetic backdrop of cancer. Early on it was  thought that certain inherited genes are 
the major factors for the occurrence of cancer. However, as research in the field grew, 
it became evident that it is not only the hereditary process that is important, but rather 
that environmental factors can both affect genetic information  as well as play a major 
role in cancer aetiology irrespective of their gene changing properties.  
 
 These epigenetic effects of environmental factors have been extensively 
studied in the past few decades and a wide variety of mechanisms have been 
described (Aguilera et al., 2010). Epigenetics describe processes and mechanisms that 
alter the expression of genes and ultimately affect the levels of protein being 
produced, not only in the context of cancer formation but also for organic needs such 
as development, immune response and differentiation among others. Epigenetic 
activities range from actions such as transcription factors driving gene expression to 
methylation and ubiquitination of messenger RNA in order to fine-tune the expression 
of genetic information. One of the latest biomolecules that has entered the realm of 
epigenetics is microRNA, a class of small-non coding ribonucleic acids, that has been 
found to be crucial in altering gene expression by modulating translation of messenger 
RNA into protein (Jing et al., 2005). This thesis investigates the impact of an 
environmental dietary factor, a heterocyclic amine known as 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP), on its ability to alter microRNA expression and 
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whether this impact has  similarity to that established at the molecular/signalling level 
between PhIP and the well-known hormone and major breast cancer factor, 17-! 
estradiol. 
 
1.1! Epigenetics: Mechanisms and involvement in cancer 
 
1.1.1 Mechanisms of epigenetic control of gene expression 
 
 Epigenetics is focussed on  the molecular processes that affect the level of 
protein being produced from  genetic information, without altering the genetic 
information itself. Epigenetic mechanisms are utilized in various physiological 
processes such as development, the immune response, homeostasis regulation and cell 
differentiation among others. The main epigenetic mechanisms are DNA methylation, 
chromatin remodelling through histone modulation, RNA transcripts and non-coding 
RNAs.  
 The most widely studied epigenetic modification is  methylation of DNA, 
specifically at the 5-position of cytosine, most commonly within CpG dinucleotides, 
by the enzymatic addition of a methyl (CH3) moiety from S-adenosylmethionine. The 
frequency of the CpG dinucleotide in human DNA is approximately 2–5%. CpG 
dinucleotides occur in clusters of either large repetitive sequences or in short CG-rich 
DNA stretches, known as ‘CpG islands', found preferentially in the promoter region 
of genes. Methylation of cytosine residues within CpG islands is associated with 
methyl-binding domain proteins, recruitment of histone deacetylases (HDACs) and 
histone methyltransferases, histone modification, chromatin condensation and 
remodelling, and transcriptional inactivation of the genes that are found downstream 
of these methylated CpG islands. The orchestration of methylation in CpG islands by 
an assortment of methylating and demethylating enzymes is thought to provide one of 
the layers of epigenetic control of germ-line and tissue-specific gene expression. 
 Histones, the protein backbone of chromatin, are also important in epigenetics. 
Histones can be modified by acetylation, methylation, phosphorylation, sumoylation, 
and ubiquitination, all of which fine-tune the accessibility of DNA to transcription 
factors and the subsequent protein interactions that also determine chromatin structure 
at the interaction sites. Particular histone tail modifications have been directly linked 
Chapter 1 General Introduction    
!
!
"'
to active or repressed transcription. For example, acetylation of certain N-terminal 
lysine residues by histone acetyltransferases is associated with actively transcribed 
regions. An example would be the acetylation of the H3K9 histone protein that results 
in chromatin positioning (Strasák et al., 2009). The reverse process of histone 
deacetylation, catalysed by histone deacetylases, results in a tighter, closed formation 
of chromatin structure and suppression of DNA transcription.  
 
 In addition to the structural changes of chromatin through histone 
modifications and DNA methylation, RNA biomolecules are also recognised as 
having an epigenetic mechanism that is utilised for gene expression regulation. RNA 
is an integral component of chromatin (Rodriguez-Campos and Azorin, 2007) and  
many  proteins (including transcription factors) have the capacity to bind RNA or 
complexes containing RNA (Mattick, 2001; Cassiday et al., 2002). Furthermore, it has 
been shown that promoter associated and nascent RNAs can regulate transcription by 
directly recruiting regulatory and effector proteins (Morris, 2008). Also  signal-
induced non-coding RNAs can act as selective ligands to modulate histone 
acetyltransferase activity at specific genomic positions (Wang et al., 2008). Histone 
methylation can also be altered by RNA as shown by a study indicating that long 
antisense RNA can act to affect histone methylation, thereby silencing gene 
expression (Yu et al., 2008). RNA-directed DNA methylation is also a well-
established process, whereby RNA Polymerase IV transcripts are processed by the 
RNA interference machinery to generate short RNA nucleotides that guide targeted 
DNA methylation activity to the genomic region homologous to the sequence of these 
small RNA molecules (Vaucheret, 2005). Small RNA molecules have also been 
shown to induce promoter methylation, which in turn affects the transcriptional 
activity of the respective gene or genes linked with that promoter (Meins et al., 2005). 
Chromatin structure and regulation have been shown to be affected by RNA 
molecules with numerous instances whereby epigenetic control of gene expression 
was established through changes in chromatin structure by RNA molecules (Mattick 
et al., 2009). 
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Figure 1.1 Overview of the three epigenetic mechanisms that control gene 
expression. DNA modifications involve the addition of methyl groups (Me in yellow 
ciricle in picture) to cytosine nucleotides in DNA, whilst histone modifications alter 
chromatin structure and might involve methylation, acetylation (Ac in orange triangle 
in picture) or phosphorylation (P in green hexagon in picture) and small RNA 
molecules interact with mRNA to post-transcriptionally regulate gene expression. 
Adopted from Stilling et al. (2014).  
 
  
 More recently, a specific class of RNA molecules has been under investigation 
as epigenetic regulators, the microRNAs. The regulatory activity of these 
biomolecules, which are found in abundance in mammals and other less evolutionary 
complex organisms, has been extensively studied in the last decade. Their biogenesis, 
mechanism and involvement in cancer will be subsequently examined, since they 
constitute the main focus of this study. 
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1.1.2 Involvement of DNA methylation and chromatin structure in tumorigenesis 
 
 Over the last decade there has been an explosion of genetic information 
underlying  human disorders and diseases with cancer being one of the most complex 
(Latham et al., 2012). The number of patients affected by diseases such as diabetes, 
asthma, obesity and neoplasias has increased at rates that cannot be explained simply 
by changes in the genetic make up of the population. Therefore, a likely cause of the 
observed increase is the exposure to environmental factors, which have rapidly 
changed in the past several decades with the progression of industrialised societies 
and lifestyles.  
 
 Epigenetic changes can arise at any time during the life of the individual, 
exerting effects on health through immediate effects on development and function, or 
through a prolonged accumulation of changes that collectively modify individual 
phenotypes. Interestingly, epigenetic changes may be retained during gametogenesis 
and might be transmissible to a certain degree to the next generation (Daxinger and 
Whitelaw, 2012), creating a potential for familial inheritance that is not strictly 
genetic.  
 
 With the onset of bisulphite modification of DNA, which led to the ability to 
detect individual CpG islands for the presence or absence of methylation, it became 
apparent that a characteristic of cancer was a global overall loss of DNA methylation 
(Chuang and Jones, 2007). Concordant with hypomethylation events, gene-specific 
DNA hypermethylation has been shown to occur in all cancers (Esteller et al., 2001), 
with tumour suppressor genes inactivated by hypermethylation events as effectively 
as by mutations (Garinis et al., 2002). Early studies pointed to an overall decrease in 
the methylated 5-methylcytosine (5mC) content of cancer genomes (Feinberg and 
Tycko, 2004; Riggs and Jones, 1983). What is often overlooked is that the presence of 
5mC in genes such as p53 is responsible for generating inactivating C-to-T transition 
mutations that can lead to loss or gain of function (Rideout et al., 1990). It has been 
reported that many well established tumour suppressor genes, such as BRCA1/2, RB 
and PTEN have been found to be hypermethylated or mutated/deleted in many 
cancers (Hatziapostolou and Iliopoulos, 2011). The epigenetic silencing of the well-
known p16ink4A tumor suppressor is one of the most common, and earliest, 
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epigenetically mediated losses of tumor suppressor function events in human cancer 
(Jones and Baylin, 2007). This silencing begins in subsets of preinvasive stages of 
lung, breast, colon and other cancers (Belinsky et al., 1998; McDermott et al., 2006; 
Reynolds et al., 2006). Recent studies of knockout mice have revealed that germline 
loss of this gene increases stem cell life span (Janzen et al., 2006; Krishnamurthy et 
al., 2006; Molofsky et al., 2006), consistent with a proposed role in tumorigenesis for 
facilitating early abnormal clonal expansion of cells at risk for cancer.  
 
 There are also several genes that are rarely found mutated as far as their 
sequence is concerned, but are nevertheless silenced in cancer, mainly due to the 
hypermethylation of their promoter regions. Genes such as the DNA repair gene 
MGMT, cyclin-dependent kinase inhibitor 2B (CDKN2B) encoding the p15 cell cycle 
regulator and RASSF1A, which encodes a protein that binds and inhibits the RAS 
oncogenes are all genes falling into this category (Baylin and Jones, 2011). 
Furthermore, other genes that have CpG islands in their promoter region have been 
shown to also be subject to aberrant hypermethylation including tumor suppressor 
genes or oncogenes whose protein products are involved in the cell cycle, DNA 
repair, apoptosis, cell adhesion, and angiogenesis, with all these processes being 
involved in tumor formation or progression (Lopez J. et al., 2009).  
 
 Based on the above it can be concluded that  genetic mutations on these 
epigenetic modifiers would lead to profound epigenetic changes, which affect gene 
expression and genome stability, thereby increasing predisposition to cancer. 
Experimental proof for the latter include the mutations of DNA methyltransferase 1 
(DNMT1) in colorectal cancer (Kanai et al., 2003) and the frequent mutation of DNA 
methyltransferase 3A (DNMT3A) in myelodysplastic syndrome (MDS) and in acute 
myeloid leukaemia (AML) (Yan et al., 2011). Single nucleotide polymorphisms of the 
DNMT3A gene have been suggested to be associated with risk of several cancers, 
such as breast and lung adenocarcinoma (Shen et al., 2002). In addition, DNMT1, 
DNMT3A and DNMT3B are often overexpressed in various cancers which could 
potentially be a contributing factor to the characteristic hypermethylation genomic 
profiles of most cancers (Wu et al., 2007).  
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 Similarly, the perturbation of chromatin structure has been shown to lead to 
tumorigenic events. It has been known for some time that Lamin A, one of the central 
proteins of chromatin scaffolding and modification, is not present in some 
haematological malignancies (Stadelmann et al., 1990), while more recently it has 
also been found that the same protein is not expressed in leukaemia and lymphoma 
cells (Agrelo et al., 2005). Moreover, risk of recurrent colon cancer has been found to 
be associated with loss of the Lamin A gene (Belt et al., 2011).  
 
 Histones constitute the majority of the DNA folding machinery in chromatin 
organization. Their biochemical modifications have been long known and now their 
implications in chromatin structure and the formation and progression of cancer are 
becoming increasingly evident. One of the most characteristic indications of their 
involvement is the global changes in  modification that histones undergo during 
tumorigenesis (Conerly et al., 2010). For example, histone deacetylation and 
methylation of specific lysine residues such as lysine 9 in histone H3 or lysine 27 in 
histone H3 clearly participate in the silencing of genes (Jenuwein, 2006).  
 
 Another example of how DNA structure might be involved in cancer 
formation is that of the DNA methylation binding protein (MBD2), which interacts 
with the nucleosomal remodeling complex (NuRD) and directs the complex to 
methylate DNA (Zhang et al., 1999). More recently the role of Brahma (Brm), which 
is a catalytic component of the SWI/SNF chromatin-remodeling complex, in its 
association with the methylated DNA binding protein MeCP2, further substantiated 
the link between methylated DNA binding proteins and chromatin restructuring 
(Harikrishnan et al. 2005). These experiments provided a potential link between DNA 
methylation and chromatin silencing. Covalent modifications of histones couple these 
processes with chromatin remodeling by ATP-dependent remodeling machines (Li et 
al., 2007; Wysocka et al., 2006). This has led to the realization that the three processes 
of DNA cytosine methylation, histone modification, and nucleosomal remodeling are 
intimately linked and that alterations in these processes result in the permanent 
silencing of cancer-relevant genes (Baxter et al., 2014). Mutations in the SNF5 gene 
stimulate cell-cycle progression and cooperate with p53 loss in oncogenic 
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transformation, and they are also associated with inactivation of the p21 and p16 
pathways (Chai et al., 2005; Roberts and Orkin, 2004). A significant part of the 
involvement of histones in cancer is linked with perturbations in the levels of histone 
modifying enzymes, namely histone methyltransferases (HMTs) and demethylases 
(HDMs) as well as histone acetyltransferases (HATs) and deacetylases (HDACs). 
Mutations or translocations of certain HAT genes are observed in colon, uterine, lung 
tumors and leukaemias (Esteller, 2007) and further, they are commonly involved in 
chromosomal translocations in hematological cancers.  
 
 Other evidence for global changes being involved in carcinogenesis come 
from studies in the polycomb group gene family, which is highly conserved 
throughout evolution (Valk-Lingbeek et al., 2004). The polycomb repressor complex 
2 (PRC2) is involved in the initiation of silencing and contains histone 
methyltransferases that can methylate histone H3 lysine 9 and 27, which are marks of 
silenced chromatin. It is well known that certain transcription factors such as c-Myc 
do not bind to their recognition sequences in the methylated condition, suggesting that 
CpG methylation may affect the ability of Myc to bind to multiple sites within the 
genome. Given that Myc can influence chromatin structure (Knoepfler et al., 2006), it 
is certainly plausible that inappropriate methylation of its recognition sites could have 
profound implications on the cancer epigenome. Perhaps more attention should be 
paid in the future to methylation of such genomic regions, in order to examine how 
methylation of binding/recognition sites affects the physiological occurrence of the 
interaction of transcritpion factors to their respective recognition sites.  
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1.2 Diet as a regulatory factor of epigenetic mechanisms 
 The link between diet and epigenetics is substantiated by experimental 
evidence. Processes as early as periconceptual and fetal development involve 
epigenetic aspects, in conjuction with dietary exposure and the interplay between the 
two. As epigenetic regulation during development undergoes dynamic changes, it 
responds to environmental stressors, including nutritional modification.  
 
 With regards to DNA methylation, dietary and nutritional components can 
influence epigenetic mechanism;  they are the changing of the availability of methyl 
donors and the alteration of the activity of enzymes that are involved in the process of 
DNA methylation, more specifically DNA methyl transferases (DNMTs). 
Supplementation or restriction of the maternal diet with a range of dietary factors, 
 Figure 1.2 Selection of genes involved in epigenetics disrupted in human tumors. 
Histone modification enzymes that might remove (histone deacetylases (HDACs), 
histone demethylases (HDMs)) or add tags to histone proteins (histone 
acetyltransferases (HATs) and histone methyltransferases (HMTs)), or enzymes 
involved in the methylation of DNA (DNA methyltransferases (DNMTs) or binding of 
methylated DNA regions with other proteins (Methyl-CpG binding proteins (MBDs)) 
have all been found deregulated in various types of cancers. Ac, acetylation; Me, 
methylation. Adopted from Rogriguez-Paredes & Esteller (2014). 
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such as folate, methionine, or choline, has been shown to affect the establishment of 
DNA methylation patterns in offspring (Sinclair et al. 2007). The production of S-
adenosylmethionine (SAM), which is the main methyl donor for the addition of 
methyl to CpG DNA sites, is heavily linked with cellular one-carbon metabolism, 
hence any dietary factors influencing that process, such as folate, choline, methionine 
and vitamins B6 and B12, may affect DNA methylation (Johnson & Belshaw, 2008). 
The S-adenosylmethionine process can also be affected indirectly, which in turn 
affects DNA methylation. Examples include dietary selenium in a rat study that was 
shown to reduce the availabiity of methionine thus affecting levels of S-
adenosylmethionine and affecting DNA methylation (Davis & Uthus, 2003) and 
dietary zinc intake, which has an impact on the metalloenzymes that are part of one-
carbon metabolism, responsible for SAM production (Hall & Gamble 2012).     
 
 DNA methylation can also be affected through dietary factors resulting in the 
alteration of the activities of DNA methyltransferases (DNMTs). Interestingly, many 
of the same dietary biomolecules influencing methyl availability, also  affect DNMT 
enzyme activity, such as selenium, genistein and choline containing polyphenols 
(McKay & Mathers, 2011). For example, DNMT1 function is inhibited by selenite 
when selenite binds to the AP1 transcription factor, which prevents the binding of AP-
1 to DNA and in turn the interaction of DNMT1 with DNA-AP1 complexes, which 
could lead to reduced DNA methylation (Handel et al., 1995, Spyrou et al., 1995).  
 
 Dietary factors can also alter the post-translational modification of histones, 
which are essential to chromatin structure. In turn, histone tails present a more 
dynamic instance for the provision of the donors required for the modification, as 
histones can be acetylated, phosphorylated, ribosylated, ubiquinated, sumolated and 
biotinilated on top of being able to be methylated. As a result, there are numerous 
opportunites for vairous dietary factors to influence these histone marks. Similarly 
with the case in DNA methylation, dietary factors can alter histone modifications by 
either altering the efficacy or abundance of the enzymes responsible for the 
modification or by altering the availability of the biomolecules that are necessary in 
order for the modification to be completed. An example is the case of butyrate and 
dietary polyphenols that have been shown to be histone deacetylase (HDAC) 
inhibitors (Link et al., 2010).  
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Figure 1.3 Dietary factors affecting epigenetic processes such as DNA methylation 
and histone modification. Dietary compounds such as catechol-containing epicatechin 
and catechin as well as genistein and resveratrol both provide the biomolecules 
through which molecular tags such S-adenosylmethionine are produced as well as 
affect the activities of DNA methyltransferases (DNMT), histone deacetylases 
(HDAC), histone acetylases (HAT) and histone methyltransferases (HMT).  
 
1.3 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) as a 
dietary carcinogenic factor  
 
1.3.1 PhIP as a mutagen and carcinogen 
 
 PhIP belongs to the class of heterocyclic amines that are created during the 
cooking of meat from the pyrolysis of aminoacids (Wakabayashi et al., 1993). PhIP is 
the most abundant  of these heterocyclic amines (Felton et al., 1986). The interest in 
these compounds came from research indicating that smoke condensates were highly 
mutagenic in the Salmonella Ames test system (Nagao et al., 1977), out of which 
numerous heterocyclic amines were purified and identified. Their importance lies in 
the fact that the exposure levels to these compounds averages from 0 to 20 
micrograms daily (Adamson et al., 1996) although latter studies indicated that these 
levels can vary up to ten-fold between different populations (Skog et al., 2002). 
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Furthermore, PhIP has been detected in a variety of cooked meat and fish products 
(Felton et al., 1986; Zhang et al., 1988; Murray et al., 1993) as well as in cigarette 
smoke condesate (Manabe et al. 1991). It can therefore be said that there are 
numerous sources of PhIP to which humans can be exposed. More importantly 
however, it has been shown that PhIP is readily absorbed and metabolised by humans 
(Lynch et al., 1992, Turesky et al., 1994).  
 
 The carcinogenic character of PhIP can be branched into two broad categories: 
genotoxic and non-genotoxic. The genotoxic character of PhIP’s carcinogenicity 
stems from it mutagenic properties. PhIP is primarily metabolised by the CYP1A2 
enzyme into its N-hydroxy derivative (Zhao et al., 1994). This metabolite is then 
esterified to a nitrenium ion that is reactive forming adducts with guanine bases of 
DNA (Rindgen et al., 1995 and Zhao et al., 1994). Those DNA adducts can 
subsequently lead to mutation if not appropriately processed by the DNA repair 
mechanism of the cell. This property of PhIP was demonstrated through numerous 
studies in both bacterial and mammalian systems, where PhIP was shown to be  DNA 
damaging (Felton et al., 1991, Boobis et al., 1996 and Yadollahi-Farsani et al, 1996) 
and mutagenic (Boyce et al., 2004). Importantly, whilst there are other ways that PhIP 
can be metabolized in humans, the N-hydroxylation pathway has been shown to be  
predominant in vivo in contrast to experimental animals such as the rat where N-
hydroxylation is less pronounced (Boobis et al., 1994, Malfatti et al., 1999, Kulp et 
al., 2000). An important finding in the context of this study is that PhIP exhibit 
mammary gland carcinogenicity (Synderwine, 1994). It is therefore important to 
further characterize the carcinogenicity of PhIP in the context of mammary neoplasia.  
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Figure 1.4 The metabolism of PhIP. The main enzymatic processing of PhIP involve 
metabolism by the CYP 1A enzyme to N-hydroxy-PhIP, which is then esterified to 
hightly electrphilis esters that cause DNA adducts. N-hydroxy-PhIP is also detoxified 
via conjugation with glucuronides. PhIP is also metabolised by CYP1B1 to 4'-
hydroxy-PhIP, which can undergo sulphation and glucuronidation.  CYP – 
Cytochrome P450, ST – Sulphotransferase, UGT – Glucuronyl transferase, NAT – N-
acetyltransferase. 
 
 Mechanistic investigations of PhIP mutagenicity in mammalian systems 
revealed a specific “mutational fingerprint” of this compound. Studies on the genetic 
toxicology of PhIP in vitro, showed that most mutations are single base substitutions 
at GC pairs (Yadollahi-Farzani et al., 1996) with the most frequent mutation variants 
being GC"TA transversions, although GC"AT transversions and GC"CG 
transversions were also reported. In addition, another feature of the genotoxic toxicity 
of PhIP is the -1 G frameshit that takes up a high percentage of PhIP genotoxic 
events. Significantly, the same charactersitc mutations have been found in PhIP-
induced colonic tumours with more than 60% of tumours expressing  -1 G frameshift 
mutation with the same characterstics (Kakiuchi et al., 1995).  Studies in rats diplayed 
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a  mutation spectrum in the mammary gland that was similar to the mutations that 
were described in vitro (Okochi et al., 1999). More specifically, an association 
between PhIP-induced mammary gland cancer initiation and the activation of the H-
ras oncogene through point mutations at guanine nucleotides with GC"AT 
transversions was drawn (Roberts-Thomson and Snyderwine, 1997; Hokaiwado et al., 
2001).  
 
 In addition to the in vitro research describing the genetic toxicology of PhIP, 
animal studies conducted further substantiate the carcinogenic character of PhIP. 
Unlike other heterocyclic amines that predominantly target the liver, PhIP has been 
shown to induce tumours of the colon, mammary glands, prostate as well as 
lymphomas in rodent bioassays (Sugimura, 2000). More specifically, a 400 parts per 
million (p.p.m.) treatment for 52 weeks in rats was shown to induce colonic 
adenocarcinomas and prostate tumours in more than half of the animals tested (Ito et 
al., 1991, Shirai et al., 1999). A 104-week administration of a 100 p.p.m dose of PhIP 
resulted in mammary adenocarcinomas in 47% of female rats compared to 0% of the 
control (Hasegawa et al., 1993) and a dose-dependent increase in tumour incidence 
and multiplicity through the administration of PhIP in Sprague Dawley rats for 48 
weeks (Imaida et al., 1996). PhIP has also been shown to induce lymphomas in CDF1 
mice (400 p.p.m dose included in the diet) (Esumi et al., 1989).   
 
1.3.2 PhIP’s non-genotoxic estrogenic character  
 
 One of the considerations that the investigations examining the potential of 
PhIP’s involvement in molecular non-genotoxic and potential carcinogenic processes, 
was the common structural features that it shares with 17-! estradiol (Lauber et al 
2004; Lauber and Gooderham 2007), the female sex hormone that has been involved 
in the aetiology of various types of cancer, such as colon, prostate and predominantly 
breast (Henderson and Feigelson, 2000; Dickson and Stancel, 2000). The 
physiological role of estrogen has been widely studied and the pathway that regulates 
the activity of this hormone is well described.  
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Figure 1.5 The molecular structures of 17-! estradiol and 2-amino-1-methyl-6-
phenylimidazo[4,5-b] pyridine (PhIP) 
 
 Most of the hormone’s activity is enacted through its interaction with the 
estrogen receptor, of which there are two isoforms ER# and ER!, that belong to the 
steroid/thyroid superfamily of nuclear receptors (Katzenellenbogen, 1996). The 
binding of the ligand results in the allowance of the homo- or hetero-dimerization of 
the receptor protein, which is then translocated to the nucleus where it interacts with 
target gene promoters and acts as a platform for various co-factors to that either 
activate or inhibit the expression of target genes dependgng on tossue distribution of 
these co-factors (Ratajczak, 2001). The receptor can either directly bind DNA through 
its DNA binding domain, which has a high degree of similarity in the two subtypes 
(Mosselman et al., 1996), to specific estrogen responsive elements (EREs), usually 
located within the 5’ promoter region of target genes. The consensus ERE sequence is 
GGTCAnnnGTACC (with n being any nucleotide), although it has been long known 
that there are numerous variations in functional EREs on one or more bases (Kumar 
and Chambon, 1988). The bound receptor can however also exert signalling events 
and influence transcription without binding to DNA. A liganded ER# can interact 
with the activation protein-1 transcription factor (AP-1) as well as the specificity 
protein-1 (SP-1) and NF-$B transcription factors to regulate transcription of genes. 
(Galien and Garcia, 1997). Another activity of the liganded receptor that does not 
involve direct DNA binding is the interaction with the fos/jun trasnscription factor in 
AP-1, with ER#! 17beta-estradiol activated transcription, whereas with ERbeta, 
17beta-estradiol inhibited transcription (Paech et al., 1997).  
 
 The role of ER also extends to non-steroid mediated regulation of transcription 
through its phosphorylation that allows ligand-independent transcriptional activation 
(Kato et al., 2000). Kinases! involved in several functions associated with the 
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hallmarks of cancer have been shown to phosphorylate the receptor, including 
mitogen activated protein kinase (MAPK) (Kato et al., 1995), cyclin dependent kinase 
2 and 7 (Rogatsky et al., 1999 and Chen et al., 2000), phosphatidylinositol-3 kinase 
(Sun et al., 2001), integrin-linked kinase (Acconcia et al., 2006), c-SRC tyrosine 
kinase (Castoria et al. 2012) as well as the tyrosine kinase receptors epidermal growth 
factor receptor (EGFR) (Marquez et al. 2001) and insulin-like growth factor receptor 
(IGFR) (Mendez et al., 2003). More importantly, all these associations lead to 
activation of target gene transcription, thereby highlighting the importance of ER in 
the context of cancer.  
 
 Initial investigations of the effects that PhIP elicited at non-genotoxic levels 
indicated that PhIP presents estrogen-like characteristics on treatment levels similar to 
human exposure. A transient gene expression assay linking ER# activation with 
ligand binding indicated that PhIP has the ability to drive ERE mediated expression in 
levels similar to the ones recorded with a 17-! estradiol treatment, also attenuated by 
an ER# antagonist (Gooderham et al. 2002). This pointed towards a potential 
interaction of PhIP with ER# and allowed for further investigation of the extent to 
which exposure to PhIP at the nanomolar level, that is, close to physiological levels, 
resembles the effects that have been recorded with 17-! estradiol. The importance of 
such investigations lie on the fact that PhIP’s carcinogenicity could also be attributed 
to non-genotoxic events, such as those that have been studied for 17-! estradiol. This 
is on top of the already known mutational properties of the compound, especially 
when these events happen at levels to which humans are exposed to regularly, based 
on their diet. Further research into the effects of PhIP on the molecular rather than 
genotoxic levels showed that PhIP-induced cell proliferation of the MCF-7 breast 
epithelial cell line was inhibited by the addition of the ER# receptor inhibitor ICI182 
780 (Lauber et al., 2004). Additionally, PhIP was also shown to act in the same way 
as 17-! estadiol in increasing the levels of progesterone receptor A and B in the T47D 
breast cancer cell line, which is known to induce progesterone receptor upregulation 
following an E2 stimulation (Liberato et al., 1993), again the PhIP-induced increase 
was attenuated by the addition of the estrogen receptor inhibitor ICI182 780 (Lauber 
et al., 2004). Further analysis in our lab showed that PhIP was able to induce the 
phosphorylation (activation) of ERK1/2 in  MCF10A cells at very low concentrations 
(10-9 to 10-7 M) (Gooderham et al., 2007). The ERK1/2 proteins are a part of the 
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central MAPK activation pathway, which plays a major role in the regulation of cell 
proliferation (Crews et al., 1992, Alessi et al., 1994). Clearly the ability of PhIP to 
increase the levels of phosphorylated ERK 1 and ERK 2 points towards its ability to  
increase the proliferative potential of the cell and hence the compound’s epigenetic 
characteristics.  
 
 This array of experiments provided an additional level of action that should be 
taken into account when the carcinogenicity of PhIP is concerned. PhIP does not only 
act as a genotoxic carcinogen, it also acts like a hormone directly affecting cellular 
processes.     
 
1.4 MicroRNAs: Biogenenesis, epigenetic mechanism, function and 
involvement in cancer 
 
1.4.1 MicroRNAs: a novel mechanism of gene regulation 
 
 MicroRNAs were initially discovered in C.elegans as the lin-4 gene, known to 
control the timing of C.elegans larval development  however lin-4 coded for a pair of 
small RNAs and not a protein (Lee et al., 1993). These short RNA molecules were  
found to have antisense complimentarity to multiple sites of the 3’ untranslated region 
(UTR) of the lin-14 gene, that was previously identified as repressed by lin-4 
(Wightman et al., 1991). These sites were  crucial for the repression of lin-14 by lin-4 
(Wightman & Ruvkun, 1993) and these studies in the early 90s formed the 
foundations for the discovery of microRNAs; a new class of regulatory tiny RNA 
molecules. The shorter lin-4 RNA is now recognized as the first microRNA 
discovered, however the discovery of the second miRNA in C.elegans, let-7 (Reinhart 
et al., 2000), which was then found to be conserved across many organisms, including 
humans (Pasquinelli et al., 2000), pointed to a more general role in biology for this 
class of regulatory RNAs. These discoveries, along with the description of the RNA 
interference pathway established what is now a whole gene silencing pathway of its 
own. Following the establishment of microRNAs as a mechanism ubiquitous in higher 
organisms, many thousands of miRNAs have been discovered in many organisms and 
there are presently 1881 precursors and 2588 mature miRNAs in the human genome 
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(Kozomara & Griffiths-Jones, 2014). The scale of the fundamental role of miRNAs as 
a critical mechanism for gene expression control is indicated by the the fact that each 
one of the 2588 miRNAs is predicted to regulate the expression of hundreds of target 
genes (Bartel, 2004).  
 
The biogenesis of microRNAs has been well decribed since their discovery. All 
microRNAs undergo a very specific sequence of processes that ultimately result in a 
biomolecule with  gene regulation properties. MicroRNA genes are located 
throughout the genome. Many miRNA genes are noncoding genes whose sole product 
is the miRNA, whilst other miRNA genes are located within introns or 3’ untranslated 
regions of exons in protein coding genes (Rodriguez et al., 2004). All DNA sequences 
from which microRNAs originate are initially transcribed by RNA polymerase II into 
a longer primary miRNA transcript (see fig 1.6). The pri-miRNA is typically spliced, 
capped and polyadenylated in a similar manner to protein coding mRNAs (Cai et al., 
2004). The limited studies on miRNA promoters indicate that they are similar in 
structure to protein coding gene promoters, including control elements and DNA-
protein interactions (Ozsolak et al., 2008). All primary miRNA transcripts feature the 
stem-loop precursor RNA structure, with usually one of the strands of the stem being 
the source of the mature miRNA (Lau et al., 2001). The primary miRNA transcript 
requires two endonuclease steps before it becomes the ~22 nucleotide long mature 
and active miRNA. The first of these steps takes place in the nucleus and is catalysed 
by the nuclear RNAse III Drosha (Lee et al., 2003). In order for Drosha to cleave the 
pri-miRNA molecule, the RNA binding protein DGCR8 is also required (Han et al. 
2004). Drosha cleavage allows the stem-loop miRNA precursor (pre-miRNA) to be 
released from flanking pri-miRNA sequences. The precursor is then exported out of 
the nucleus by the Ran-GTPase dependent Exportin 5 (Yi et al. 2003) to the 
cytoplasm. In the cytoplasm, the pre-miRNA is further processed by the Dicer 
RNAase III, associated with the TRBP RNA binding protein (Chendrimada et al., 
2005), that cleaves the loop region of the precursor, thereby producing the mature 
miRNA molecule (Hutvagner et al. 2001). The product of Dicer’s activity is a double-
stranded RNA molecule, usually 21 nucleotides in length. The miRNA-induced RNA 
Interference Silencing Complex (miRISC) ultimately interacts with one strand of the 
molecule, usually the strand from the 5’ end of the stem-loop, although recent next 
generation sequencing studies have shown that miRISC complexes for certain 
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microRNAs might be produced by loading either of the two strands of the mature 
duplex RNA molecule (Guo et al., 2012). The majority of miRNAs are produced 
through the Drosha/Dicer processing steps, however there are cases, where the 
cleaving of Drosha or Dicer is bypassed. Some intronic sequences close to exon 
juction sites, mimic the structure of pri-miRNA transcripts after being processed by 
the splicing machinery in featuring short intronic hairpins. These molecules, termed 
mitrons, are not processed by Drosha but merge with the normal miRNA-generating 
pathway during hairpin export by Exportin 5 (Okamura et al., 2007). Similarly, Dicer 
independent biogenesis has also been described; after Drosha clevage the hairpin 
precursor  directly binds Ago, and Ago cleaves the one of the two strands as well as 
trims the loop sequence to generate the mature microRNA molecule that is 
incorporated into miRISC (Cifuentes et al. 2010, Cheloufi et al., 2010 & Yang and 
Lai, 2010).  A brief representaion of both pathways is shown in Figure 1.6. 
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Figure 1.6 A schematic representation of microRNA biogenesis and processing. 
MicroRNAs are transcribed from their genomic region and processed like mRNA 
molecules into pri-miRNA transcripts. The pri-miRNA is then cleaved by Drosha to 
produce the pre-miRNA precursor. The precursor is transported to the cytoplasm via 
Exportin 5 function, where it is further cleaved by Dicer, yielding the mature miRNA 
molecule, which subsequently becomes incoroporated into miRISC, though its 
interaction with Ago2. The Drosha-independent pathway involves creation of the pri-
miRNA transcript with a shot hairpin, through the splicing machinery. The transcripti 
is then also exported to the cytoplasm through Exportin 5. Adopted from Hammond, 
2015.     
 
miRISC is the miRNA-binding protein complex that leads to the repression of 
the translation and/or stability of target mRNAs. Although the accurate composition 
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of the complex has not been described yet, it is known that miRISC contains the 
essential protein Argonaute. The Argonaute group of proteins contains four subtypes 
(Ago 1-4) (Hammond et al, 2001). Initially the RNA duplex is loaded into RISC and 
one of the two strands is removed by Argonaute2 (Ago2). Further degradation is 
carried out by the C3PO nucelase complex, when there is complementarity in the 
central region of the double-stranded RNA molecule (Matranga et al. 2005 & Liu et 
al., 2009), or through strand unwinding when there is no central complementarity in 
the double-stranded RNA molecule. In the latter case, a number of helicases, such as 
helicase A, have been associated with this unwinding activity (Meister et al., 2005 & 
Robb et al., 2007). Subsequently, Argonaute, as part of the RISC complex, binds the 
mature miRNA and searches for target mRNA molecules that have complementarity 
with the miRNA. The most important part of the miRNA sequence for the interaction 
with the mRNAs are nucleotides 2-7, which is termed the “seed region” (Lewis et. al, 
2003), although there have been reports where the 3’ area of the miRNA also 
contributes to target recognition and central sequence complemetarity (nucleotides 9-
11) leads to mRNA cleavage via the endonuclease activity of Argonaute2 (Grimson et 
al., 2007, Shin et al., 2010 & Liu et al., 2004).  
 
However, most mRNA targets are not directly cleaved by Ago2 endonuclease 
activity, since that central complementarity is missing. The most common processes 
that take place when a miRNA-loaded miRISC identifies a target mRNA sequence, 
usually in the 3’ untranslated region (UTR) of that mRNA, are either translational 
repression or degradation of the mRNA molecule (Fabian and Sonenberg, 2012). In 
the case of translational repression, the core of miRISC, that is the miRNA loaded 
Argonaute protein and a glycine-tryptophan repeat-containing protein, GW182 
protein, which acts as a molecular platform that binds a multitude of silencing 
effectors, associate with an mRNA molecule based on complementarity with the seed 
region of the miRNA. Following association, the GW182 protein mediates the 
downstream steps of gene silencing through various processes. It has been shown that 
GW182 interaction decreases the association of eukaryotic translation initiation 
factors eIF4E and eIF4G thereby inhibiting cap-dependent initiation of translation 
(Pfaff and Meister, 2013, Zekri et al., 2013). Futhermore, to repress initiation of 
tranlation the miRISC complex has been shown to interfere with ribosome 
recruitment, more specifically by preventing 60s ribosomal subunits from joining 
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miRNA-targeted mRNAs (Wang et al., 2008). These effects have been postulated to 
be mediated by the interaction of GW182 with poly (A) binding protein, which in turn 
affects the interaction between PABP and eIF4G and mRNA circularization (Fabian 
et al., 2009). Other effects of the interaction between GW182 and PABP have been 
proposed, although studies show that the role of PABP in repression is not yet clear 
(Fabian and Sonenberg, 2012). Another critical interaction between GW182 and one 
of its effectors is  with the CCR4-NOT deadenyalse complex, which is not only 
responsible for miRNA-mediated deadenylation, but has recently been shown to be 
necessary for deadenylation-independent translational repression (Cooke et al., 2010 
& Chekulaeva et al., 2011). In the case of miRNA mediated deadenylation and 
subsequent mRNA destabilization the picture is more clear; the Ago-associated 
GW182 protein allows for the recruitment of the CCR4-NOT and PAN2-PAN3 
deadenylase complexes through interations between GW182 and NOT1 and PAN 3 
respectively, that engender deadenylation of the polyA tail of the target mRNA 
(Behm-Ansmant et al., 2006 and Braun et al., 2013). The further destabilization of the 
target mRNA molecule is facilitated by the removal of the 5’ cap, which is catalysed 
by the DCP1/2 decapping enzyme, recruited through their interaction with GW182 
(Rehwinkel et al. 2005). Subsequently, mRNA degradation is effected by the activity 
of Xrn 5’-3’ exonuclease (Nagarajan et al., 2013). Recent studies have also 
highlighted the potential for a temporal order of the mechanisms of action for 
miRNA-mediated repression of translation, with two studies providing evidence that 
repression of translation preceeds deadenylation and mRNA decay and is also 
independent of deadenylation. This evidence supports a model where miRNAs act 
through a two-step mode of repression, whereby they initially inhibit tranlsation in a 
deadenylation-independent manner, followed by deadenylation, decapping and 
destabilization of target mRNA (Djuranovic et al. 2012 and Bazzini et al., 2012). 
Figure 1.7 illustrates the alternative pathways of the action of miRISC.  
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Figure 1.7 The miRISC interaction with a target mRNA molecule. The miRISC gets 
guided towards its target through the interaction of the Ago-bound miRNA with the 
miRNA target site. Following the binding of miRISC to the mRNA molecule, the 40s 
and 60S ribosomal units fail to interact in forming the functional 80S ribosome that 
dives translation. This could be attributed to the dissocation of the eIF4 proteins from 
the mRNA molecule, due to their interaction with GW182 through PABP. The 
GW182 protein is a critical component of the miRISC, since it also recruits the 
CCR4-NOT and PAN2-PAN3 deadenylation complexes that are responsible for the 
removal of the poly(A)-tail. CCR4-NOT has also been shown to be involved in 
translational repression. Following deadenylation, the target mRNA molecule is 
further destablized through the action of the DCP1-DCP2 decapping complex that 
removes the methyl cap and is recruited by GW182 and then by cytoplasmic Xrn1.  
Modified from Fabian and Sononberg, 2012.  
 
1.4.2 Biological roles of microRNAs 
 
 MicroRNAs are now  recognized as a crucial part of the cellular machinery in 
the fine-tuning of gene expression. Their significance in mammalian systems was 
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demonstrated by the generation of knockout mice for Dicer and DGCR8 (an essential 
and miRNA-specific partner of the Drosha RNAase), which result in embryonic 
lethality (Bernstein et al., 2003 and Wang et al., 2007). Similarly, when these two 
genes are knocked out in separate tissues, developmental and functional defects of 
that specific tissue are engendered, underlining the importance of microRNAs in most 
tissues (Park et al., 2010). Most miRNA-specific knockout models result in the 
development of functional tissues and organs (Wienholds et al., 2005); however, the 
proper regulation of function of these organs is perturbed in these knockout models. 
Furthermore, adult mice also show dysfunctioning issues with a conditional Dicer 
knockout, with a recent example being the essential character of Dicer in adult 
midbrain dopaminergic neuron maintenance and survival (Pang et al., 2014). For 
example, the cardiac specific miR-208 knockout leads to defects in stress response 
and cardiac hypertrophy (van Rooij et al., 2007). Such knockout studies, along with 
overexpression studies of miRNAs that account for potential redundancy mechanisms 
and miRNA target network identification studies, have created a wealth of 
information involving miRNAs with a wide array of biological functions. Another 
hint that points towards the importance of microRNAs is the striking evolutionary 
conservation of many microRNAs across species, highlighting their functional 
relevance across many species (Shi et al., 2012). MicroRNAs have been shown to 
play roles in numerous activities of neuronal function, such as dendritic spine 
development (Schratt et al., 2006) and developmental remodelling (Somel et al., 
2011) but also in the function of many blood-related cell lineages such as 
lymphocytes (Vigorito et al., 2007) and megakaryocytes (Lu et al, 2008). Other roles 
include skeletal muscle development (Ma et al., 2015), kidney development and 
function (Hohenstein et al., 2015 & Butterworth, 2015), blood vessel inflammation 
modulation (Cheng et al. 2014) and the innate immune response (Saba et al., 2014). 
Futhermore microRNAs have been found to be involved in bone development and 
regeneration (Fang et al., 2015) and in the regulation of intestinal homeostasis 
(Runtsch et al., 2014). However, the vast majority of the rapidly growing studies on 
miRNA functions are related with pathological conditions such as heart disease 
(Kalozoumi et al., 2014), atherosclerosis (Hosin et al., 2014) and viral infections such 
as hepatitis B (Mizuguchi et al., 2015 & Fiorino et al., 2014) and herpesvirus 
(Frappier, 2015). Nevertheless, based on the premise that microRNAs are potent post-
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trascriptional modulators of gene expression, the largest portion of these studies have 
focussed in the involvement of microRNAs in cancer.  
 
 
1.4.3 MicroRNAs and cancer 
 
 The rapid advancement of sequencing techniques coupled with the increased 
interest in microRNAs in the last decade, have resulted in a plethora of information 
that links almost all types of neoplasias with altered miRNA expression. Initial 
functional studies pointed towards their involvement and currently there are a myriad 
of studies that look into specific cancer types and how these might be affected by or 
can be detected with microRNAs. One of the first studies that used microarray and 
Northern blot analysis, and showed approximately a quarter of the miRNAs studied 
were deregulatd in at least one cancer type (Volinia et al., 2006). Initially, disagreeing 
results indicated that there could be either an overall downregulation of miRNAs or 
an upregulation. With more research being conducted in this field, the narrative was 
soon disentagled, when it was discerned that certain microRNAs act as oncogenes and 
are upregulated in cancer, obtaining the term oncomiRs, while some act a tumor 
suppressor genes and are downregulated in cancer, coined tumor suppressor miRNAs. 
Following that distinction, numerous studies have probed different tumor types for 
aberrant microRNA expression patterns, yielding results that have established 
microRNA dysregulation as one of the hallmarks of neoplasia. Most such studies are 
genetic screens that compare expression patterns between normal and tumorous 
tissue, with initial disoveries made in chronic lymphocytic leukaemia (Calin et al., 
2002), colon cancer (Michael et al., 2003), lung cancer (Takamizawa et al., 2004) and 
breast cancer (Iorio et al., 2005). Subsequently, mechanistic approaches  investigated  
critical events in cancer progression such as cell cycle progression and proliferation, 
apoptosis, signalling and metabolism. Some microRNAs have been found 
dysregulated in many different types of tumors and focus has been directed to them 
for purposes of cancer diagnosis as well as cancer treatment.  
  
 As far as the oncogenic microRNA (oncomiRs) are concerned, the 
polycystronic miR-17-92 cluster has been frequently reported to be  upregulated in 
numerous cancers. Increased levels of miR-17-92 have been found in a variety of 
Chapter 1 General Introduction    
!
!
$*
human cancers, including neuroblastoma, medulloblastoma, gastric cancer, 
osteosarcoma, small cell lung cancer and colon cancer (Ventura and Jacks, 2009). 
Recent mechanistic studies in a colorectal cancer model indicated that overexpression 
of miR-92a, one of the miR-17-92 polycystron, promotes proliferation, migration and 
invasion by targeting the known tumor suppressor PTEN (Zhang et al., 2013). 
Moreover, in a lympoma cell model, miR-92a has been  shown to target a negative 
regulator of the PI3K/Akt/mTOR pathway, which is an important pathway for the 
regulation of apoptosis, thereby inhibiting cell death (Rao et al., 2012). miR-92a and 
miR-25 have also been linked with the downregulation of Bim, a pro-apoptotic factor 
of the Bcl-2 apoptotic mechanism, so upregulation of the miR-17-92 cluster leads to 
the inhibition of the mitochondrial pathway of apoptosis (Niu et al., 2012). Another 
crucial and very well known tumor suppressor that is targeted by miR-17-92 is the 
p53 protein, that has been found to interact with and be negatively regulated by miR-
25 (Kumar et al., 2011). miR-25 also binds and suppresses the Death receptor 4 (DR 
4) protein, a member of the tumor necrosis factor receptors (TNFR), thereby 
protecting cells from TNF-related induced apoptosis (Razumilava et al., 2012). One 
paralogue of the miR-17-92 cluster, miR-106b-25, which is another polycystron, has 
also been found dysregulated in cancer, with upregulation in hepatocellular carcinoma 
and a subset of gastric cancer (Petrocca et al., 2008). It is embedded within an intron 
of the minichromosome maintenance protein 7 (MCM7) gene and expression has 
been shown to be driven by the c-Myc transcription factror that is oftenly upregulated 
in hepatocellular carcinomas (Schlaeger et al., 2008). In turn, and similarly to miR-
17-92, components of the miR-106b-25 cluster, target PTEN (Poliseno et al., 2010). 
One more cluster that is amongst the most dysregulated in cancer is the miR-222/221 
cluster. It is highly overexpressed in a variety of solid tumors including 
hepatocarcinoma (Formari et al., 2008), thyroid cancer (Pallante et al., 2006) and 
melanoma (Felicetti et al., 2008) 
  
 Single microRNAs can also have a significant role within the cancer context; 
one such microRNA that has been well described as an oncomir is miR-155, with 
hematopoietic malignancies consistently displaying upregulated miR-155 levels 
(O’Connel et al., 2008). miR-155 represses a set of genes that play roles in the 
development of myeloid hyperplasia (Di Leva et al., 2014). Another example is miR-
21, which is overexpressed in both solid and haenatopoetic tumors (Medina et al., 
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2010). Transgenic mice with loss and gain of function of miR-21 confirmed the role 
of this microRNA as a promoter of tumorigenesis (Hatley et al., 2010).  
  
 Nevetheless, oncomiRs are only half the picture when it comes to the full scale 
of microRNA involvement in cancer. The second half consists of the tumor 
suppressor miRNAs with numerous examples already established and many still being 
identified today. One the most well-known tumor suppressor microRNAs is the let-7 
family. The proximity to fragile sites associated with lung, breast, urothelial and 
cervical cancers (Calin et al., 2004), pointed to its significance. More direct evidence 
followed, with transcripts of let-7 homologs significantly downregulated in lung 
cancer and these levels correlated with poor prognosis (Takamizawa et al., 2004). 
Other studies that link let-7 with cancer include the downregulation of three of the 
microRNAs in the let-7 family in breast cancer patients with lymph node metastasis. 
Decreased let-7 levels led to an increased expression of the Ras oncogene (Johnson et 
al., 2005). A tumor suppressor profile is also deduced for the miR-34 paralogue, 
which is driven directly by p53 and its upregulation induces apoptosis and cell cycle 
arrest (He et al., 2007). Two of the targets of miR-34, are BCL2 and MYCN and they 
are thought to be the most likely mediators of the tumor suppressor phenotype 
(Bommer et al., 2007). One last example of a tumor suppressor microRNA is the 
miR-200 family. Members of this family are  downregulated in human cancer cells 
and tumors and play a critical role in the suppression of epithelial to mesenchymal 
transformation (EMT), a critical step in the progression of tumor metastasis. miR-200 
targets the ZEB transcription factors, that potently induce EMT (Mongroo and Rustgi, 
2010). Recent work showed that, miR-200 also targets TGF-! transcripts, which are a 
key player in the differentiation of tumors in their EMT stage (Pedrigão-Henriques et 
al., 2016).  A high-thoughput sequencing screen idenitified a group of miR-200 target 
genes that control the actin cytoskeleton to inhibit cell migration (Bracken et al., 
2014), so decreased miR-200 would lead to more invasive tumorous cells.  
  
 The aforementioned examples of microRNA involvement in cancer formation 
or progression indicate their validity and relevance as important factors in 
investigations that look into the potential carcinogenic character of any compound. 
Numerous studies linking chemicals known for their involvement in neoplasias in 
distinct cancers with characteristic changes in microRNAs are rapidly expanding our 
Chapter 1 General Introduction    
!
!
%"
knowledge of the involvement of microRNAs in those tumors. An example that is 
relevant to the context of this study is the one of estrogen and its effects on 
microRNA levels in breast cancer. AGO2, the critical component of the RISC 
complex, is inhibited in the presence of 17-! estradiol throught the activation of the 
epifermal growth factor (EGF)-MAPK signalling cascade (Adams et al., 2009).  
Numerous results have highlighted the significance of the relationship between 
estrogen signalling and microRNAs. Results range from a few tens of microRNAs 
being up-or downregulated up to more than 200 significant changes in distinct 
microRNAs (Ferraro et al. 2012). Furthermore, recent studies indicated that 
microRNAs are regulated by estrogen in a wide range of time frames, ranging from 
10 or 40 minutes, up to 3 days (Hah et al., 2011; Ferraro et al., 2012). Correlation 
studies with in vivo binding of ER# showed binding of the receptor within a 10kB 
genomic region of six distinct miRNAs, and six more miRNA molecules that are 
embedded in protein-coding genes having ER# binding sites within a 50kB distance 
from those genes (Ferraro et al., 2012). Another finding that further underlines the 
importance of microRNA in estrogenic carcinogenesis of the breast is the differential 
expression of microRNAs that have been detected in the presence of inhibitors of the 
endogenous synthesis of estrogens, as well as the well-known and widely studied 
estrogen antagonist tamoxifen. Recent studies also involve endocrine disruptors and 
differential microRNA levels in breast cancer models, with fenhexamid and 
fludioxonil producing changes in microRNAs that had been previously shown to be 
differentially regulated by estrogen (Teng et al., 2013). Similar analogies can also be 
drawn in other cancer types, that can either be hormonally relevant (ovary, colon and 
prostate) or not (liver, pancreas and haematological cancers).  
 
1.5 Hypothesis and aims 
 
 Heterocyclic amines, and PhIP in particular, are potent carcinogens that are 
genotoxic (Kakiuchi et al., 1995; Okochi et al., 1999) and induce carcinogenic non-
genotoxic responses at low concentrations (Lauber et al., 2004). Such levels of this 
chemical can be found in Western diets that are meat-rich, with the epidemiological 
observations of increased colon, breast and prostate cancers acting as a pointer to the 
significance of these dietary compounds within the context of cancer-related studies 
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of dietary habits. In fact an elevated risk of these cancers assiciated with intake of 
PhIP has been reported (Sinha et al. 2000; Sinha et al. 2001; Bogen and Keating, 
2001). Having established the estrogenic character of PhIP, the epigenetic 
implications of  PhIP treatment on the level of microRNA expression and how these 
compare to the changes that are caused by a treatment with estrogen requires 
investigation. The hypothesis, therefore, was that the estrogenic character of the 
heterocyclic amine PhIP affects microRNA expression, which is an additional 
epigenetic mechanism that could contribute to PhIP’s carcinogenic profile.  
 
 The aims of this project were to establish an in vitro culture model, to study 
estrogen and PhIP induced cellular responses and subsequently probe the 
microRNAome of these cells to test for similartities in any changes observed on the 
microRNA level. The cellular model of choice was the breast cancer epithelial cell 
line MCF-7, a well-established model in our laboratory.  
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CHAPTER 2: General Methods 
 
2.1 Cell Culture 
 
2.1.1 Materials  
 
 MCF-7 human breast adenocarcinoma cells and A549 human lung carcinoma 
were obtained from the European Collection of Cell Cultures (ECACC; Salisbury, 
UK). Minimal Essential Media (MEM), Dulbecco-Vogt’s modified Eagle Media 
(DMEM), foetal bovine serum (FBS), L-glutamine, non-essential aminoacids 
(NEAA), trypsin-EDTA and penicillin/streptomycin were obtained from Invitrogen 
(Paisley, UK).  Protease inhibitor cocktail was purchased from Thermo Fisher 
Scientific (Rockford, Illinois, USA). (All other chemicals and cell culture 
consumables were obtained from Sigma (Poole, UK). 
 
2.1.2 Cell line maintenance 
 
 The cell lines that were used during this project were the immortalized breast 
adenocarcinoma MCF-7 line, originally derived from a low passage population and 
the lung carcinoma A549 cell line. Both cell lines are morphologically epithelial and 
are characterized by anchorage-dependent growth as monolayers. Handling and 
culture of all cells was performed under aseptic conditions. MCF-7 cells were 
routinely grown in phenol red free MEM supplemented with 10% v/v FBS, 2mM L-
glutamine, 1% w/v non-essential aminoacids, 100 units/ml penicillin and 100 units/ml 
streptomycin at 37°C in a 5% v/v CO2 humidified atmosphere. A549 cells were 
grown in DMEM supplemented with 10% v/v FBS, 2mM L-glutamine, 100 units/ml 
penicillin and 100 units/ml streptomycin in a 5% v/v CO2 humidified atmosphere at 
37°C. For both MCF-7 and A549 cells the initial seeding concentration was 2-4 x 
10,000 cells/cm2. For serial passaging or utilization in studies, sub-confluent cells (70-
80% confluency) were briefly rinsed in pre-warmed sterile phosphate buffered saline 
(PBS) not containing calcium chloride or magnesium chloride, and then treated with 
0.25% w/v trypsin EDTA in a solution of a 1:1 ratio of trypsin-EDTA:PBS. Cells 
were incubated at 37°C and 5% v/v CO2 for 5 minutes and gently shaken until they 
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had detached from the flask. Dislodgement of the monolayer cells was confirmed 
microscopically. The trypsinisation process was then terminated by adding an equal 
volume of serum-containing media to the trypsinised cells. Cells were subsequently 
pelleted by centrifugation at 1000 rpm for 5 minutes. The supernatant was displaced 
in order to remove the trypsin from the cells, which were then resuspended in culture 
media. The cells were then counted with an improved Neubauer haemocytometer and 
were diluted appropriately to the recommended seeding concentrations and placed in 
a culture flask in 5% v/v CO2 and 37°C.  
 
2.1.3 Cell freezing  
 
 In order to store cells for future use, cells cultures were brought to confluency 
(almost 100% confluent) and were subsequently trypsinised as described in Section 
2.1.2. The cells were then resuspended appropriately to a concentration of 1-2 x 106 
cells/ml in cell culture media containing 10% v/v dimethyl-sulfoxide (DMSO). One 
ml of the cell suspension was then added to a cryo-tube and the tubes were placed at -
80°C for at least one day, followed by long term storage in liquid nitrogen. In the case 
of cell freezing for uses such as protein analysis or RNA isolation the trypsinised cells 
were centrifuged according to the procedure set in Section 2.1.2, the supernatant was 
removed and the cell pellet was snapped-frozen in liquid nitrogen. The cells were 
subsequently stored at -80°C until further use. 
 
2.1.4 Cell counting  
 
 Cells were trypsinised as described in Section 2.1.2 and they were maintained 
in suspension at 5% v/v CO2 and 37°C. A small fraction of the cell suspension was 
added to Trypan Blue at a ratio of 1:4 cells:Trypan Blue, in order to assess the 
viability of the trypsinised cell population. Approximately 20 µl were added to each 
side of an improved Neubauer haemocytometer. The cells were then viewed under a 
microscope and those within the four individual squares around the cross-like 
structure of the haemocytometer were counted.  Cells stained with Trypan Blue 
correspond to dead cells, whilst those that do not take up the dye are alive. The sum of 
the count from the four squares was then averaged and multiplied by 104 to correct for 
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volume and dilution factors to give number of cells per ml of suspension. The 
numbers for both alive and dead cells were calculated and the viability was assessed.   
 
2.2 Molecular Biology 
 
2.2.1 Lysis of cells for Immunoblotting 
 
 Cells were trypsinised as described in Section 2.1.2 and were kept in 
suspension. They were centrifuged for 5 minutes at 1000 rpm and the cell pellet 
washed with PBS. The cells were centrifuged again, the supernatant was removed and 
the pellet was resuspended in PBS and then transferred in a protease free Eppendorf 
tube. The cells were lysed with the addition of lysis buffer (150mM NaCl, 50mM 
Tris, 1mM EDTA, 1% v/v Ethoxylated Octylphenol surfactant (IGEPAL from 
Solvay), pH 7.4 in protease free H2O) containing a protease inhibitor cocktail (Pierce 
Bioscience), at a rough estimate concentration of 106 cells/ ml of lysis buffer. The 
lysis process was allowed to take place for 5 minutes in ice and the suspension was 
repeat-pippetted in order to fully dissolve the pellet. In the case of visible cell debris, 
the lysate was centrifuged briefly at 10,000 rpm and the clear supernatant was 
transferred to a fresh Eppendorf tube. The cell lysate was subsequently aliquoted in 
appropriate volumes and stored at -80°C for further use.  
 
2.2.2 Determination of protein content in cell lysates 
 
 The assay utilised for the calculation of  total protein content of cell lysates for 
immunoblotting is the bichinchoninic (BCA) protein assay, which is compatible with 
the lysis buffer used. The reaction is based on the formation of Cu+1 ions from Cu+2 
ion from a reducing reaction that takes place in an alkaline media. The reduction 
reaction has a linear correlation with increasing protein content. Chelation of one 
molecule of BCA with two cuprous ions (Cu+1) gives a colored product. Briefly, the 
working reagent mixture was made by mixing manufacturer’s Reagent A with 
Reagent B (from Pierce Bioscience) with a 50:1 ratio and the protein standards were 
prepared by a serial dilution of a 2mg/ml bovine serum albumin (BSA) solution with 
PBS. The protein standards ranged from 2,000 µg/ml to 25 µg/ml. The microplate 
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procedure was preferred due to the small amount of cell lysate available. The cell 
lysates were diluted 1:10 in order to make up the 25 µl required for the reaction to 
take place. The working reagent mixture was added to the microplate with a multi-
pipettor and then both the standards for the standard curve and the protein samples 
were loaded on the microplate. The plate was gently shaken and then placed at 37°C 
for at least 30 minutes to allow the reduction to take place. The plate was then 
removed and brought to room temperature in order to halt the reduction reaction. The 
plate was then inserted into the FluorStar absorbance reader and the absorbance at 562 
nm was calculated for the samples. The standard curve was plotted and the 
corresponding concentrations of the unknown protein samples were calculated from 
the curve.  
 
2.2.3 Polyacrylamide gel electrophoresis 
 
 Cell lysates were thawed from -80°C in ice and an amount of 10 µg of total 
protein were mixed with 5x sample buffer (0.25 M Tris-HCl, 10% w/v SDS, 1 mg/ml 
bromophenol blue, 0.5 M DTT, 50% v/v Glycerol) also containing a 
Pepstatin/Leupeptin protease inhibitor cocktail (From Thermo Fisher Scientific) at a 
1: 5 dilution ratio.  The samples were incubated at 95° C for 5 minutes in a heat block 
then briefly centrifuged to collect the sample at the bottom of the tube. The samples 
were then loaded on a polyacrylamide gel, typically of a 10% v/v percentage 
depending on the size of the protein of interest (see Table 3.1), in a Protean II PAGE 
mini kit (Pierce Bioscience, California USA). The gel was electrophoretically 
resolved in the presence of running buffer (25mM Tris, 192mM glycine, 1% w/v 
SDS, pH 8.3) initially at 120V until the dye front passed through the stacking gel and 
then at 200V until the dye barrier passed through the end of the resolving gel and into 
the running buffer.    
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Table 2.1 Polyacrylamide Gel ingredients and quantities for four concentrations of 
acrylamide resolving gel. TEMED stands for Tetramethylethylenediamine.   
 
2.2.4 Immunoblotting 
 
 The protein samples were fractionated by molecular weight through 
polyacrylamide gel electrophoresis. The separated proteins in the polyacrylamide gel 
were subsequently transferred onto a Hybond-C nitrocellulose membrane for 90 
minutes at 400mA in a transfer buffer (25mM Tris, 192mM glycine, 20% v/v 
methanol, pH 8.3) kept at room temperature. Immediately afterwards, the efficiency 
and the uniformity of the transfer as well as equal protein loading of the samples were 
checked by Ponceau red staining of the nitrocellulose membrane. The membrane was 
rinsed with PBS-T (25mM phosphate buffered saline, containing 0.1% v/v Tween-20) 
until the majority of the dye was rinsed from the membrane. Subsequently the 
membrane was blocked by a 5% w/v milk powder solution in PBS-T for 1 hour at 
room temperature or alternatively overnight at 4°C.  The membrane was washed three 
times for a 5 minute duration each with PBS-T and then incubated with an appropriate 
dilution of a primary antibody in 5% w/v milk in PBS-T either for one hour at room 
temperature or overnight at 4°C (depending on the availability of the epitope of 
interest as well as the efficacy of the primary antibody).  After washing the blot three 
times with PBS-T each for 5 minutes, it was incubated with appropriate dilutions of 
horseradish peroxidase-conjugated secondary antibody (HRP-conjugated secondary 
Amounts per gel (1.5 mm spacers) Final acrylamide concentration 
in resolving gel (w/v) 
Stock solutions                                         Stacking gel     7.5%     10%     12%     15% 
H20                                                                1.525 ml    
1.5 M Tris-HCl pH 8.8                                         - 
0.5 M Tris-HCl pH 6.8                                 0.625 ml 
20% SDS (w/v)                                                12.5 µl   
30% Acrylamide/0.8% bisacrylamide          0.345 ml 
100mg/ml Ammonium Persulphate                12.5 µl 
TEMED                                                                5 µl 
4.85      4.05     3.35      2.35 ml 
2.5         2.5       2.5        2.5  ml 
  -             -          -            - 
50          50         50         50  µl 
2.5         3.3         4           5   ml 
10          10         10         10  µl 
50          50         50         50  µl 
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antibody) for 1 hour at room temperature. The membrane was washed again three 
times each for 5 minutes with PBS-T. Proteins of interest were visualised using an 
enhanced chemiluminescence (ECL) detection kit (Pierce Bioscience, IL USA), 
according to the manufacturer’s instructions. Briefly, the membrane was treated with 
the working solution (chemiluminescent substrate) prepared by mixing equal volumes 
of the two solutions in the kit. After 5 minutes of incubation at room temperature, 
most of the working solution was removed from the blot, which was placed in an 
exposure cassette. The blot was then exposed to hyperfilm (Amersham, Germany) in 
the dark for various exposure times until the bands appeared on the film. Additionally 
the signal on the membrane was also captured digitally with a Fujifilm 3000 Imager!. 
After detection of all the proteins of interest the blots were stored at -80°C for 
potential further use. All the incubations and washes were performed on a rocking 
incubator. 
 
! Increasing amounts of protein (cell lysates) were analysed for !-actin by 
Immuno-blotting in order to construct a calibration curve (Figure 2.1 and 2.2). 
Relative band intensities were quantified using Scion Image Beta 4.02 software 
(Scion Corporation, Maryland, USA). 
! !!!!!!!!!!"!!!!!!!!!!!#!!!!!!!!!!!!!!$%&!!!!!!!!!!!!!&!!!!!!!!!!!!!#"!!!!!!!!!!!!!$" 
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Figure 2.1 Immunoblot of !-actin from cell lysates. Values indicate concentration of 
total protein of cell lysate loaded in µg/ml. 
!
!
!
!
!
!
!
!
!
!
Figure 2.2 Calibration curve for !-actin. Constructed by quantifying !-actin 
calibration immunoblot band intensities. 
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2.2.5 Isolation of RNA from mammalian cells with TRIzol reagent" 
 
 Cell pellets were lysed in TRIzol Reagent " by repetitive pipetting with a ratio 
of 1 ml of reagent per 5-10 x 106 cells. The sample was homogenised and incubated 
for 5 minutes at room temperature to allow for the complete dissociation of 
nucleoprotein complexes. The reagent was mixed with chloroform at 0.2 ml of 
chloroform per 1 ml of reagent. The mixture was vigorously shaken by hand for at 
least 15 seconds and then incubated at room temperature for 3 minutes in order for the 
organic and aqueous phases to separate. The sample was centrifuged at 12,000 rcf 
(relative centrifugal force) for 15 minutes at 4°C. Following centrifugation the 
separated colourless aqueous phase containing RNA was transferred into a fresh 
eppendorf tube, whilst the organic phase, containing DNA and protein was stored at -
80°C. Isopropyl alcohol (0.5 ml) was added to the aqueous phase, incubated at room 
temperature for 10 minutes and then centrifuged at 12,000 rcf at 4°C for another 10 
minutes. The RNA pelleted on the side of the bottom of the tube, the supernatant was 
discarded and the pellet washed with 75% v/v ethanol. The pellet was mixed by 
vortexing and then centrifuged at 7,500 rcf for 5 minutes at 4°C. The washing 
procedure was repeated once more and the pellet was left to air dry. The RNA pellet 
was subsequently resuspended in an appropriate amount of nuclease free deionised 
water and quantified by spectroscopy. The total RNA was stored at -20°C for future 
use. 
 
2.2.6 Reverse transcription polymerase chain reaction for cDNA synthesis  
 
 In order to create a cDNA library, an appropriate amount of total RNA, 
ranging from 0.1 to 3 µg was used. For cDNA synthesis directly subsequent to the 
isolation of RNA, polyadenylation of the latter is not required, however when cDNA 
is to be synthesised from stored RNA, polyadenylation was performed. For the 
polyadenylation step, total RNA was mixed with 1mM Tris (pH 8.0), 10mM adenine 
triphosphate (ATP) solution with a dilution factor depending on the amount of RNA 
being adenylated (ATP dilution factor = 5000/amount of RNA used in nanograms), 
MnCl2 at a final concentration of 2.5 mM, 0.5 µl of Poly A Polymerase and the 
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corresponding reaction buffer solution (both supplied from Invitrogen) topped with 
nuclease free deionised water up to 20 µl. The tube was mixed gently and the reaction 
was allowed to take place at 37°C for 15 minutes in a water bath. Immediately after 
the polyadenylation step a fraction of the polyadenylated RNA was transferred into a 
new Eppendorf tube and oligo dT primers were added at a final concentration of 
10µM as well as nuclease free water up to 20 µl in order for the oligo dT primers to 
attach to the poly A tail of the RNA strands. The mixture was placed in a thermal 
cycler for 3 minutes at 80°C followed by 2 minutes at 1°C. Following the thermal 
cycler program the first DNA strand was synthesised by adding a mixture of all four 
types of deoxyribonucleotide tri-phosphate (dNTP) at a final concentration of 200µM 
each, 0,5 µl of RNAse inhibitor, 1 µl of MML-Reverse Transcriptase and the 
corresponding Reverse Transcription reaction buffer (all supplied from Promega) 
topped with nuclease free water to final reaction volume of 50 µl. The tube was then 
placed in the thermal cycler and incubated for 90 minutes at 42°C followed by 
incubation at 94°C for 2 minutes in order to stop the reaction. Following thermal 
cycling the tube was chilled on ice, the reaction mixture was aliquoted in Eppendorf 
tubes (5 µl) and the cDNA synthesis was confirmed with the quantification of the 
reaction mixture in a spectrophotometer (nanodrop) (high DNA content: > 2 mg/µl). 
 
2.2.7 Polymerase chain reaction 
 
 DNA amplification in this study was mainly performed from cDNA libraries 
rather than from genomic DNA extractions. The general protocol for PCR 
amplifications used a 50 µl total reaction in a nuclease free PCR Eppendorf tube 
containing DNA template, 1.5 µl of a 50mM MgCl2 solution, 5 µl of 10x PCR buffer 
(supplied from Promega), 1µl of a 10mM dNTP solution containing all four dNTPs, 2 
µl each of the two primers at a concentration of 10 pmol/µl, 0.2 µl of Taq Polymerase 
(i.e. 1 unit) and nuclease-free deionised water up to 50 µl total volume. The tube was 
briefly mixed by tapping or pipetting and then centrifuged. The generic PCR program 
on the thermal cycler for PCR reaction with Taq DNA polymerase constituted of 1 
cycle at 95°C for 5 minutes (activation step) followed by 30 cycles of 95°C for 25 
seconds (separation of strands), 60°C for 30 seconds (annealing of primers) and 72°C 
for 45 seconds (elongation) and finally 1 cycle at 72°C for 10 minutes (completion of 
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polymerisation of all fragments). The reaction was then cooled down to 4°C ad 
infinitum, until it was removed from the thermal cycler. The amplification of the 
fragment of interest was confirmed by visualisation of the DNA fragment with 
agarose gel electrophoresis as described below.  
 
2.2.8 Agarose gel electrophoresis 
 
 Agarose gel electrophoresis was commonly used in order to confirm 
successful and specific PCR amplification of a DNA fragment as well as for 
confirmation of cDNA synthesis. The most common gel made for such purposes 
contained 1% w/v agarose. Briefly, 1 gram of agarose powder (supplied from Sigma) 
was added to 100ml of TAE (Tris-acetate-EDTA) buffer (pH 8.0) and mixed in a 
flask. The mixture was heated in a microwave until the grains of agarose were 
completely resolved in the solution. Subsequently ethidium bromide was added to the 
solution at a final concentration of 0.5 µg/ml and the mixture was poured in a gel 
casting tray with the sample combs placed appropriately. The mixture was allowed to 
settle and solidify and the combs were carefully removed from the gel without ripping 
the bottom of the gel. The tray was then put into an electrophoresis chamber 
containing TAE, covered with the buffer. The gel was then loaded with a DNA 
hyperladder corresponding to the sizes of the DNA fragment of interest and the DNA 
samples to be examined. The DNA samples were mixed with 10x sample buffer (30% 
v/v glycerol, 10% w/v SDS, 0.1% w/v xylene cyanol and 0.1% w/v bromophenol blue 
in dH2O) with a dilution factor of 10 and were subsequently loaded into the wells of 
the gel. The electrophoresis chamber was then connected to a power supply and an 
electrical current of 4V/cm was applied to the chamber. The migration of the 
negatively charged DNA molecules could be monitored by tracking the dyes 
(bromophenol blue migrates through agarose gels at roughly the same rate as a 300bp 
long fragment, whilst xylene cyanol migrates like a 3000bp fragment). The gel was 
subsequently put on a transilluminator and the DNA fragments were visualised with 
UV light. Ethidium bromide intercalates between bases of DNA and fluoresces under 
the light of such frequency. The visualisation process took place shortly after the 
cessation of the electrophoresis, since DNA diffuses through the agarose gel and the 
images lose resolution. Furthermore the hyperladder can also provide information 
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about the quantity of DNA loaded into the gel by comparing the closest corresponding 
band of the hyperladder to the band of interest. 
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CHAPTER 3: Cellular and molecular effects of 17 !-estradiol and 
PhIP on MCF-7 cells 
 
3.1 Introduction 
 
The significance of the signalling processes that are attributed to estrogen and 
estrogen-like compounds in relation to the development of breast cancer has been 
firmly established (Brown and Hankinson, 2015). Investigations into the nature of the 
intricate network operating during these processes has aided our understanding of 
these interactions and has provided therapeutic solution and cure for this type of 
cancer, which is one of the most common primary tumours in women (Zelnak and 
O’Regan, 2015). The mechanisms involved, in the events that take place when 
mammary gland cells are exposed to this hormone, have been well studied (Thomas 
and Gustaffson, 2015).  
 
A recent discovery is the involvement of microRNAs in the development and 
progression of cancer (Volinia et al., 2006). It has been shown that microRNAs can 
act as oncogenes or tumour suppressor genes and have been termed as such, even 
though they are not characterised by the basic properties of a gene (Zhang B. et al., 
2006). There are numerous examples of specific microRNAs contributing to increased 
cell growth in model cell-based studies and to accelerated tumour formation in animal 
models (Tam and Dahlberg, 2006 and Hatley et al., 2010). The basic function of 
microRNAs, that is the controlling and fine tuning of gene expression, allows for all 
these interactions to occur as cancer is a disease of mal-controlled expression of 
genes. The additional property of microRNAs, their putative ability to control the 
expression of a large number of genes at the same time, is another niche that signifies 
the important role of microRNAs. The intricacy of their signalling properties makes 
microRNAs a very significant factor in cancer biology.  
 
Most reports attribute differing levels of specific microRNAs between 
cancerous tissue and its surrounding normal tissue and very few link a specific 
microRNA with a specific signalling process. Additionally, the possibility of 
microRNAs acting as effectors of small biologically active compounds has not been 
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explored as of yet. For example, is there is a relationship between hormone activity 
and microRNAs? It is likely that there is a relatively high degree of certainty that 
compounds that have been found to affect cellular behaviours and are implicated with 
cancer formation and progression, are also affecting microRNA levels, which in turn 
act as effectors of these compounds in the context of cancer inducing properties. 
Compounds that are genotoxic carcinogens, such as PhIP, and more significantly 
compounds that have an epigenetic carcinogenic property, should have very strong 
links with microRNAs, that is factors that affect gene expression rather than actual 
gene sequences.  In the context of breast cancer, carcinogens such as 17-! estradiol 
and PhIP constitute very strong candidates for investigating the hypothesis that 
microRNAs, are effectors of their carcinogenic activity.  
 
In this chapter, I hypothesize that 17-! estradiol and PhIP influence 
microRNA expression. In exploring this hypothesis I have established the temporal 
and dose-dependent effect of 17-! estradiol and PhIP on MCF-7 cells to define the 
phenotypic response. I then explored the potential of estrogen and the estrogenic 
compound PhIP to affect microRNA levels using a bioinformatic analysis searching 
for estrogen response elements in genomic regulatory regions.  
 
Specifically, the effects of 17-! estradiol and PhIP on the growth of MCF-7 
cells were determined through an E-Screen experiment that examined both dose and 
time dependency of these effects. The E-Screen experiment is a trypan blue exclusion 
cell count, providing information for both cellular growth and apoptosis. The E-screen 
was conducted in three independent technical repeats, in order for statistical analysis 
to be carried out. Additionally, in order to substantiate that signalling events occur in 
the presence of these compounds, a molecular marker known to be affected by 
estrogenic signalling, the progesterone receptor, was also examined for reaffirmation 
of the signalling dynamics of these two compounds. To assess the likelihood of 
microRNA expression levels being altered in the presence of these estrogenic 
compounds, a bioinfomatic analysis mining estrogen response elements upstream and 
downstream of the transcriptional start sites of microRNA sequences in the human 
genome, was also conducted. The purpose of these experiments was to support the 
hypothesis that 17-! estradiol and PhIP alter the levels of expression of microRNAs 
and link this to phenotypic anchorage.  
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3.2 Materials and Methods 
 
3.2.1 Preparation of dextran coated charcoal stripped serum  
!
Ten ml of dextran-coated charcoal (DCC, Sigma Aldrich, Poole, UK) was 
added to 500 ml FBS and stirred overnight at 4ºC. This was then centrifuged at 1000 
rpm for 20 minutes at 4ºC. The FBS was then decanted and a further 10 ml of DCC 
was then added to the 500 ml of serum. This was incubated for 45 minutes at 50ºC, 
and then cooled to 4ºC. The serum was then centrifuged for 20 minutes at 1000 rpm at 
4ºC. The FBS was decanted and the process repeated twice from addition of 10 ml 
DCC to incubation at 50ºC. Finally the serum was centrifuged for 30 minutes at 
3000rpm and filtered twice through a 0.2 µM filter. The dextran-coated charcoal 
triple-stripped serum (DCCSS) was stored at   -20ºC until required. 
 
3.2.2 E-Screen 
 
An E-Screen assay was performed following the method of Soto et al. (1994), 
with several modifications. MCF-7 cells were routinely maintained in MEM 
supplemented with 1% w/v non-essential amino acids, 10% v/v FCS, 2 mM L-
glutamine and 100 IU/ml penicillin/100µg/ml streptomycin in an incubator 
maintained at 5% v/v CO2 95% v/v air and 37°C. Cells were subcultured every 5 days 
at a split ratio of 1:3. For experiments, MCF-7 cells were cultured in phenol red-free 
MEM supplemented with 10% v/v dextran coated charcoal stripped serum until they 
were approximately 80% confluent for at least 2 days prior to the treatment of the 
cells with the test compounds. The cells were removed from culture flasks with 
trypsin, harvested by centrifugation at 1000 rpm for 5min, and the number of cells 
was determined by counting. Cells were seeded into 6-well plates at 2.5 x 105 
cells/well in phenol red-free MEM supplemented with 10% v/v dextran-coated 
charcoal-stripped serum (DCCSS) prepared as described in 3.2.1 along with 
appropriate concentrations of the compound of interest. Dilutions of test compounds 
were made up in absolute ethanol and administered so that the final ethanol 
concentration was 1% v/v in the media. Ethanol alone, at 1% v/v, was found to have 
no influence on cell proliferation. Each treatment was carried out in triplicate. Control 
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cells were incubated with a media containing an equivalent amount of solvent without 
the test compound. The cells were incubated for 24, 48 and 72 hours without 
replenishing the media and they were harvested accordingly at the specified 
timepoints. The cells were split into two harvests, one for RNA isolation and one for 
Immunoblot analysis, the methods of which are provided in Chapter 2. The cell 
suspensions were centrifuged at 1000 rpm and the supernatant was removed from the 
tube. The total cells were then resuspended in Eppendorf tubes, centrifuged again then 
the supernatant was removed and the cells snap-frozen and then stored at -80°C until 
required. 
 
3.2.3 Protein electrophoresis  
 
 Cell lysates were thawed from -80°C in ice and an amount of 10 µg of total 
protein were mixed with 5x sample buffer (0.25 M Tris-HCl, 10% w/v SDS, 1 mg/ml 
bromophenol blue, 0.5 M DTT, 50% v/v Glycerol) also containing a 
Pepstatin/Leupeptin protease inhibitor cocktail (From Thermo Fisher Scientific) at a 
1: 5 dilution ratio.  The samples were incubated at 95° C for 5 minutes in a heat block 
then briefly centrifuged to collect the sample at the bottom of the tube. The samples 
were then loaded on a polyacrylamide gel, typically of a 10% percentage depending 
on the size of the protein of interest (see Table 3.1), in a Protean II PAGE mini kit 
(Pierce Bioscience, California USA). The gel was electrophoretically resolved in the 
presence of running buffer (25mM Tris, 192mM glycine, 1% w/v SDS, pH 8.3) 
initially at 120V until the dye front passed through the stacking gel and then at 200V 
until the dye barrier passed through the end of the resolving gel and into the running 
buffer. Table 3.2.1 summarizes the volumes of each reactant for the construction of 
the polyacrylamide gel.    
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Table 3.2.1 Polyacrylamide Gel ingredients and quantities for four concentrations of 
acrylamide resolving gel. TEMED stands for Tetramethylethylenediamine.   
Amounts per gel (1.5 mm spacers) Final acrylamide concentration 
in resolving gel (w/v)  
Stock solutions                                         Stacking gel     7.5%     10%     12%     15% 
H20                                                                1.525 ml    
1.5 M Tris-HCl pH 8.8                                         - 
0.5 M Tris-HCl pH 6.8                                 0.625 ml 
20% (w/v) SDS                                               12.5 µl   
30% Acrylamide/0.8% bisacrylamide          0.345 ml 
100mg/ml Ammonium Persulphate                12.5 µl 
TEMED                                                                5 µl 
4.85      4.05     3.35      2.35 ml 
2.5         2.5       2.5        2.5  ml 
  -             -          -            - 
50          50         50         50  µl 
2.5         3.3         4           5   ml 
10          10         10         10  µl 
50          50         50         50  µl 
 
3.2.4 Immunoblotting 
 
 The protein samples were fractionated by molecular weight through 
polyacrylamide gel electrophoresis. The separated proteins in the polyacrylamide gel 
were subsequently transferred onto a Hybond-C nitrocellulose membrane for 90 
minutes at 400mA in a transfer buffer (25mM Tris, 192mM glycine, 20% v/v 
methanol, pH 8.3) kept at room temperature. Immediately afterwards, the efficiency 
and the uniformity of the transfer as well as equal protein loading of the samples were 
checked by Ponceau red staining of the nitrocellulose membrane. The membrane was 
rinsed with PBS-T (25mM phosphate buffered saline, containing 0.1% v/v Tween-20) 
until the majority of the dye was rinsed from the membrane. Subsequently the 
membrane was blocked by a 5% w/v milk powder solution in PBS-T for 1 hour at 
room temperature or alternatively overnight at 4°C.  The membrane was washed three 
times for a 5 minute duration each with PBS-T and then incubated with an appropriate 
dilution of a primary antibody in 5% w/v milk in PBS-T either for one hour at room 
temperature or overnight at 4°C (depending on the availability of the epitope of 
interest as well as the efficacy of the primary antibody).  After washing the blot three 
times with PBS-T each for 5 minutes, it was incubated with appropriate dilutions of 
horseradish peroxidase-conjugated secondary antibody (HRP-conjugated secondary 
antibody) for 1 hour at room temperature. The membrane was washed again three 
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times each for 5 minutes with PBS-T. Proteins of interest were visualised using an 
enhanced chemiluminescence (ECL) detection kit (Pierce Bioscience, IL USA), 
according to the manufacturer’s instructions. Briefly, the membrane was treated with 
the working solution (chemiluminescent substrate) prepared by mixing equal volumes 
of the two solutions in the kit. After 5 minutes of incubation at room temperature, 
most of the working solution was removed from the blot, which was placed in an 
exposure cassette. The blot was then exposed to hyperfilm (Amersham, Germany) in 
the dark for various exposure times until the bands appeared on the film. Additionally 
the signal on the membrane was also captured digitally with a Fujifilm 3000 Imager!. 
After detection of all the proteins of interest the blots were stored at -80°C for 
potential further use. All the incubations and washes were performed on a rocking 
incubator. 
 
3.2.5 Immunoblot quantitation 
 
 Images of immunoblots captured by the Fujifilm 3000 Imager! were 
quantified with the densitometry tool of the ImageJ programm. Protein bands were 
quantified by using relative band intensity compared to the vehicle control as the 
standard. Values of relative intensity were expsessed as fold-changes compared to 
control. 
 
3.2.6 Statistical analysis of quantified Immunoblots 
 
 Relative intensity values of protein bands from immunoblots were 
incorporated into the GraphPad Prism program and two-way analysis of variance 
(ANOVA) was conducted with a Dunnet’s post-test. Statistical significance was 
concluded for p<0.05   
 
3.2.7 Mining of microRNA genomic sequences for detection of estrogen 
responsive elements (ERE)    
 
Genomic sequences from all the human microRNA sequences present in miR-
Base version 11.0 were extrapolated in FASTA format 
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(http://www.mirbase.org/index.shtml) along with 2000 base pairs upstream and 500 
base pairs downstream of the transcriptional start site of the microRNA (TSS). This 
region usually includes proximal putative promoter sequences as well as putative 
distal promoter sequences. The sequences were incorporated in the Dragon ERE 
Finder web tool (Bajic et al., 2003) as a FASTA sequence and the putative ERE were 
located as well as their palindromic character and exact location in relation to the TSS 
of the microRNA. 
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3.3 Results 
 
3.3.1 E-Screen for both temporal and dose dependent aspects of 17-! estradiol 
and PhIP. 
 
 The carcinogenic and epigenetic character of these two compounds has been 
described previously (Lauber and Gooderham, 2007), thus the current experiments 
were carried to validate the estrogenic responsiveness of the cell system to these 
chemicals and to optimize the appropriate concentration of 17-! estradiol and PhIP to 
use in the microRNA analysis. The E-Screen was used to define a phenotypic 
anchorage point for the MCF-7 cells (estrogen receptor positive) in the presence of 
17-! estradiol and PhIP over a range of concentrations for both compounds (10-6 to 
10-11 M). Additionally, the temporal aspects of the phenotypic response were also 
addressed. The results indicate that, as expected, in the presence of 17-! estradiol or 
PhIP, cell growth is increased. With 17-! estradiol, as it can be seen on Figure 3.1, the 
effects of the compound on cell growth are more pronounced with lower 
concentrations rather than higher ones. The concentration that presents the highest and 
most consistent effect along all three timepoints of the E-Screen was 10-8 M and the 
timepoint with the most pronounced effects on cell growth was 72 hour post 
treatment. The dissociation constant for 17-! estradiol in the estrogen receptor is 0.9 x 
10-10 M (Thorpe & Rose, 1988), whilst the dissociation constant for PhIP has not been 
uncovered by research yet. The results of the E-Screen for 17-! estradiol are 
summarised in Figure 3.1. 
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Figure 3.1 E-Screen of MCF-7 cells with 17-! estradiol at three timepoints. Bars 
represent percentage of cell number relative to the vehicle control. Values are mean ± 
SEM for triplicate experiments. Asterisks represent statistically significant changes 
(*=p<0.05., **=p<0.01) using ANOVA with a Dunnett’s post-test. 
 
 
In the case of PhIP, a similar observation to the one made for 17-! estradiol 
was evident with regards to potency over the concentration range. As can be seen in 
Figure 3.2, the effect on cell growth was less at the highest concentrations, whilst 
lower concentrations induced a strong increase in cell growth. The optimal 
concentrations for increased cell growth was 10-7 M of PhIP and the optimal 
timepoint was judged to be 72 hours, similar to 17-! estradiol.  
 
 
 
 
 
* * 
* 
* 
* 
* 
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Figure 3.2 E-Screen of MCF-7 cells with PhIP at three timepoints. Bars represent 
percentage of cell number relative to the vehicle control. Values are mean ± SEM for 
triplicate experiments. Asterisks represent statistically significant changes (*=p<0.05., 
**=p<0.01) using ANOVA with a Dunnett’s post-test. 
 
3.3.2 Effect of 17-! estradiol and PhIP on Progesterone Receptor in MCF-7 cells 
  
 As an indication of the responsiveness of the cell based model to estrogenic 
compounds, the effect of 17-! estradiol and PhIP on the levels of the progesterone 
receptor were examined. It is well established that 17-! estradiol increases the levels 
of progesterone receptor in MCF-7 cells (Cormier E.M. et al., 1989). Our laboratory 
has also shown that progesterone receptor levels are also increased by PhIP (Lauber et 
al., 2004). Hence, an examination of the levels of the progesterone receptor was 
conducted in order to affirm the responsiveness of the cell system for estrogen-based 
signalling. For this experiment, the optimal concentrations for both 17-! estradiol (10-
8 M) and PhIP (10-7 M) were used. Since the primary aim of these studies was to 
investigate the short-term epigenetic effects of these compounds on microRNAs, 
timepoints were examined within the first 24 hours of treatment.  
 
* 
* * 
* 
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 The immunoblot results showed that both compounds had an effect on the 
levels of progesterone receptor (Figure 3.3). More specifically, maximal responses 
were observed at 12 hours post treatment, with PhIP producing a bigger increase in 
the level of expression of the progesterone receptor than 17-! estradiol. The blots 
were quantified by densitometry, normalized to !- actin and expressed as a percentage 
of the vehicle control (Figure 3.3 B). The  17-! estradiol or PhIP treatment of these 
cells did result in altered expression of progesterone receptor, which constitutes an 
additional phenotypic anchor for the responsiveness of the cell system to the 
estrogenic treatment, consistent with previous studies (Cormier et al., 1989 and 
Lauber et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Immunoblot analysis of time-dependent effects of 17-! estradiol (10-8 M) 
and PhIP (10-7 M) on progesterone receptor in MCF-7 cells.  
A) A representative immunoblot.  
B) Bars represent percentage change relative to the vehicle control. Values are mean ± 
SEM for triplicate experiments. Asterisks represent statistically significant changes 
(*=p<0.05) using ANOVA with a Dunnett’s post-test 
 
 
A 
B * * 
* 
* 
Chapter 3 Cellular and molecular effects of 17-! estradiol and PhIP on MCF-7 cells    
!
!
'%
 
3.3.3 Bioinformatic analysis of estrogen responsive elements flanking microRNA 
genomic sequences 
 
 To investigate the postulation that 17-! estradiol and PhIP have epigenetic 
properties through alterations of microRNAs, the presence of estrogen responsive 
elements in the proximities of genomic sequences of microRNAs was examined. 
These palindromic genetic motifs constitute putative sites of interaction between 
promoter elements of genes and the estrogen receptor following its binding to the 
estrogenic ligand (such as 17-! estradiol or PhIP,) and its translocation from the cell 
membrane into the nucleus of the cell. Such motifs could be used in the potential 
interaction between estrogen-like compounds and microRNAs and could provide the 
mechanistic link that connects the two. Since microRNAs are transcribed under the 
same control mechanism as other genes, the presence of promoter sequences in their 
proximal upstream or downstream region allows for this kind of investigation. 
Therefore, 2000 base pairs upstream of the transcriptional start site and 500 base pairs 
downstream of the end of the transcript of all the human microRNAs (version 11.0 of 
miR-Base (Griffiths-Jones, 2004)) were salvaged from the Ensembl site and were 
subjected to bioinformatic analysis with the use of the Dragon ERE Finder 2.0 web 
tool program (Bajic et al., 2003). This program identifies palindromic sequences that 
match or closely resemble the estrogen responsive element. The results obtained 
describe putative (not established) motifs, but nevertheless provide an indication of 
whether or not estrogen responsive elements could be used by the cell to direct and 
control expression of microRNAs. The analysis showed that almost a third of all the 
microRNAs examined contain one or multiple putative estrogen responsive elements 
in their proximal genomic sequences and that some contain as many as eleven 
putative motifs (hsa-miR-127) (Table 3.3.1). In the majority of the microRNAs, there 
were more than one estrogen responsive motifs present. A table of the microRNAs 
that were found to have multiple estrogen responsive elements and therefore could be 
estrogen responsive genes is presented in Table 3.1 below. 
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Table 3.3.1 MicroRNAs with multiple estrogen responsive element motifs flanking 
their genomic sequences. The number of the motifs as well as whether the microRNA 
sequence is located in a sense or antisense strand is also presented. Cases of 
microRNAs involved in estrogen-related cancers are referenced. 
MicroRNA 
Name 
Number of 
EREs 
Sense (+)  
Antisense (-) Strand 
MicroRNA involvement in estrogen-
related cancer 
hsa-let-7b 5 + Targets CYP450 epoxygenase J2J (Chen et al., 2012) 
 
hsa-mir-9-1 4 - 
Hypermethylated in primary breast 
tumors (Lehman et al., 2008) 
hsa-mir-26b 4 + 
Targets oncogenes CDH1, GREB1, 
KPNA1 and CDK8 (Lin et al., 2014 
and Tan et al, 2014) 
hsa-mir-34a 4 - 
Inactivated in cancers; targets CD44, 
AXL, Bcl-2, SIRT1, HDAC1 (see 
Discussion for references) 
hsa-mir-98 4 - Overexpressed in FFPE breast cancer tissue (Deng et al., 2014) 
hsa-mir-126 4 + Regulates invasion by targeting ADAM 9 (Jiang et al., 2014) 
hsa-mir-127 11 + Targets BCL6 senescence inhibitor (Chen et al., 2013) 
hsa-mir-133a-2 9 + -- 
hsa-mir-136 7 + -- 
hsa-mir-139 4 - Regulator of metastatic breast cancer pathways (Krishnan et al., 2013) 
hsa-mir-152 6 - Targets DNMT1 expression in ovarian cancer (Xiang et al., 2014) 
hsa-mir-185 6 + Targets c-Met (Fu et al., 2014) 
hsa-mir-196a-1 4 - Interacts with PTEN/Akt/FOXO1 pathway (Shang et al., 2015) 
hsa-mir-199a-1 4 - 
Negative regulator of TGF-! 
signalling pathway (Zhang et al., 
2012) 
hsa-mir-200a 4 - 
Suppressor of connexin 43 (Ming et 
al., 2015), controls SIRT1 expression 
(Eades et al., 2011) 
hsa-mir-200b 4 - 
Inhibits EMT in breast cancer 
(Rhodes et al., 2015 ); reduces ZEB1 
(Kong et al., 2015)  
hsa-mir-433 12 + -- 
hsa-miR-519 
(cluster) 12 + 
Targets Orai1/GSK3! pathway 
(Deng et al., 2014) 
hsa-mir-769 6 + Downregulates NDRG1 and enhances apoptosis (Luo et al.,2014) 
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3.4 Discussion 
 
 The experiments reported in this chapter provide a phenotypic anchor for the 
response of MCF-7 cells to estradiol and PhIP. They also give initial indications in 
support of the hypothesis that 17-! estradiol and PhIP could alter microRNA levels in 
MCF-7 cells. Initially, the capability of both compounds to affect the growth of these 
cells was assessed. The E-Screens indicated that both compounds induced cell growth 
by significant margins at a range of concentrations and time points. This is consistent 
with previous studies from our laboratory that showed similar effects for these 
compounds (Lauber et al., 2004). The fact that similarities in the nature of the 
response curve are seen between 17-! estradiol and PhIP suggest that PhIP’s 
dissociation constant is expected in a similar range with 17-! estradiol’s and therefore 
the occupancy competition between the two ligands is expected to be similar in these 
concentrations. Moreover, the experiments indicated that the optimal concentrations 
for growth induction for 17-! estradiol was 10-8 M, and PhIP 10-7 M for all the three 
timepoints of the E-Screen. These concentrations were therefore chosen for the 
subsequent experiments of this study. It can be suggested however, that molecular 
based events might not accord with those occurring at the cellular level. Such a 
possibility could potentially compromise the hypothesis. However, the scope of this 
study was to examine whether the estrogenic character of E2 and PhIP extends to the 
level of microRNA expression, so the data generated can be used for such assessment 
regardless of whether they were generated at optimal molecular concentrations or not.  
 
The validity of using the chosen concentrations of 17-! estradiol and PhIP to 
alter events at the molecular level was achieved through the increased levels of 
expression of the progesterone receptor. Again, these observations are in agreement 
with previous reports from our laboratory that showed upregulation of progestrerone 
receptor in MCF-7 cells after their exposure to these two compounds (Lauber et al., 
2004). The ability of 17-! estradiol to increase expression of progesterone receptor 
had been already reported in MCF-7 cells (Cormier et al., 1989) as part of the 
endocrine signalling network involving these hormones. The upregulation of this 
receptor provides support that the selected concentrations of 17-! estradiol and PhIP 
do instigate events at the molecular level and therefore it is plausible that such 
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treatment in MCF-7 cells could invoke microRNA related responses. The profile of 
the upregulation of progesterone receptor appears to oscillate. This observation could 
relate to the turnover of the protein, which has been reported to be around 6 to 8 hours 
for a turnover of the receptor in the presence of 17- ! estradiol (Mullic and 
Katzenellenbogen, 1986). Furthermore, PhIP has also been shown to stimulate the 
expression of progesterone receptor in MCF-7 cells in an ER-dependent manner and 
with temporal and potency similarities to the progesterone receptor response observed 
with 17- ! estradiol (Lauber et al., 2004).  Therefore this observation, notwithstanding 
the inconsistencies presented in the time course chosen, does provide evidence for the 
molecular based activities of both compounds as well as further support for the 
estrogenic character of PhIP to the level of endocrine signalling.  
 
The discovery of a broad number of estrogen responsive elements in genomic 
sequences flanking microRNA locations offers the exciting prospect that E2 and PhIP 
may be able to influence the regulation of microRNAs. These putative promoter 
sequences could drive the transcription of microRNAs in the presence of the 
estrogenic stimulus in the form of the ligand bound to the estrogen receptor, as both 
17-! estradiol and PhIP act as ligands and can activate its translocation to the nucleus 
(Bennion et al., 2005). In many cases the estrogen responsive elements present 
number more that one (see table 3.1), thereby increasing the probability of that 
specific microRNA being driven by the receptor acting as a transcriptional regulator 
in the presence of the estrogenic signal. Almost one third of all the microRNAs 
present in the miR-Base version 11.0 library contain one or more estrogen responsive 
elements. Interestingly, some of the microRNAs that presented with numerous 
estrogen responsive elements in their sequences have been linked with estrogen-
related cancers involving aberrant cell growth (see table 3.1). Examples include let-7b 
that has been found to target cytochrome P450 epoxygenase J2J, which promotes 
cancer phenotypes (Chen et al., 2012), mir-9-1 found to be hypermethylated in 
primary breast cancer specimens (Lehmann et al., 2008) and mir-26b that has recently 
been involved with breast cancer based on its targeting of CDH1, GREB1, KPNA2 
(Tan et al., 2014) and CDK8 (Li et al., 2014) in breast cancer cell lines. The 
extensively studied tumor suppressor mir-34a, which has been shown to target 
multiple genes including CD44 (Liu et al., 2011), AXL tyrosine kinase receptor 
(Mackiewicz et al., 2011), Bcl-2 and SIRT1 (Li et al. 2013), LMTK3 (Zhao et al., 
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2013) and histone deacetylases HDAC1 and HDAC7 (Wu et al., 2014), is another 
microRNA that is flanked with multiple estrogen responsive elements. Based on these 
findings, the possibility that microRNA expression is driven by 17-! estradiol and 
PhIP, and the affected microRNAs in turn affect cell growth, is further supported.  
Additionally, the data suggest the importance of microRNAs in being the effector of 
many cellular based obervations that are related to estrogenic signalling. 
 
The experiments and bioinformatics analysis reported in this chapter support 
the notion that the chosen treatment on these cells could result in molecular events at 
the level of microRNAs. These events could provide functional links between 17-! 
estradiol and PhIP and the cellular and molecular events they induce.  
 
 
3.5 Conclusion 
 
 The results from the experiments reported in this chapter indicate that both 17-
! estradiol and PhIP induce molecular events that could involve microRNAs. The 
findings from the E-Screen experiments indicated that the optimal concentrations for 
the treatments were 10-8M for 17-! estradiol and 10-7 M for PhIP and those 
concentrations were also validated for the upregulation of the progesterone receptor. 
Additionally, a bioinformatic inspection of genomic sequences flanking microRNAs 
for estrogen responsive elements indicated that almost a third of all microRNAs 
examined contain putative estrogen responsive elements in their proximities. This 
observation further supported the hypothesis that estrogen and estrogenic compounds 
could be utilising microRNAs in order to exert their epigenetic properties. 
 
 
 
 
 
3.6 Supplementary Data 
 
Chapter 3 Cellular and molecular effects of 17-! estradiol and PhIP on MCF-7 cells    
!
!
'*
 Table of estrogen responsive elements present in flanking genomic sequences 
of all microRNAs. Presented are the microRNA, its respective chromosome and  
chromosomal location, the sense/antisense strand location of the coding sequence of 
the microRNA, the palindromic sequence of the putative estrogen responsive element 
and the location of the latter in relation to the transcriptional start site of the 
microRNA.  
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CHAPTER 4: Genome wide microRNA changes from 17-! estradiol 
and PhIP treatment in MCF-7cells 
 
4.1 Introduction 
 
 The experiments and bioinformatics analysis described in the previous chapter 
indicated that 17-! estradiol and PhIP induce molecular events that could involve 
miRNAs. A reported study, investigating the effects of 17-! estradiol on the levels of 
microRNAs, was previously described in whole zebrafish (Cohen et al., 2008) and the 
results indicated that treatment with the compound did result in significant changes in 
a number of microRNA molecules. Some of these miRNA changes had been 
described by previous studies as being involved in the process of cancer initiation and 
promotion.  For example, the let-7 group of microRNAs (present in both humans and 
zebrafish), which regulate the Ras oncogene (Johnson et al., 2005) as well as miR-29b 
that is involved in the apoptotic process through regulation of Mcl-1, a Bcl-2 family 
member of apoptotic proteins (Mott et al., 2007). The fact that 17-! estradiol had an 
effect on microRNA expression in zebrafish may not be relevant to human cells, since 
zebrafish are genetically distant organisms from Homo Sapiens and are predominantly 
used as models in developmental studies (Ellet and Lieschke, 2010).  
 
 The goal of the current experiments were to examine the effect of PhIP and 
17-! estradiol on the short-term temporal aspects of the treatments, probing the 
totality of the microRNA population over a period of twenty four hours. The 
examination was carried out with the use of the recently constructed genome wide 
microRNA array microchip (Wang et al., 2007) that contains multiple probes for all 
the human microRNA molecules discovered up to the time of its production. This 
technique allows for a holistic approach to understanding cellular responses to 
treatment through an epigenetic scope. For the field of microRNA research, the direct 
linkage between microRNAs and mRNA and particularly the potential interaction of 
each, results in a broad interacting network that can aid the understanding of 
mechanisms of signalling and the enactment of properties deriving from such 
interactions. For carcinogenic compounds, the case for microRNA in the 
carcinogenesis process is rationally plausible. 
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 Despite the high amount of novel information that microarray experiments 
provide, the data need to be validated using other detecting techniques such as real-
time quantitative PCR (rt-qPCR) (Provenzano and Mocellin, 2007). However 
confirming techniques can be time consuming and PCR-based molecular biology 
protocols need a case-to-case optimization for each reaction. The combinatorial 
approach though, involving both microarray and targeted rt-qPCR protocols embodies 
a much more efficient approach, with microarrays providing the novel information on 
a genomic scale and the rt-qPCR validating the microarray. This strategy was 
followed in this study, with differential changes in microRNAs being reconfirmed via 
the rt-qPCR process. The results from both techniques are correlated to confirm 
concordance. Accumulating high correlation values for differentially regulated 
microRNAs increases the confidence of the validity of the microarray results.  
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4.2 Materials and Methods 
 
542.1 Characterisation of total RNA 
 
 Total RNA was extracted from frozen pelleted MCF-7 cells via the Trizol 
method described in Chapter 2. In addition to the standard A260/A230 ratios the Agilent 
2100 Bioanalyzer was used to confirm the quality of the RNA molecules within the 
total RNA samples. This system consists of microcapillaries that act as matrices 
through which the RNA migrates and the presence of protein contaminations, phenol 
or excessive salts can be monitored in real time. The analysis takes into consideration 
the entire electrophoretic trace of the RNA samples including the presence or absence 
of degradation products and it assesses the quality of the samples via the calculation 
of the RNA integrity number (RIN), which is generated by the examination of the 
bands expected in total RNA samples, such the ribosomal 18S and 28S RNA 
molecules. The samples were loaded onto chips and inserted into the Agilent 2100 
Bioanalyzer. The samples were run and the resulting electropherograms (the plots of 
band formations) as well as the RIN values were calculated.  
 
4.2.2 Fluorescent labelling of RNA samples 
 
 The system that was utilised for the labelling process was Agilent’s miRNA 
labeling system, which generates fluorescent miRNA. This method involves the 
ligation of one Cyanine 3-pCp  (Cyanine 3-Cytidine 3',5'-bisphosphate)  or Cyanine 5-
pCp (Cyanine 5-Cytidine 3',5'-bisphosphate) molecule to the 3' end of an RNA 
molecule. In this experiment, Cyanine 3-pCp was ligated onto RNA from cells kept in 
control media and Cyanine 5- pCp onto RNA extracted from cells treated with either 
PhIP or 17-! estradiol. Total RNA (100 ng) was labeled for subsequent use in the 
arrays with a concentration of 25ng/µl and was initially dephosphorylated.  The RNA 
solutions (4µl) were transferred into an Eppendorf tube and were kept on ice. A 
dephosphorylation Master Mix was prepared by mixing 0.7 µl of Calf Intestine 
Alkaline Phosphatase (CIP) with 1.6 µl of RNase –free water and 0.7 µl of CIP buffer 
per sample. Subsequently 3 µl of the Master Mix were added to the RNA samples and 
were gently mixed by pipetting. The dephosphorylation reaction was allowed to occur 
Chapter 4 Genome wide microRNA changes from 17-! estradiol and PhIP treatment  
in MCF-7 cells 
!
!
)(
for 30 minutes at 37°C in a water bath. Subsequently the samples were denatured in 
order to achieve efficient labelling of the molecules. Five µl of 100% v/v DMSO 
(supplied from Sigma, Poole UK) were added to each sample and they were incubated 
in a water bath at 100°C for 5 minutes. The samples were transferred immediately to 
an ice-water bath in order to retain the RNA molecules in their denatured form. The 
ligation step was carried out immediately in order to ensure high efficiency of dye 
ligation. For the ligation process the 10x T4 RNA (supplied from Ambion, California 
USA) ligation buffer was prewarmed at 37°C in order to dissolve all the precipitate 
and then cooled down to room temperature. The ligation master mix was prepared 
immediately prior to its use; for each sample 2 µl of 10x T4 RNA ligase buffer 1 µl 
RNase-free water, 3 µl of fluorescent dye (pCp-Cy3 or pCp-Cy5) and 2 µl of T4 RNA 
ligase (supplied from Ambion, California USA) were mixed gently and kept on ice. 
The master mix was mixed into the denatured RNA samples for a total volume of 20 
µl and the solution was gently mixed and briefly centrifuged in order to collect the 
mixture at the bottom of the tube. The ligation reaction was carried out with a 2 hour 
incubation of the samples at 16°C. The labelled microRNAs were subsequently 
isolated with the use of Micro Bio-Spin columns (supplied from Bio-Rad, California 
USA). The columns were shaken and then the SSC buffer (150 mM sodium chloride, 
17.5 sodium citrate, pH 7.0 with 0.02% w/v sodium azide) was drained into a 2 ml 
microcentrifuge tube (supplied with the columns) by removing the tip from the 
columns and then uncapping the columns for at least two minutes. The columns were 
subsequently centrifuged at 1000 x g for 2 minutes and then transferred into a fresh 15 
ml Eppendorf tube. RNase-free water (30 µl) was added to the labelled samples for a 
total volume of 50 µl and the solution was loaded onto the column without disturbing 
the gel bed. The columns were centrifuged at 1000 x g for 2 minutes and the eluted 
purified samples were kept on ice ready for hybridization. Figure 4.2.1 summarizes 
the two-dye labelling and hybridization process.  
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Figure 4.2.1 Flow diagram of production of fluorescently labelled array samples. The 
mixing step allows for comparisons to vehicle control within one sample (red-
downregulation, green-upregaulation, yellow-no change.) 
 
4.2.3 Hybridization of RNA samples to the Agilent miRNA microarray chip 
 
 For the hybridization process, the samples were kept on ice whilst the buffers 
and master mixes were prepared. For the blocking agent, the 10x GE Blocking Agent 
was prepared by adding 125 µl of nuclease free water to the lyophilised buffer and the 
pellet was dissolved by pippeting after heating it at 37°C in a water bath. Any 
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undissolved material was collected at the bottom of the tube by a short centrifugation 
for 10 seconds. Samples were dried down using a speed-vac at 45°C and were 
resuspended in 18 µl of DNase/RNase-free water and 4.5 µl of 10x blocking agent and 
22.5 µl of 2x Hi-RPM Hybridization Buffer were added to each sample for a total 
volume of 45 µl per sample. The samples were gently mixed with a vortex for 2 
minutes, incubated at 100°C for 5 minutes and immediately transferred to an ice water 
bath for 5 minutes. The samples were briefly centrifuged to collect any possible 
condensation. The samples were subsequently applied to the gasket slide that was 
assembled into the Agilent SureHyb chamber base. For the application the samples 
were loaded carefully onto the gasket well making sure that the gasket slide is not 
disturbed by the pipette tip and the gasket walls are not disturbed by the hybridization 
solution. Subsequently, the array slide was carefully placed on the gasket slide and the 
SureHyb chamber was clamped on the assembled slides. Potential bubbles that were 
trapped within the assembly were tapped towards the edges of the chamber and the 
slide chamber was placed in rotisserie in an array hybridization oven set at 55° C with 
the hybridization rotor set at 20 rpm. The hybridization of the samples with the arrays 
was performed for 20 hours at 55°C.  
 
4.2.4 Washing of Agilent microarray chip 
 
 Following hybridization for 20 hours and prior to disassembling the 
hybridization chambers, the washing equipment was prepared. For the wash buffers, 2 
ml of 10% v/v Triton X-102 were added to the stock of wash buffer 1 (Agilent’s Gene 
Expression Wash Buffer Kit™) and mixed thoroughly, whilst for wash buffer 2 
preparation, the buffer was warmed overnight at 37° C. For the washing of the array 
slides, the first washing glass dish was filled with wash buffer 1 at room temperature, 
the second with wash buffer 1 with a slide rack and enough wash buffer 1 to cover the 
rack with a magnetic stirrer and placed on a magnetic stir plate. The third prewarmed 
glass dish (37°C) was filled three-fourths with prewarmed wash buffer 2 and placed 
with a magnetic stir bar on a magnetic stir plate set at 37°C. Following preparation of 
the washing apparatus, the hybridization chambers were removed. The slide assembly 
was carefully unclamped from the hybridization chamber and was quickly transferred 
into the first washing glass dish. The slide-gasket assembly was opened up from the 
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barcode end only,  by using blunt-ended forceps, with the gasket slide allowed to drop 
to the bottom of the dish and the array slide removed from the dish and placed into the 
slide rack of the second washing glass dish. The slide was subsequently washed in the 
second was plate with a magnetic stirrer for 5 minutes at a moderate speed. 
Subsequently, the slide rack was transferred to the third glass dish containing wash 
buffer 2 at 37° C and was stirred for 5 minutes at 37° C. The rack was slowly 
removed from the washing soution in order to minimise droplets on the slides and the 
slides were immediately scanned.  
 
4.2.5 Scanning and feature extraction of Agilent microarray chip 
 
 The washed slide was assembled in a slide holder and placed into the scanner 
carousel. The scanner (SureScan Microarray Scanner Model G2505B by Agilent) was 
then appropriately set at scan region: 61 x 21.6 mm, scan resolution (µm): 5, 5µm 
scanning mode: single, dye channel: yellow. Subsequently the scanner status was 
verifies as “scanner ready” and the scan was commenced by clicking Scan Slot. 
Following the scanning of the slide and the generation of the microarray fluorescent 
images the feature extraction programme was run in order to generate measureable 
data for microRNA comparisons (Agilent Feature Extraction software). Following 
completion of the extraction the Quality Control report was examined to determine 
whether the extraction carried out was correct. The resulting .txt files are the ones 
used for the analysis of the results using array data analysis programmes. 
 
4.2.6 MicroRNA real-time quantitative PCR using SYBR Green  
 
 For rt-qPCR the cDNA library constructed via RT-PCR (described in Section 
2.2.7) was utilised and was diluted in a 1:10 ratio in DNase/RNase-free water. For 
each reaction 5 µl of this dilution were used and was mixed with 25 µl of the SYBR 
Green mixture (Platinum# SYBR# Green qPCR SuperMix-UDG, supplied by 
Invitrogen), 1 µl of the microRNA-specific forward primer at a final concentration of 
200 nM, 1µl of the Universal qPCR primer with the same final concentration (both 
primers were supplied from Invitrogen) and 1µl of ROX reference dye (supplied from 
Invitrogen). The reaction was topped to a total volume of 50 µl with DNase/RNase-
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free water and was gently mixed by pipetting and briefly centrifuged in order to 
ensure that all liquid was collected at the bottom and that no bubbles were present in 
the qPCR tube. A master mix containing the SYBR Green Mix, both primers and 
ROX reference dye was prepared. The reactions were placed in a preheated ABI 7500 
Real-Time PCR instrument (supplied from Applied Biosystems) and were ran with 
the following cycling programme: a) 50°C for 2 minutes b) 95°C for 2 minutes, 40 
cycles of c) 95°C for 15 seconds, 60°C for 30 seconds and d) 4°C indefinitely. 
Following the completion of the cycling programme the cycle threshold values were 
calculated. The calculations of the microRNA values were derived via the relative 
quantitation method with the reference sample being the ribosomal U6 small nuclear 
RNA (snRNA).   
 
4.2.7 Heatmap generation using Cluster 3.0 and TreeView software 
 
 In order to create heatmap representations of potential microRNA changes the 
array data were loaded onto the Cluster 3.0 programme in the tabbed .txt. The filtering 
options for the data analysis were 90% of the values in any column to be present with 
a standard deviation of less than 0.1. The absolute value filters were not applied. For 
data adjustment the results were transformed with a log base 2 transformation, then 
the genes were centred with the row-wise median and normalised, then the different 
arrays (i.e. timepoints and treatments) were centred with the column-wise median and 
normalised. The microRNA genes that were filtered through and adjusted 
appropriately were subsequently clustered with the hierarchical clustering method in 
order to produce the heatmaps. 
 
4.2.8 Statistical analysis of results 
 
 Log 2 normalised data from the array experiment were analysed using ANOVA 
with Tukey’s or Dunnet’s post-test. Since both the RNA samples from the vehicle 
control and treatment sample were hybridized on the same array, the results present 
relative fold values. For the validation of array results through rt-qPRC, Pearson’s R 
Test was performed to find the correlation between the array and the rt-qPCR results. 
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4.3 Results  
 
4.3.1 MicroRNA array results 
 
4.3.1.1 4 hour 17-! estradiol treatment 
 
 The RNA extracts used in the microarray experiment were derived form the 
same cell population that were examined in the E-Screen. During the analysis of the 
array scan data, the boundaries for the detection of any significant changes in the 
microRNAs were set for fold changes greater than 1.3 as well as statistical 
significance p<0.1. The resulting analysis indicated a wide range of differentially 
expressed microRNAs for 17-! estradiol, with the majority of the values being in the 
range of less than 2-fold difference. In the case of 17-! estradiol treatment, 69 
microRNA molecules were differentially regulated, with 53 of them found to be 
downregulated whilst the remaining 16 were upregulated. All the differentially 
regulated microRNAs are presented in the Supplementary Data section at the end of 
this chapter. The microRNA molecules that displayed the highest upregulation were 
miR-34b, miR-424, miR-574-3p and miR-197. In turn the microRNAs that resulted in 
the highest downregulation were miR-663, miR-638, miR-92b*, miR-330-5p and 
miR-150*.  Table 4.3.1.1 presents the biggest changes observed for the 17-! estradiol 
treatment at the 4 hour timepoint. 
 
 Table 4.3.1.1 Table of most differentially regulated microRNAs after treatment of 
MCF-7 cells with 10-8 M 17-! estadiol for 4 hours. Values are fold change after 
treatment with 17-! estradiol for 4 hours, with standard deviation of the mean 
included. The miRNAs listed here differ at least two standard deviations from 
vehicle-treated cells. 
'()*+,-.!-/'0! '()*+,-.!102304)0! 5+67!89/4:0!
,-./012/$%3! CAAUCACUAACUCCACUGCCAU "4%!56/!+4+'!
,-./012/%#%! CAGCAGCAAUUCAUGUUUUGAA "4%!56/!+4"$!
,-./012/&(%/$7! CACGCUCAUGCACACACCCACA "4%!56!/+4#!
,-./012/"*(! UUCACCACCUUCUCCACCCAGC "4&!56/!+4"%!
,-./012/"&+8! CUGGUACAGGCCUGGGGGACAG +4'!56/!+4+#!
,-./012/$$+/&7! UCUCUGGGCCUGUGUCUUAGGC +4&!56/!+4+"!
,-./012/*#38! AGGGACGGGACGCGGUGCAGUG +4&!56/!+4+%!
,-./012/''$! AGGCGGGGCGCCGCGGGACCGC +4$!56/!+4+"!
,-./012/'$)! AGGGAUCGCGGGCGGGUGGCGGCCU +4%!56/!+4+%!
Chapter 4 Genome wide microRNA changes from 17-! estradiol and PhIP treatment  
in MCF-7 cells 
!
!
*$
N=3; p < 0.1 
 
4.3.1.2 8 hour 17-! estradiol treatment 
 
 The results produced from the RNA isolations obtained from the cells treated 
for 8 hour with 17-! estradiol were subjected to the same analysis. The total number 
of microRNAs that passed through the statistical analysis of a greater than 30% 
change and statistical significance of p<0.1 were 54, with most of them displaying 
small changes in their levels. The altered microRNAs at 8 hours produced a similar 
profile to the 4 hour treatment, with the majority of altered microRNAs displaying a 
decrease in their levels. More specifically, out of 54 differentially regulated 
microRNAs, 42 were downregulated with the remaining 12 upregulated. All the 
differentially regulated microRNAs at this timepoint are presented in a separate table 
in the Supplementary Data section at the end of this chapter. In the case of 
downregulated microRNAs, the highest changes were observed for the microRNAs 
miR-638, miR-663, miR-92b*, miR-330-5p and miR-150*. The mostly upregulated 
microRNAs were miR-34b, miR-768-3p, miR-197 and miR-532-3p. Table 4.3.1.2 
displays the most notable upregulations and downregulations observed in the 8 hour 
17-! estradiol treatment. 
 
Table 4.3.1.2 Table of most differentially regulated microRNAs after treatment of 
MCF-7 cells with 10-8 M 17-! estadiol for 8 hours. Values are fold change after 
treatment with 17-! estradiol for 8 hours, with standard deviation of the mean 
included. The miRNAs listed here differ at least two standard deviations from 
vehicle-treated cells. 
N=3; p<0.1 
'()*+,-.!-/'0! '()*+,-.!102304)0! 5+67!89/4:0!
,-./012/$%3! CAAUCACUAACUCCACUGCCAU "4%!56/!+4+'!
,-./012/(')/$7! CUGGGAUCUCCGGGGUCUUGGUU "4$!56/!+4+&!
,-./012/"*(!! UUCACCACCUUCUCCACCCAGC "4%!56/!+4"+!
,-./012/&$#/$7! CCUCCCACACCCAAGGCUUGCA "4%!56/!+4"%!
,-./012/"&+8! CUGGUACAGGCCUGGGGGACAG /+4'!56/!+4+"!
,-./012/$$+/&7! UCUCUGGGCCUGUGUCUUAGGC +4'!56/!+4+&!
,-./012/*#38!! AGGGACGGGACGCGGUGCAGUG +4&!56/!+4+%!
,-./012/''$!! AGGCGGGGCGCCGCGGGACCGC +4%!56/!+4+%!
,-./012/'$)! AGGGAUCGCGGGCGGGUGGCGGCCU +4%56/!+4+$!
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4.3.1.3 12 hour 17-! estradiol treatment 
 
 In the case of treatment of MCF-7 cells for 12 hours with 10-8 M 17-! estradiol, 
the microRNA changes that were produced were few in comparison to the results 
obtained for previous timepoints. More specifically the microRNAs that manifested as 
differentially regulated at this timepoint in the treatment were 11, out of which 6 were 
upregulated and 5 were downregulated. The highest upregulation was displayed by 
miR-424 with a Log 2 normalised score of 0.24 and the highest downregulation 
microRNAs were miR-663 and miR-638 with Log 2 normalised scores of -1.22 and -
0.98 respectively. Table 4.3.1.5 presents all the microRNAs that were altered in this 
treatment.  
 
Table 4.3.1.3 Table of most differentially regulated microRNAs after treatment of 
MCF-7 cells with 10-8 M 17-! estadiol for 12 hours. Values are fold change after 
treatment with 17-! estradiol for 12 hours, with standard deviation of the mean 
included. The miRNAs listed here differ at least two standard deviations from 
vehicle-treated cells. 
 N=3; p<0.1 
 
4.3.1.4 24 hour 17-! estradiol treatment  
 
 The 24-hour timepoint was the longest exposure for the MCF-7 cells that were 
treated with 10-8 M 17-! estradiol. This treatment resulted in a high number of altered 
microRNAs. The microRNAs that were differentially regulated with this treatment 
were a total of 58, with 45 of them found downregulated and the remaining 13 
upregulated. All the differentially regulated microRNAs are presented in a separate 
'()*+,-.!-/'0! '()*+,-.!102304)0! 5+67!89/4:0!
,-./012/%#%! CAGCAGCAAUUCAUGUUUUGAA "4$!56/!+4+&!!
,-./012/"##(! CGUGCCACCCUUUUCCCCAG +4(!56/!+4"$!
,-./012/"%&! GUCCAGUUUUCCCAGGAAUCCCU "4$!56/!+4+(!
,.-/012/"#$$! UGAGCCCUGUCCUCCCGCAG "4#!56/!+4#"!
,-./012/"*(! UUCACCACCUUCUCCACCCAGC "4"!56/!+4#"!
,-./012/"##)8! GUGGGCGGGGGCAGGUGUGUG "4"!56/+4("!
,-./012/#+'! UGGAAUGUAAGGAAGUGUGUGG +4'!56/!+4#&!
,-./012/*#38! AGGGACGGGACGCGGUGCAGUG +4*!56/!+4'&!
,-./012/'$)! AGGGAUCGCGGGCGGGUGGCGGCCU +4(!56/!+4$%!
,-./012/''$! AGGCGGGGCGCCGCGGGACCGC +4$!56/+4$$!
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table in the Supplementary Data section at the end of this chapter. The microRNAs 
that were  decreased were consistent with the previous time points. More specifically, 
the highest changes were found for miR-663, miR-638, miR-92b*, miR-330-5p and 
miR-1228*. In the case of upregulated microRNAs, these were miR-1227, miR-424, 
miR-1233, miR-574-3p and miR-197.  Table 4.3.1.4 presents the most upregulated 
and downregulated microRNAs for the 24 hour treatment with 17-! estradiol.  
 
Table 4.3.1.4 Table of most differentially regulated microRNAs after treatment of 
MCF-7 cells with 10-8 M 17-! estadiol for 24 hours. Values are fold change after 
treatment with 17-! estradiol for 24 hours, with standard deviation of the mean 
included. The miRNAs listed here differ at least two standard deviations from 
vehicle-treated cells. 
'()*+,-.!-/'0! '()*+,-.!102304)0! 5+67!89/4:0!!
,-./012/"##*! GCAGCAGAGAAUAGGACUACGUC "4(!56/!+4#'!
,-./012/%#%!! CAGCAGCAAUUCAUGUUUUGAA "4'!56/!+4"%!
,.-/012/"#$$!! UGAGCCCUGUCCUCCCGCAG "4'!56/!+4#*!
,-./012/&(%/$7!! CACGCUCAUGCACACACCCACA "4(!56/!+4#$!
,-./012/"*(! UUCACCACCUUCUCCACCCAGC "4'!56/!+4"%!
,-./012/"##)8! GUGGGCGGGGGCAGGUGUGUG +4'!56/!+4+(!
,-./012/$$+/&7! UCUCUGGGCCUGUGUCUUAGGC +4&!56/!+4+#!
,-./012/*#38! AGGGACGGGACGCGGUGCAGUG +4&!56/!+4+$!
,-./012/'$)! AGGGAUCGCGGGCGGGUGGCGGCCU +4$!56/!+4+$!
,-./012/''$! AGGCGGGGCGCCGCGGGACCGC +4$!56/!+4+$!
  N=3; p<0.1 
 
4.3.1.5 4 hour PhIP treatment 
 
 The treatment of MCF-7 cells with PhIP for 4 hours also altered a wide range of 
microRNAs. The majority of the changes observed were in the range of less than two-
fold as in the case of the estradiol treatment. The 4 hour PhIP treatment resulted in the 
differential upregulation of a total of 35 microRNAs with the majority of them 
showing downregulation. More specifically, out the 34 differentially regulated 
microRNAs, 31 were downregulated and only 3 were found to be upregulated. All the 
observed changes are presented in the Supplemetary Data section at the end of this 
chapter. Amongst the downregulated microRNAs the highest changes were observed 
in the cases of miR-638, miR-663, miR-330-5p, miR-92b* and miR-5198c*. The 
three upregulated microRNAs were miR-30c, miR-1233 and miR-483-5p. Table 
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4.3.1.5 presents the most downregulated and upregulated microRNAs found in the 4 
hour PhIP treatment.  
Table 4.3.1.5 Table of most differentially regulated microRNAs after treatment of 
MCF-7 cells with 10-7 M PhIP for 4 hours, with standard deviation of the mean 
included. Values are fold change after treatment with PhIP for 4 hours. The miRNAs 
listed here differ at least two standard deviations from vehicle-treated cells. 
 
'()*+,-.!-/'0! '()*+,-.!102304)0! 5+67!89/4:0!
,-./012/$+9! UGUAAACAUCCUACACUCUCAGC +4)!56/!+4"#!
,-./012/&(%/&7! AAGACGGGAGGAAAGAAGGGAG "4(!56/!+4"%!
,.-/012/"#$$! UGAGCCCUGUCCUCCCGCAG "4%!56/!+4#"!
,-./012/&")98!! UCUCUGGAGGGAAGCACUUUCUG +4'!56/!+4+&!
,-./012/*#38!! AGGGACGGGACGCGGUGCAGUG +4&!56/!+4+*!
,-./012/$$+/&7!! UCUCUGGGCCUGUGUCUUAGGC +4&!56/!+4+"!
,-./012/'$)!! AGGGAUCGCGGGCGGGUGGCGGCCU +4&!56/+4+%!
,-./012/''$!! AGGCGGGGCGCCGCGGGACCGC +4%!56/!+4+"!
 N=3; p<0.1 
 
4.3.1.6 8 hour PhIP treatment  
 
 As in the case of the 4 hour treatment, the treatment of the MCF-7 cells with  
10-7M PhIP for 8 hours resulted in a wide range of differentially regulated 
microRNAs. The microRNAs that passed the cut-off values for change and statistical 
significance in this treatment amounted to a total number of 61, more than the amount 
that was found in the 4 hour treatment. The trend of the majority of the differentially 
regulated molecules being downregulated was maintained, with 50 out of 61 
microRNAs displaying decreasing levels and the remaining 11 increasing levels. All 
the differentially regulated microRNAs for the 8 hour PhIP treatment are presented in 
a separate table in the Supplementary Data section at the end of this chapter. In the 
case of downregulation, the highest displays in this treatment were miR-638, miR-
663, miR-330-5p, miR-92b* and miR-21. Out of the 11 upregulated microRNAs the 
ones with the highest log 2 normalised scores were miR-30c, miR-574-5p, miR-494 
and miR-1233. Table 4.3.1.6 shows the most differentially regulated microRNAs 
found in this treatment.  
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Table 4.3.1.6 Table of most differentially regulated microRNAs after treatment of 
MCF-7 cells with 10-7 M PhIP for 8 hours, with standard deviation of the mean 
included. Values are fold change after treatment with PhIP for 8 hours. The miRNAs 
listed here differ at least two standard deviations from vehicle-treated cells. 
'()*+,-.!-/'0! '()*+,-.!102304)0! 5+67!89/4:0!!
,-./012/$+9!! UGUAAACAUCCUACACUCUCAGC +4(!56/!+4+$!
,-./012/&(%/&7!! UGAGUGUGUGUGUGUGAGUGUGU "4(!56/!+4#*!
,-./012/%*%!! UGAAACAUACACGGGAAACCUC "4&!56/!+4"+!
,-./012/"#$$!! UGAGCCCUGUCCUCCCGCAG "4$!56/!+4"&!
,-./012/#"! UAGCUUAUCAGACUGAUGUUGA +4'!56/!+4+&!
,-./012/*#38! AGGGACGGGACGCGGUGCAGUG +4&!56/!+4"#!
,-./012/$$+/&7! UCUCUGGGCCUGUGUCUUAGGC +4'!56/!+4+&!
,-./012/''$! AGGCGGGGCGCCGCGGGACCGC +4&!56/!+4+%!
,-./012/'$)! AGGGAUCGCGGGCGGGUGGCGGCCU +4&!56/!+4+$!
   N=3; p<0.1 
 
4.3.1.7 12 hour PhIP treatment 
 
 As in the case of the disproportionate findings in the 12 hour treatment of 17-! 
estradiol, similarly the 12 hour 10-7 M PhIP treatment displayed smaller number of 
altered microRNAs compared to those at other timepoints. This treatment resulted in 
the differential regulation of 16 microRNAs, with 14 of them found reduced and only 
2 increased.  These changes are presented in the Supplementary Date section at the 
end of the chapter. The highest values for the decreased microRNAs were once more 
miR-663, miR-638 along with miR-1, miR-92b* and miR-193a-3p The two 
upregulated microRNAs were miR-30c and miR-1233.  Table 4.3.1.7 presents the 
changed microRNAs in the 12 hour PhIP treatment.  
 
Table 4.3.1.7 Table of most differentially regulated microRNAs after treatment of 
MCF-7 cells with 10-7 M PhIP for 12 hours, with standard deviation of the mean 
included. Values are fold change after treatment with PhIP for 12 hours. The miRNAs 
listed here differ at least two standard deviations from vehicle-treated cells. 
'()*+,-.!-/'0! '()*+,-.!102304)0! 5+67!89/4:0!
,-./012/$+9! UGUAAACAUCCUACACUCUCAGC +4)!56/!+4+*!
,.-/012/"#$$! UGAGCCCUGUCCUCCCGCAG "4$!56/!+4+'!
,-./012/$+:! UGUAAACAUCCCCGACUGGAAG +4'!56/!+4"%!
,-./012/#'.! UUCAAGUAAUCCAGGAUAGGCU +4'!56/!+4"'!
,-./012/*#38!! AGGGACGGGACGCGGUGCAGUG +4&!56/!+4+*!
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,-./012/"!! UGGAAUGUAAAGAAGUAUGUAU +4'!56/!+4+(!
,-./012/'$)!! AGGGAUCGCGGGCGGGUGGCGGCCU +4)!56/!+4"*!
,-./012/''$!! AGGCGGGGCGCCGCGGGACCGC +4'!56/!+4"&!!
  
 
4.3.1.8 24 hour PhIP treatment 
 
 With 24-hour 10-7 M PhIP treatment, microRNAs that were found to be 
differentially regulated by more than 30% and with a statistical significance of p<0.1 
was a total of 23. Out of those, 19 were decreased and only 3 increased. All of the 
changes observed are presented in the Supplemetary Data section. The most 
downregulated microRNA molecules were miR-663, miR-638, miR-26a, miR-330-
5p,  miR-92b* and miR-30d. The three microRNAs that were found to be upregulated 
were miR-574-5p, miR-1233 and miR-30c. Table 4.3.1.8 shows the most 
differentially regulated microRNAs in the 24-hour 10-7 M PhIP treatment.  
 
Table 4.3.1.8 Table of most differentially regulated microRNAs after treatment of 
MCF-7 cells with 10-7 M PhIP for 24 hours, with standard deviation of the mean 
included. Values are fold change after treatment with PhIP for 24 hours. The miRNAs 
listed here differ at least two standard deviations from vehicle-treated cells. 
'()*+,-.!-/'0! '()*+,-.!102304)0! 5+67!89/4:0!
,-./012/&(%/&7!! UGAGUGUGUGUGUGUGAGUGUGU "4(!56/!+4#+!!
,.-/012/"#$$! UGAGCCCUGUCCUCCCGCAG "4&!56/!+4"#!
,-./012/$+:! UGUAAACAUCCCCGACUGGAAG +4'!56/!+4"%!
,-./012/*#38!! AGGGACGGGACGCGGUGCAGUG +4&!56/!+4"'!
,-./012/$$+/&7!! UCUCUGGGCCUGUGUCUUAGGC +4'!56/!+4+$!
,-./012/#'.!! UUCAAGUAAUCCAGGAUAGGCU +4'!56/!+4"'!
,-./012/'$)! AGGGAUCGCGGGCGGGUGGCGGCCU +4'!56/!+4+$!
,-./012/''$!! AGGCGGGGCGCCGCGGGACCGC +4&!56/!+4+$!
  N=3; p<0.1 
 
 
 
 
 
 
 
N=3; p<0.1 
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4.3.2 Temporal representation of induced microRNA changes 
 
4.3.2.1 17-! estradiol 
 
 With the 17-! estradiol treatment, changes in microRNAs were observed at all 
the chosen timepoints, and a few were found altered at all the timepoints. From the 
upregulated microRNAs these are namely miR-424, miR-197, miR-1227, miR-1233. 
As it can be seen in Figure 4.3.2.1, the pattern of microRNA regulation is similar for 
all 4 differentially regulated microRNA. More specifically, the effect of 17-! estradiol 
appears to decrease after the initial 4 hour treatment levels at the 8 and 12 hour 
timepoints, followed by a sharp increase at the 24 hour timepoint. Figure 4.3.2.1.1 is 
presented below.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.2.1.1 Temporal changes of upregulated 
microRNAs in 17-! estradiol treated MCF-7 cells. Y-axis values are ratios of vehicle 
control:PhIP treatment after log 2 normalization.  Values are the means, n=3. 
 
 In the case of downregulated microRNAs there are similarly a few microRNAs 
that displayed a significant change at all four timepoints examined. These are miR-
663, miR-638, miR-92b* and miR-1228*. Each downregulated microRNA showed 
temporal changes with one common characteristic, that is also shared with the 
upregulated microRNAs. This was that the 12 hour timepoint produced the 
comparatively smallest response. The temporal change in relative expression of these 
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microRNAs is presented in Figure 4.3.2.1.2 below.  
 
 
 
 
      
 
       
 
 
 
 
 
Figure 4.3.2.1.2 Temporal changes of downregulated microRNAs in 17-! estradiol 
treated MCF-7 cells. Y-axis values are ratios of vehicle control:PhIP treatment after 
log 2 normalization.  Values are the means, n=3. 
 
4.3.2.2 PhIP 
 
 Similarly with the 17-! estradiol treatment, there were some microRNAs that 
were differentially regulated at all the timepoints of the PhIP treatment. In the case of 
upregulated microRNAs, the molecules that were found changed across all four 
timepoints of the PhIP treatment were miR-30c, miR-1233. As  can be seen in Figure 
4.3.2.2.1 the temporal behavior of these microRNAs is mixed. The two microRNAs, 
miR-30c and miR-1233 do not have similar expression behaviour in response to the 
PhIP treatment. The temporal pattern of upregulated microRNAs for the PhIP 
treatment is presented in Figure 4.3.2.2.1. 
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Figure 4.3.2.2.1 Temporal changes of upregulated microRNAs in PhIP treated MCF-
7 cells. Y-axis values are ratios of vehicle control:PhIP treatment after log 2 
normalization.  Values are means, n=3. 
 
 The microRNAs that were downregulated at all four timepoints were miR-663, 
miR-638, miR-92b*, miR-30d, miR-106b, miR-93, miR-23b, miR-26a and miR-
193a-3p. As seen in Figure 4.3.2.2.2 the temporal profile of the response to PhIP 
treatment generated by these commonly changes microRNAs follows a general trend. 
The weakest response seems to be the 12 hr timepoint for all microRNAs, whilst the 
strongest one is the 24 hour timepoint. The temporal response of the PhIP treatment is 
presented in Figure 4.3.2.2.2.  
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Figure 4.3.2.2.2 Temporal changes of downregulated microRNAs in PhIP treated 
MCF-7 cells. Y-axis values are ratios of vehicle control:PhIP treatment after log 2 
normalization.  Values are means, n=3. 
 
4.3.3 Similarities between 17-! estradiol and PhIP treatments 
 
 The most interesting finding from the array experiment was the fact that for 
both the 17-! estradiol and the PhIP treatments and across all four timepoints, the 
differentially regulated microRNAs that displayed the largest change were the same. 
Furthermore, the patterns of all the changes observed in both treatments and 
timepoints were concordant between 17-! estradiol and PhIP. The microRNAs, miR-
663, miR-638 and miR-92b* were the most changed  and their temporal behavior 
were similar with the 12 hour timepoint being the one that produced the least response 
and the 24 hour timepoint the most (see Figure 4.3.3.1). In addition, numerous 
differentially regulated microRNAs exhibited similar changes with both 17-! estradiol 
and PhIP treatments (see Venn diagram 4.3.3.2 below).  
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Figure 4.3.3.1 Similar temporal expression patterns in the three most markedly 
changed microRNAs after the treatment of MCF-7 cells with either 10-8 M 17-! 
estradiol (blue line) or 10-7 M PhIP (red line). Values for miR-638 (middle), miR-
92b* (top) and miR-663 (bottom) are presented. Y-axis values are ratios of vehicle 
control:treatment after log 2 normalization. Values are means, n=3. 
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Figure 4.3.3.2 Venn Diagram comparing the effects of 17-! estradiol and PhIP on 
microRNA expression in the MCF-7 cell line at different timepoints (A) after 4h; (B) 
after 8h; (C) after 12h; (D) after 24h. Each oval represents a timepoint of treatment. 
MicroRNAs responsive to both 17-! estradiol and PhIP are shown in the intersection 
region of the ovals. MicroRNAs with downregulated expression are depicted as 
underlined.  
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4.3.4 Heatmap representation of results and clustering 
 
4.3.4.1 17-! estradiol treatment 
 
 In order to further assess the effect of the treatment on microRNA levels on a 
macroscopic level, heatmaps of all the observed changes were generated. The graphic 
representation of the changes on microRNA levels shows that almost two thirds of the 
changes observed were cases of downregulation of microRNA expression. 
Furthermore, the heatmap (Figure 4.3.4.1) is also characteristic of the fact that more 
than half of the microRNA changes are observed in one or two timepoints in 
comparison to those that are observed throughout the whole treatment period. The 
results observed at the 12 hour timepoint did not come through the filtering criteria of 
the Cluster 3.0 programme and are not presented in this heatmap. 
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Figure 4.3.4.1 Heatmap representation of all the changes observed in the treatment of 
MCF-7 cells with 10-8 M 17-! estadiol at 4, 8, and 24 hours. Green colours represent 
downregulation, red upregulation and black no change. Different microRNAs are centred 
with the row-wise median and different arrays (timepoints) are centred with the column-
wise median and subsequently hierarchically clustered. 
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4.3.4.2 PhIP treatment 
 
 In the case of treatment of MCF-7 cells with 10-7 M PhIP, the heatmap produced 
according to the criteria described in Section 4.2.6, presents many more microRNA 
changes that are only detected in one or two timepoints rather than in all the four 
different timepoints of the treatment. However, as in the case of 17-! estradiol 
treatment, the majority of the observed changes are downregulations of the levels of 
microRNAs. Figure 4.3.2.2 represents the heatmap generated from all the treaments 
of the cells with 10-7 M PhIP. 
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Figure 4.3.4.2 Heatmap representation of all the changes observed in the treatment of 
MCF-7 cells with 10-7 M PhIP at 4, 8, and 24 hours. Green colours represent 
downregulation, red upregulation and black no change. Different microRNAs are 
centred with the row-wise median and different arrays (timepoints) are centred with the 
column-wise median and subsequently hierarchically clustered. 
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4.3.4.3 17-! estradiol and PhIP treatments 
 
 The heatmap generated with the 17-! estradiol and PhIP treatments was 
indicative of  similarities induced by the two treatments Again, most of the 
microRNA changes observed are downregulated. The results are summarised in 
Figure 4.3.4.3 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.4.3. Heatmap displaying average expression of microRNAs responsive to 
17-! estradiol or PhIP with time of treatment. Green colours represent 
downregulation, red upregulation and black no change. Different microRNAs are 
centred with the row-wise median and different arrays (timepoints) are centred with 
the column-wise median and subsequently hierarchically clustered. 
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4.3.5 Validation of microarray results 
 
 The qPCR method is the most accurate procedure for detecting even minute 
levels of change in RNA levels and has recently been applied to microRNAs as well 
(Siva et al., 2009). This method is performed on a case-to-case basis. Therefore, a 
handful of microRNA that were found to be changed were chosen in order to assess 
their levels via the quantitative PCR method. Abox plot representation of all the 
microarray results, where the distribution and deviation of the data can be visualized 
was also conducted. In this latter representation, a similarly distributed sample range 
supports  the validity of the microarray results.  
    
4.3.5.1 miR-663 qPCR vs array results: Plot and Pearson’s correlation 
 
 MiR-663 was one of the microRNAs that consistently displayed downregulation 
by treatments with both 17-! estradiol and PhIP and was therefore chosen as one of 
the microRNAs to be examined with qPCR. The microarray results for miR-663 in the 
17-! estradiol treatment were consistently above the two fold range for all the 
timepoints. Similarly in the case of PhIP treatment, the levels of downregulation were 
above two fold for most of the timepoints. The qPCR experiments for all treatments 
and timepoints correlated well with the microarray experiment. The correlation from 
the two data sets resulted in a Pearson’s correlation of 0.77. The data used and the 
correlation plot are presented in Table 4.3.5.1 and Figure 4.3.5.1 respectively 
 
Table 4.3.5.1 Comparison between fold changes from microRNA microarray 
experiment and qPCR detection for miR-663. Values are fold changes compared to 
vehicle control, with standard deviation shown  
 Array result qPCR result 
4 hour E2 0.3 +/- 0.01 0.9 +/- 0.49 
4 hour PhIP 0.4 +/- 0.01 0.5 +/- 0.13 
8 hour E2 0.4 +/- 0.04 0.3 +/- 0.09 
8 hour PhIP 0.5 +/- 0.04 0.3 +/- 0.03 
12 hour E2 0.4 +/- 0.17 0.6 +/- 0.20 
12 hour PhIP 0.6 +/- 0.15 0.4 +/- 0.14 
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24 hour E2 0.3 +/- 0.03 0.2 +/- 0.11 
24 hour PhIP 0.5 +/- 0.13 0.4 +/- 0.11 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.5.1. Correlation plot of fold range data sets from microarray experiment 
(X axis) and qPCR detection (Y axis) for miR-663. The correlation value for the two 
data sets was calculated at 0.57 
 
4.3.5.2 miR-638 qPCR vs array results: Plot and Pearson’s correlation 
 
 The second mostly downregulated microRNA by both the 17-! estradiol and 
PhIP treatments and consistent across the chosen timecourse was miR-638. In the case 
of miR-638 the changes observed were similar for both treatments and were very 
close to the two-fold range for most of the timepoints. The qPCR procedure indicated 
that the results obtained from the array experiment were representative of the 
treatment-induced changes. The results of the qPCR procedure for all the timepoints 
and both treatment are presented in comparison to the respective values from the array 
experiment in Table 4.3.5.2 As can be seen from the Table, the two data sets are well 
correlated and the correlation plot drawn predicted an excellent Pearson’s correlation 
value of 0.89. The correlation plot is presented in Figure 4.3.5.2. 
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Table 4.3.5.2 Comparison between fold changes from microRNA microarray 
experiment and qPCR detection for miR-638. Values are ratios of vehicle control: 
treatment after log 2 normalization. 
 Array result qPCR result 
4 hour E2 0.4 +/- 0.04 0.6 +/- 0.34 
4 hour PhIP 0.5 +/- 0.04 0.4 +/- 0.02 
8 hour E2 0.4 +/- 0.03 0.9 +/- 0.07 
8 hour PhIP 0.5 +/- 0.03 0.5 +/- 0.12   
12 hour E2 0.7 +/- 0.34 0.8 +/- 0.20 
12 hour PhIP 0.8 +/- 0.29 0.4 +/- 0.10 
24 hour E2 0.3 +/- 0.03 0.3 +/- 0.01 
24 hour PhIP 0.6 +/- 0.03 0.4 +/- 0.14 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.5.2 Correlation plot of fold-range data sets from microarray experiment (X 
axis) and qPCR detection (Y axis) for miR-638. The correlation value for the two data 
sets was calculated at 0.81.  
 
 An additional microRNA, miRNA923, was also examined by qPCR. However, 
it is now known that this is not a true miRNA, but is a fragment of the 28S ribosomal 
RNA (Kozomara and Griffiths-Jones, 2014). The correlation for this fragment 
between the array experiment and the qPCR was 0.85, again validating the microarray 
data. 
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4.3.5.3 Box plot of microarray results 
 
 In order to assess the reliability of the array experiment with higher confidence, 
a box plot of the results was generated. The box plot analysis allowed for an overall 
evaluation of the distribution of the data. The results, as seen in Figure 4.3.3.3, 
indicate that the distributions of each sample are comparable. Moreover, the triplicate 
samples display a similar data distribution. Thus the robust nature of results of the 
array experiment is further supported. The box plot is presented in Figure 5.3.3.3 
below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.5.3 Box plot analysis of microarray results of all samples treated with 17-! 
estradiol and PhIP. Y-axis value are ratios of vehicle control:treatment after log 2 
normalization. Each box plot on the x-axis represents a treatment sample and data 
points are individual microRNAs. E=17-! estradiol, P=PhIP. 
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4.4 Discussion  
 
 The emerging role of microRNAs in the progression of disease such as 
malignacies is increasingly evident (Orellana and Kasinski, 2015). As more 
research becomes available about the estrogen-related mechanisms involved in 
carcinogenesis, microRNAs have become a new emerging pathway through which 
estrogens can influence cancer formation and progression. Recent reports indicate that 
estradiol can affect the expression of microRNAs, some of which have been shown to 
play a role in cancer. Initial observations were made in zebrafish (Cohen et al., 2008) 
as well as rats (Kovalckuk et al., 2007) and recently in mouse splenocytes (Dai et al. 
2013). Similarly, in cell line models estrogen downregulated miR-206 (Adams et al. 
2007) as well as controlled the expression of members of the oncogenic polycistronic 
miR-17-92 cluster (miR-18a and miR-19b), which in turn control the levels of 
estrogen receptor alpha in a negative feedback loop (Castellano et al., 2009). Another 
microRNA that was shown to be downregulated by estrogen receptor # activity was 
miR-21 (Wickramasinghe et al., 2009). The occurrence of interactions between 
microRNAs and estrogen activity were also underlined by the regulation of estrogen 
receptor !1 by miR-92 as shown by in vitro experiments (Al-Nakhle et al., 2010).  
 
 In addition to 17-! estradiol, the effect on microRNA expression by the 
estrogen-like compound PhIP was also of significant interest in order to investigate 
the estrogenic character of the latter at the microRNA level. The exerted effects of 
estradiol on various cell types and tissues have also been reported with the use of 
other compounds that have been termed estrogenic. These compounds exhibit similar 
actions to estradiol and continuing research is comparing their effetcts and similarity 
to estradiol on different levels. The heterocyclic amine PhIP is a diet-derived 
carcinogen with a structural similarity with 17-! estradiol and is a candidate 
estrogenic compound in addition to its genotoxic properties (Gooderham et al., 2002, 
Lauber et al., 2004). The transcriptional activation of an estrogen responsive reporter 
construct by PhIP, the upregulation of progesterone receptor in an estrogen responsive 
cell line and the ability of PhIP to induce proliferation in the estrogen-dependent 
MCF-7 breast cancer line all attest to this estrogenic property (Gooderham et al., 
2002).   
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 The MCF-7 breast adenocarcinoma cell line utilised in the expression analysis 
was validated for estrogen responsiveness as described in chapter 3 in order to ensure 
that the cell population used displayed the established estrogenic response from both 
compounds. Subsequently, the cellular RNA was extracted for array analysis as well 
as quantitative real-time PCR. The doses for both 17-! estradiol and PhIP were 
chosen to achieve maximum phenotypic change, thereby anchoring the response (E-
Screen, described in Chapter 3). The time course for the treatment was designed to 
adress the short term effect of these compounds on microRNA status and were suited 
to the cell-based model selected.   
 
 Indeed the chosen concentrations did result in differentially regulated 
microRNAs, in some cases numbering more than 60. As a general observation, it can 
noted that the timepoints where microRNAs seem to be more affected by the 
treatment are the earlier ones, as in both the 4 and 8 hour timepoints the amount of 
microRNAs that were found to be deregulated was higher than in the late timepoints. 
This findings is in line with recent findings that 17-! estradiol can activate estrogen 
receptor # and affect microRNA expression by diverse mechanisms that include direct 
binding to promoters and enhancer elements that affect transcription and by affecting 
microRNA processing (Klinge, 2012). In the ER#-positive MCF-7 cell line these 
mechanisms can explain the changes that we observed. The direct effect of both 
compounds on the expression of the regulatory microRNAs can be topics of further 
research that will examine even shorter treatments of these estrogenic compounds in 
order to assess the contribution of both estrogen receptor dependent and independent 
effects on microRNA expression, in both estrogen receptor-positive and estrogen 
receptor-negative cell lines.    
 
 Another general observation that can be made from the obtained results is that, 
as a rule, the majority of deregulated microRNAs with both treatments and timepoints 
are found downregulated. With the exception of the 17-! estradiol 12 hour treatment, 
where the amount between upregulated and downregulated microRNAs is similar, 
downregulation microRNAs predominated at around 80%. This can be viewed as a 
decrease in the restriction or regulation of gene expression at the transcriptional level, 
which is in accordance with the cell proliferation-function of both compounds.  
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 Out of the microRNAs with altered levels, some have been implicated with 
estrogen related signalling. miR-21, that was downregulated in the 17-! estradiol 
treatment based on raw data, has been shown to be transcriptionally regulated by ER# 
(Wickramasinghe et al., 2009), whilst in the 4, 8 and 24 hour treatments with 17-! 
estradiol, members of the let-7 family were found upregulated. A study linked %R# 
activity with downregulation of the let-7 family of microRNAs and also found 
upregulation of the let-7 family in MCF-7 cells (Zhao et al., 2011), which is in 
accordance with the results of the array experiment presented here. One of the most 
downregulated microRNAs detected in the experiment, miR-92b has been linked with 
expression of ER! levels, although the concordant increase of ER! followed by the 
downregulation of miR-92b, which was reported in that study (Al-Nakhle et al., 2010) 
was not confirmed in this experiment. miR-424, which was upregulated in all 17-! 
estradiol treatments, has been shown to target the G-protein-coupled estrogen 
receptor-1, which might lead to PI3K/AKT pathway inactivation (Zhang et al., 2015), 
a pathway that has been shown to be activated and inactivated through estrogen 
activity (Lengyel et al., 2007).  
 
 Further into the observed microRNA changes that were elicited by the exposure 
to 17-! estradiol, another microRNA that was downregulated was miR-125a that has 
been shown in a recent study to reduce proliferation and invasion by targeting 
estrogen-related receptor 1, which is upregulated in many cancers (Tiwari et al., 
2014), hence a downregulation of miR-125a is in concordance with the carcinogenic 
effect of 17-! estradiol. The member of the miR-520/373 family, miR-373 that was 
downregulated in the 4 and 8 hour treatments with 17-! estradiol has been shown to 
act as a tumor suppressor by targeting NF-$B and TGF! pathways (Keklikoglou et al., 
2012). Furthermore, miR-143 was downregulated at the 4 and 24 hour timepoint.  
This microRNA has been postulated as an inhibitor of 17-b estradiol-induced cell 
proliferation in ER positive breast cancer cells, and was also found downregulated in 
that study (Yu et al., 2012). Another microRNA, relevant to estrogen signalling is 
miR-17, which targets the AIB1 protein (Abundant In Breast cancer). This microRNA 
was also found downregulated in this study’s experiment just as it was reported in the 
initial study (Hossain et al., 2006). Conversely, another tumor suppressor described in 
a ER#-positive/wild-type p53 breast cancer model study (Lee et al., 2011), miR-34b 
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was detected with slight upregulation in the array experiment. One more estrogen-
responsive microRNA that was detected in the array study was miR-191, however it 
was decreased as opposed to reports that suggest that it is an ER#-driven microRNA 
that promotes estrogen-mediated cell proliferation (Nagpal et al., 2013) 
 
 A comparison of the results from the two different treatments shows that the 
two compounds have similar effects on microRNA levels. Specifically, many affected 
microRNAs were the same in both treatments and in all the timepoints as can be seen 
in Figures 4.3.3.1 and 4.3.3.2. Most of the aforementioned, estrogen signalling-related 
microRNAs that were differentially regulated in the 17-! estradiol treatment were also 
similarly changed in the PhIP treatment. In addition, the temporal analysis of the 
changes observed in the two treatments indicated similar patterns through the chosen 
timecourse. Especially in the case of downregulation, which is the most common 
observation for both 17-! estradiol and PhIP, the pattern shape is very similar with the 
12 hour treatment producing the least response and the 24 hour treatment the most. 
These temporal similarities further substantiate the claim for the estrogenic-like 
response of PhIP on the microRNA level. Moreover in the case of microRNAs that 
were specific to either 17-! estradiol or PhIP, the observed changes were smaller, 
thereby suggesting that most likely the main mechanisms that drive the observed 
changes in the two treatments are the same. Crucially, our results show for the first 
time that PhIP exposure elicits wide-spread effects on the microRNAome of a breast 
cancer cell line and furthermore that these effects are similar to those elicited by 17-! 
estradiol.  
 
 These similar effects provide grounds for PhIP driving microRNA deregulation 
through the activation of ER#. Given that microRNA deregulation can drive breast 
carcinogenesis (Shimono et al., 2009; Song et al., 2013) it is plausible that the ability 
of PhIP to deregulate microRNA through the activation of ER# could be an important 
mechanism in PhIP-mediated carcinogenesis and be implicated in the phenotypic 
consequences of exposure to the chemical. However, in the absence of additional 
experimental data, it is not possible to differentiate between microRNA expression 
changes that are directly mediated by %R# and those that might stem from secondary 
events of PhIP exposure. Such discrimination would require additional experiments 
such as chromatin immunoprecipitation to detect the sequences that %R# bound and 
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subsequently mine for microRNA sequences located in those genomic areas. PhIP 
treatment has been reported to upregulate the anti-apoptotic BCL-2 in the mammary 
gland of rats (Venugopal et al., 1999). Interestingly, BCL-2 expression has been 
shown to be repressed in MCF-7 cells by miR-21 (Wickramasinghe et.al., 2009), 
miR-16 (Yu et.al., 2012), and miR-24 (Srivastava et.al., 2011), all of which were 
downregulated by PhIP in the array experiment. PhIP has also been shown to affect 
metastatic potential in vitro (Lauber and Gooderham, 2011). In this study PhIP 
repressed miR-200c/141, an miRNA cluster that is a master regulator of invasiveness 
and metastasis (Burk et al., 2008). H-Ras, an oncogene that is mutated in PhIP-
induced breast cancer (Yu and Snyderwine, 2002) is also targeted by miR-663 (Yang 
et al., 2013), one of the most strongly suppressed microRNAs identified in this study. 
However, whether the microRNA deregulation identified in this experiment can be 
extrapolated to in vivo mammary tissue in exposed animals or humans is not clear. 
Our previous reports show that the effects of xenobiotics on microRNA profiles in 
vivo are highly dependent on the dose and time of exposure (Koufaris et.al., 2013). 
Additionally, estrogenic effects on miRNA expression are reported to be variable 
according to cell culture conditions (Klinge, 2012).  
  
 Another observation that can be made from analyzing the microarray data is that 
the majority of the affected microRNAs by both treatments displayed reduced 
expression (Section 4.3.1 Tables and Supplementary Data). This wide-spread 
repression of microRNAs rather than upregulation is in accordance with a few studies 
(Maillot et al, 2009 and Snyderwine, 2002) but disagree with another (Klinge, 2012). 
The repression of microRNAs by 17-! estradiol is suggested to be involved with 
increased proliferation of mammary cells when stimulated with the hormone (Maillot 
et al., 2009, Yu et al., 2012). It also generally accepted that a downregulated 
microRNAome is indicative of many cancers, where increased expression of 
oncogenes drives neoplasias (Sarkar et al., 2013) 
 
 The array results were validated by correlation of the microRNAs that 
demonstrated the highest observed changes through quantitative real-time PCR. The 
correlation for all the examined microRNAs was relatively good with values of 0.77, 
and 0.89 for miR-663 and miR-638 respectively. As aforementioned a third 
microRNA was also correlated, however it has been removed from the data as it is 
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now classified as part of the 28S ribosomal RNA. Furthermore, the box plot analysis 
of the array results indicated comparable distributions for individual samples and 
importantly, similar distributions between the triplicate samples in most cases. 
Consequently, the box plot analysis further supports the validity of the observed 
results by confirming the robustness of the dataset generated. 
  
 Interestingly, another study recently reported the results of similar treatment of 
MCF-7 cells with 17-b estradiol, with same concentration but at only a 48 hour 
timepoint (Maillot et al. 2009). Strikingly all of the affected microRNAs of this 
reported study were different to those detected with the 17-! estradiol treatment in 
this thesis, but 11 out of the 23 microRNAs that were found downregulated in the 
Maillot study were also found downregulated in the PhIP treatment. Four of them 
(miR-27a, miR-26a, miR-193a and miR-23b) were consistently downregulated in all 
timepoints of the treatment with PhIP and with similar downregulation values. 
However, three more reports have investigated the effect of 17-! estradiol on MCF-7 
cells and all of them present different expression patterns from 17-! estradiol 
exposure. In one report (Bhat-Nakshatri et al., 2009) ten of the microRNAs that were 
downregulated in the study by Maillot et al. (2009) were found upregulated, whilst 
only two were similarly downregulated (Bhat-Nakshatri et al., 2009). Importantly, the 
cells in the Bhat-Nakshatri et. al. experiment were exposed to 17-! estradiol for 4 
hours and they were transfected with a plasmid vector control. In a comparison 
between the latter study and the results from this thesis, 5 microRNAs show the same 
regulation and are consistently deregulated in 17-! estradiol treatment (let-7b, miR-
424, let-7i, miR-524 and miR-143). Again, when the results from the aforementioned 
17-! estradiol treatments are compared with the report of Cicatiello (Cicatiello et al., 
2010), it is evident that the microRNA response to 17-! estradiol is varied and 
depends on cell type and treatment. Although the findings presented in this thesis did 
not present absolute fold change values when compared with the study by Maillot et 
al., (2009) only two out of 25 microRNAs were commonly found in the two studies 
and just one was changed in the same direction (mir-26b), whereas the report from 
Bhat-Nakshatri et al., has 6 microRNAs that are found in a total of 29 differentially 
regulated microRNAs in the Ciciatiello et al. study. In this manner, the results from 
this examination correlate best with all three other studies, since the individual 
similarities between them and the reported results are highest in number, since there 
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are 12 microRNA that are commonly differentially upregulated with the Cicatiello 
report as well. However this might also be due to more stringent analyses of 
microarray data between the datasets. In another paper, (Farazi et al., 2011) MCF-7 
cells reportedly present increased levels of the miR-17-92 polyciston as well as the 
miR-106a-363 cluster, when compared to normal mammary tissue, although these 
results represent precursor microRNA molecules and cannot be directly compared to 
the studies looking at mature microRNAs, since the process of microRNA maturation 
and post-transcriptional modification has been shown to be heavily regulated and 
important in the final fate of the transcripts (Farazi et al., 2011). In fact, a compilation 
of all the published changes observed in microRNAs based on 17-! estradiol amounts 
to more than one hundred upregulated microRNAs and a similar figure for 
downregulated microRNAs. All these changes are compiled and presented in Tables 
4.6.9 and 4.6.10, the former for upregulated microRNAs and the latter for 
downregulated, which can be found in the Supplementary Data section at the end of 
this chapter.   
 
 Despite the fact that various factors of the 17-! estradiol treatments in all the 
aforementioned experiments may differ, the observation that certain microRNAs are 
similarly and consistently changed between the studies, with the most highly 
deregulated ones always being different, raises the possibility that the batches of 
MCF-7 lines used in the treatments probably belong to different MCF-7 cell stocks 
that react differently to estradiol. This phenomenon has been observed widely within 
the MCF-7 cell population, due to its long term laboratory use, and it has been shown 
that different stocks of the MCF-7 cell line (BUS, ATCC, UCL, BB, BB104) display 
different proliferative responses to estrogen (Villalobos et al., 1995, Payne et al., 
2000) but also different results in copy number changes from 17-! estradiol treatment 
(Jones et al., 2000).  
 
 Out of the most affected microRNA molecules, three were downregulated and 
one was found to be increased at all the timepoints in both treatments. Several reports 
implicate those microRNAs partially to breast cancer or in some other cases to other 
types of cancer. In the case of miR-663, it has recently been shown that this 
microRNA (along with mir-9-1, mir-124a3, mir-148 and mir-152) was 
hypermethylated in 34-86% of cases in a series of 71 primary human breast cancer 
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specimens (Lehmann et al., 2008). Its hypermethylation in breast cancer correlates 
well with the discovery that miR-663 was also downregulated in human gastric cell 
lines compared to normal gastric cells and that transient introduction of miR-663 into 
human gastric cancer cell lines induced suppression of proliferation and phenotypes 
of mitotic catastrophe in these tumour cells (Pan et al., 2010). Thereby it is proposed 
that miR-663 has a tumour suppressor function, which is also in accordance with our 
proposal of estrogenically driven cancer progression through regulation of 
microRNAs.  
 
 In turn, miR-638 has also been found to be downregulated in a study analysing 
the microRNA expression profile of human gastric cancer, that was also confirmed 
with quantitative real-time PCR (Yao et al., 2009). More importantly, it was recently 
shown in a luciferase reporter assay that miR-638 targeted the well known tumour 
suppressor BRCA1 gene and moreover that this interaction was affected from a single 
nucleotide polymorphism, located within the mRNA::miRNA interacting region, that 
is correlated with breast cancer susceptibility (Chang et al., 2008), although the allele 
that presents higher association to breast cancer displayed weaker miR-638 dependent 
BRCA1 reduction (Nicoloso et al., 2010).  
 
 For the two remaining microRNAs, little has been so far established in relation 
to their function and any potential involvement in cancer formation or progression. In 
the case of miR-923, a recent work reported its upregulation in paclitaxel-resistant 
cancer cells (Zhu et al., 2010), while another reports miR-923 downregulation in 
bladder urothelial carcinoma (Xie et al., 2010). However, these studies were 
diagnostic in nature and just detected changes of this molecule, which has recently 
been described as part of the 28S ribosomal RNA and as such any mechanistic 
involvement for this molecule cannot be supported in light of these new findings. 
Considering miR-92b, which was found downregulated in this thesis, one study also 
reports its downregulation in lymphoid cancer cell lines as well as mantle cell 
lymphoma clinical samples and also connects its downregulation with higher levels of 
protein arginine methyltransferase PRMT5, which in turn increases methylation of 
certain histones that repress the suppressor of tumourogenicity 7 (St7), resulting in 
increased growth of lympoid cells (Pal et al. 2007). Conversely, the upregulation of 
miR-92b in brain primary tumours in comparison to primary tumours from other 
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tissues and their metastases to brain (Nass et al. 2009) underscores the diverse effects 
of microRNA function and their tissue-specific effects in their deregulation when 
considering their contribution to cancer formation.   
 
5.5 Conclusion 
 
 In this set of experiments the already established estrogenic character of PhIP at 
the cellular level was expanded to a specific area of gene expression level as well. 
More specifically, it was shown that PhIP and 17-! estradiol affect similar microRNA 
molecules that could be regulating expression patterns of genes that promote cell 
proliferation and favour cancer formation in breast cancer as well as in other tissues. 
It is the first report identifying the activity of PhIP at the level of microRNA 
alterations as similar to the one of 17-! estradiol. It also provides an initial indication 
for potentially similar modes of action for the two compounds in the involvement of 
deregulation of microRNA expression as an additional contributing factor to their 
carcinogenic properties. 
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4.6 Supplementary Data 
 
Table 4.6.1 Table of all differentially regulated microRNAs after treatment of MCF-7 
cells with 10-8 M 17-! estadiol for 4 hours. Values are ratios of vehicle control:17-! 
estradiol treatment after log 2 normalization.  
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Table 4.6.2 Table of all differentially regulated microRNAs after treatment of MCF-7 
cells with 10-8 M 17-! estadiol for 8 hours. Values are ratios of vehicle control:17-! 
estradiol treatment after log 2 normalization.  
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,-./<;=/(1! UGAGGUAGUAGUUUGUGCUGUU +4$%)''#*(!
,-./012/"$*/$7! GGAGACGCGGCCCUGUUGGAGU /+4$%#'$($$!
,-./012/&"+! UACUCAGGAGAGUGGCAAUCAC /+4#(&#"("!
,-./012/$#%/&7! ACUGCCCCAGGUGCUGCUGG /+4$"+")$&$!
,-./012/"%$8! GGUGCAGUGCUGCAUCUCUGGU /+4#)#%&%&!
,-./012/'""! GCGAGGACCCCUCGGGGUCUGAC /+4#((')""%!
,-./012/&''! GGGCGCCUGUGAUCCCAAC /+4#)**+*+$!
,-./012/$("/&7! ACUCAAACUGUGGGGGCACU /+4#(&"*'+&!
,-./012/&$#/$7!! CCUCCCACACCCAAGGCUUGCA +4%+'()#&%!
,-./012/*%+! AAGGCAGGGCCCCCGCUCCCC /+4$')(%+((!
,-./012/"(8! ACUGCAGUGAAGGCACUUGUAG /+4#))'&$('!
,-./012/%&$! AACUGUUUGCAGAGGAAACUGA +4$%&+*+)(!
,-./012/"#*/$7! AAGCCCUUACCCCAAAAAGCAU +4#)(%'((#!
,-./012/$%3!#! CAAUCACUAACUCCACUGCCAU +4%&+&*'%&!
,-./012/"%*8! AGGGAGGGACGGGGGCUGUGC /+4''&#+)'!
,-./012/&)&! UGGGCGUAUCUGUAUGCUA /+4&+&#&+#!
,-./012/&*'! AAGCCUGCCCGGCUCCUCGGG /+4$)%$$#*)!
 
Table 4.6.3 Table of all differentially regulated microRNAs after treatment of MCF-7 
cells with 10-8 M 17-! estadiol for 12 hours. Values are ratios of vehicle control:17-! 
estradiol treatment after log 2 normalization. 
'()*+,-.!-/'0! '()*+,-.!102304)0! ;+:!$!4+*'/6(107!1)+*0!!
,-./012/*#$.! GCAGCAGAGAAUAGGACUACGUC +4)""*"&!
,-./012/%#%! CAGCAGCAAUUCAUGUUUUGAA +4#$)("(($!
,-./012/"##(! CGUGCCACCCUUUUCCCCAG +4#$+$(#+*!
,-./012/"%&! GUCCAGUUUUCCCAGGAAUCCCU +4#$'*)%$!
,.-/012/"#$$! UGAGCCCUGUCCUCCCGCAG +4##&&($($!
,-./012/"*(! UUCACCACCUUCUCCACCCAGC +4"(&$"($*!
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,-./012/#"! UGUCGGGUAGCUUAUCAGACUGAU /+4&"%&($"(!
,-./012/"##)8! GUGGGCGGGGGCAGGUGUGUG /+4"+*#$%%(&!
,-./012/#+'! UGGAAUGUAAGGAAGUGUGUGG /+4#''('"%&!
,-./012/*#38! AGGGACGGGACGCGGUGCAGUG /+4$)*$&)#!
,-./012/'$)! AGGGAUCGCGGGCGGGUGGCGGCCU /+4*)++$$'!
,-./012/''$! AGGCGGGGCGCCGCGGGACCGC /"4##*%)$#!
 
Table 4.6.4 Table of all differentially regulated microRNAs after treatment of MCF-7 
cells with 10-8 M 17-! estadiol for 24 hours. Values are ratios of vehicle control:17-! 
estradiol treatment after log 2 normalization. 
'()*+,-.!-/'0! '()*+,-.!102304)0! ;+:!$!4+*'/6(107!1)+*0!!
,-./012/*#$.!! GCAGCAGAGAAUAGGACUACGUC "4$($'$&$!
,-./012/''$! AGGCGGGGCGCCGCGGGACCGC /"4('(#'$)!
,-./012/'$)! AGGGAUCGCGGGCGGGUGGCGGCCU /"4(&$)*!
,-./012/*#38! AGGGACGGGACGCGGUGCAGUG /"4$%(%!
,.-/012/"#$$!! UGAGCCCUGUCCUCCCGCAG +4'()"&!
,-./012/"*(! UUCACCACCUUCUCCACCCAGC +4'+(+*&%!
,-./012/"##)8! GUGGGCGGGGGCAGGUGUGUG /+4*%$"%!
,-./012/"##(!! CGUGCCACCCUUUUCCCCAG +4)""*"&!
,-./012/%#%!! CAGCAGCAAUUCAUGUUUUGAA +4(%'*)"!
,-./012/'#$! AUCCCUUGCAGGGGCUGUUGGGU /+4%$+''&#)!
,-./012/%$$! AUCAUGAUGGGCUCCUCGGUGU /+4&""')&'(!
,-./012/'"&/&7! GGGGGUCCCCGGUGCUCGGAUC /+4')##%$'&!
,-./012/$+.8! CUUUCAGUCGGAUGUUUGCAGC /+4%)()#)!
,-./012/"##'8! GUGAGGGCAUGCAGGCCUGGAUGGGG /+4&%#)#&%!
,-./012/)+".! CAGUAACAAAGAUUCAUCCUUGU /+4&)$&)'%!
,-./012/$$+/&7! UCUCUGGGCCUGUGUCUUAGGC /+4*&#&'%&%!
,-./012/))(! GUGAACGGGCGCCAUCCCGAGG /+4%"+)("&!
,-./012/'("/$7! UCCGGUUCUCAGGGCUCCACC /+4$'*)+%(!
,-./012/")'! CAAAGAAUUCUCCUUUUGGGCU /+4%$+(%'(!
,-./012/#&8! AGGCGGAGACUUGGGCAAUUG /+4$&%)*+)#!
,-./012/))'/&7! UCCAUUACACUACCCUGCCUCU /+4$"%"%)&#!
,-./012/*$$! UGUGCGCAGGGAGACCUCUCCC /+4%)"%)#"&!
,-./<;=/(1! UGAGGUAGUAGUUUGUGCUGUU +4$$*")%+)!
,-./012/"$*/$7! GGAGACGCGGCCCUGUUGGAGU /+4$*)#+(+%!
,-./012/&(%/$7!! CACGCUCAUGCACACACCCACA +4'$('%!
,-./012/&"+! UACUCAGGAGAGUGGCAAUCAC /+4$"&$'%"&!
,-./012/$#%/&7! ACUGCCCCAGGUGCUGCUGG /+4%&+$+#"#!
,-./012/"%$8! GGUGCAGUGCUGCAUCUCUGGU /+4$""$*+#&!
,-./012/'""! GCGAGGACCCCUCGGGGUCUGAC /+4%&&'&'(%!
,-./012/&$#/$7! CCUCCCACACCCAAGGCUUGCA +4&+''$$('!
,-./012/*%+! AAGGCAGGGCCCCCGCUCCCC /+4%''+'"#'!
,-./012/"(8! ACUGCAGUGAAGGCACUUGUAG /+4$#*$)(+%!
,-./012/%&$! AACUGUUUGCAGAGGAAACUGA +4%$"%((#)!
,-./<;=/(3! UGAGGUAGUAGGUUGUGUGGUU +4#($+'&$!
,-./012/#*'/&7! AGGGCCCCCCCUCAAUCCUGU /+4%($*"$&)!
,-./012/"#*/$7! AAGCCCUUACCCCAAAAAGCAU +4$$*#"#(!
,-./012/$%3! CAAUCACUAACUCCACUGCCAU +4&)&("#($!
,-./012/&#%/$7! GAAGGCGCUUCCCUUUGGAGU /+4$&&$)&"&!
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,-./012/'+#! GACACGGGCGACAGCUGCGGCCC /+4$%)(*""#!
,-./012/&*'! AAGCCUGCCCGGCUCCUCGGG /+4%(#+$)#(!
,-./012/'$%! AACCAGCACCCCAACUUUGGAC +4$'(#*')%!
,-./012/&"):/$7! CAAAGCGCUUCCCUUUGGAGC /+4$(#)$"+)!
,-./012/"*"8! GCUGCGCUUGGAUUUCGUCCCC /+4$+*$()%!
,-./012/&)&! UGGGCGUAUCUGUAUGCUA /+4'()&%'#&!
,-./012/#"! UGUCGGGUAGCUUAUCAGACUGAU /+4($'*'&&*!
,-./012/&+)/&7! UACUCCAGAGGGCGUCACUCAUG /+4&#*++)&(!
,-./012/%)'/$7! CGGGGCAGCUCAGUACAGGAU /+4#*&)&*!
,-./012/'+*! AGGGUGUUUCUCUCAUCUCU /+4$""+&("!
,-./012/"$&38! AUGUAGGGCUAAAAGCCAUGGG /+4$++%++'%!
,-./012/&"*.8! CUCUAGAGGGAAGCGCUUUCUG /+4$%)%'$'&!
,-./012/'%'! AAGCAGCUGCCUCUGAGGC /+4$+*+)%'&!
,-./012/'&+! AGGAGGCAGCGCUCUCAGGAC /+4#)%*"*((!
,-./012/&+$! UAGCAGCGGGAACAGUUCUGCAG /+4$*$##'!
,-./012/$$"/$7! GCCCCUGGGCCUAUCCUAGAA /+4#*+)+(%!
,-./012/&#$! GAACGCGCUUCCCUAUAGAGGGU /+4#*+*+#($!
,-./012/&##8! CUCUAGAGGGAAGCGCUUUCUG /+4$"'"#&)%!
,-./012/'&#! AAUGGCGCCACUAGGGUUGUG /+4$$)"#(('!
,-./012/&"*3/&7! CUCUAGAGGGAAGCGCUUUCUG /+4$$'+#("&!
,-./012/&"*9/&7! CUCUAGAGGGAAGCGCUUUCUG /+4$(%$"("%!
 
Table 4.6.5 Table of all differentially regulated microRNAs found after treatment of 
MCF-7 cells with 10-7M PhIP for 4 hours. Values are ratios of vehicle control:PhIP 
treatment after log 2 normalization. 
'()*+,-.!-/'0! '()*+,-.!102304)0! ;+:!$!4+*'/6(107!<)+*0!
,-./012/*#$.! GCAGCAGAGAAUAGGACUACGUC "4#$%#)%!
,-./012/''$! AGGCGGGGCGCCGCGGGACCGC /"4#''&&#"!
,-./012/'$)! AGGGAUCGCGGGCGGGUGGCGGCCU /"4+&''%##!
,-./012/*#38! AGGGACGGGACGCGGUGCAGUG /+4'*'$#$%!
,.-/012/"#$$! UGAGCCCUGUCCUCCCGCAG +4#)'((&!
,-./012/#(.! UUCACAGUGGCUAAGUUCCGC /+4$+#&!
,-./012/"+'3! UAAAGUGCUGACAGUGCAGAU /+4$%'+#'%#!
,-./012/$+9! UGUAAACAUCCUACACUCUCAGC +4''%#('"!
,-./012/"*$./$7! AACUGGCCUACAAAGUCCCAGU /+4$&#"&!
,-./012/$+:! UGUAAACAUCCCCGACUGGAAG /+4$&!
,-./012/#'.! UUCAAGUAAUCCAGGAUAGGCU /+4$(&)#!
,-./012/#$3! AUCACAUUGCCAGGGAUUACC /+4$%*)%!
,-./012/*$! CAAAGUGCUGUUCGUGCAGGUAG /+4#*#))!
,-./012/'(&! UGGUGCGGAGAGGGCCCACAGUG /+4$+&()%*!
,-./012/'("/&7! AGGAAGCCCUGGAGGGGCUGGAG /+4%)')+$+&!
,-./012/%*+/&7! CCAUGGAUCUCCAGGUGGGU /+4$)$+%$$#!
,-./012/'#$! AUCCCUUGCAGGGGCUGUUGGGU /+4$'*%%(+)!
,-./012/%$$! AUCAUGAUGGGCUCCUCGGUGU /+4%$)"%%*&!
,-./012/"##&/&7! GUGGGUACGGCCCAGUGGGGGG /+4%$('%'#%!
,-./012/'"&/&7! GGGGGUCCCCGGUGCUCGGAUC /+4'""+&&(!
,-./012/*$*! UGGGGAGCUGAGGCUCUGGGGGUG /+4$*%%+'$&!
,-./012/"#&./$7! ACAGGUGAGGUUCUUGGGAGCC /+4$+""&&$'!
,-./012/'&%/&7! UGGUGGGCCGCAGAACAUGUGC /+4&*+'%*)%!
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,-./012/#&! CAUUGCACUUGUCUCGGUCUGA /+4$#%""+'!
,-./012/"&+8! CUGGUACAGGCCUGGGGGACAG /+4&*#%&#(!
,-./012/$+.8! CUUUCAGUCGGAUGUUUGCAGC /+4%+#"$'&$!
,-./012/%#$/$7! AGCUCGGUCUGAGGCCCCUCAGU /+4#*'$('&$!
,-./012/"##'8! GUGAGGGCAUGCAGGCCUGGAUGGGG /+4%*%*)#"#!
,-./012/$+;8! CUUUCAGUCGGAUGUUUACAGC /+4$")*%+##!
,-./012/)+".! CAGUAACAAAGAUUCAUCCUUGU /+4'%(%(&#%!
,-./012/'"#! GCUGGGCAGGGCUUCUGAGCUCCUU /+4'+&*&$#!
,-./012/&")98! UCUCUGGAGGGAAGCACUUUCUG /+4'%&$"&#!
,-./012/$$+/&7! UCUCUGGGCCUGUGUCUUAGGC /+4)*'+*)&&!
,-./012/%)$/&7! AAGACGGGAGGAAAGAAGGGAG +4$""##'&!
,-./012/#"8! CAACACCAGUCGAUGGGCUGU /+4$#&$)"#&!
 
Table 4.6.6 Table of all differentially regulated microRNAs found after treatment of 
MCF-7 cells with 10-7M PhIP for 8 hours. Values are ratios of vehicle control:PhIP 
treatment after log 2 normalization. 
'()*+,-.!-/'0! '()*+,-.!102304)0! ;+:!$!4+*'/6(107!1)+*0!!
,-./012/*#$.! GCAGCAGAGAAUAGGACUACGUC "4+$#%##%!
,-./012/''$! AGGCGGGGCGCCGCGGGACCGC /"4"$")%%#!
,-./012/'$)! AGGGAUCGCGGGCGGGUGGCGGCCU /"4"(&%*$'!
,-./012/*#38! AGGGACGGGACGCGGUGCAGUG /+4)#(%+&&!
,.-/012/"#$$! UGAGCCCUGUCCUCCCGCAG +4%&&(('!
,-./012/#(.! UUCACAGUGGCUAAGUUCCGC /+4%(*#+%((!
,-./012/"+'3! UAAAGUGCUGACAGUGCAGAU /+4%(++)**%!
,-./012/$+9! UGUAAACAUCCUACACUCUCAGC +4'%"#*&!
,-./012/"*$./$7! AACUGGCCUACAAAGUCCCAGU /+4%&'%"!
,-./012/$+:! UGUAAACAUCCCCGACUGGAAG /+4%*'""*)'!
,-./012/#'.! UUCAAGUAAUCCAGGAUAGGCU /+4&)&+#$*%!
,-./012/#$3! AUCACAUUGCCAGGGAUUACC /+4%'+(++$'!
,-./012/*$! CAAAGUGCUGUUCGUGCAGGUAG /+4%#*(&""$!
,-./012/'(&! UGGUGCGGAGAGGGCCCACAGUG /+4$$')+&$%!
,-./012/'("/&7! AGGAAGCCCUGGAGGGGCUGGAG /+4&#+%(&%!
,-./012/%*+/&7! CCAUGGAUCUCCAGGUGGGU /+4%#&)$$(!
,-./012/'#$! AUCCCUUGCAGGGGCUGUUGGGU /+4$'$&%($&!
,-./012/%$$! AUCAUGAUGGGCUCCUCGGUGU /+4%&)(()%!
,-./012/"##&/&7! GUGGGUACGGCCCAGUGGGGGG /+4%)")&+'&!
,-./012/'"&/&7! GGGGGUCCCCGGUGCUCGGAUC /+4'$"(&&&$!
,-./012/*$*! UGGGGAGCUGAGGCUCUGGGGGUG /+4%$'")'%'!
,-./012/"#&./$7! ACAGGUGAGGUUCUUGGGAGCC /+4$#$&(%"!
,-./012/'&%/&7! UGGUGGGCCGCAGAACAUGUGC /+4%()#)$)&!
,-./012/#&! CAUUGCACUUGUCUCGGUCUGA /+4$'#%)#+%!
,-./012/"&+8! CUGGUACAGGCCUGGGGGACAG /+4'""+***!
,-./012/$+.8! CUUUCAGUCGGAUGUUUGCAGC /+4%+*")%)!
,-./012/%#$/$7! AGCUCGGUCUGAGGCCCCUCAGU /+4$)+*&%((!
,-./012/"##'8! GUGAGGGCAUGCAGGCCUGGAUGGGG /+4%)*$%&*!
,-./012/$+;8! CUUUCAGUCGGAUGUUUACAGC /+4$$#($$"&!
,-./012/)+".! CAGUAACAAAGAUUCAUCCUUGU /+4&''"***'!
,-./012/'"#! GCUGGGCAGGGCUUCUGAGCUCCUU /+4&%'*#&&%!
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"#*
,-./012/&")98! UCUCUGGAGGGAAGCACUUUCUG /+4'&#(%+#!
,-./012/$$+/&7! UCUCUGGGCCUGUGUCUUAGGC /+4)$&)"('%!
,-./012/"+(! AGCAGCAUUGUACAGGGCUAUCA /+4#*)%$'##!
,-./012/#$.! AUCACAUUGCCAGGGAUUUCC /+4$'#%$))$!
,-./012/"+$! AGCAGCAUUGUACAGGGCUAUGA /+4#**+'&*#!
,-./012/#*.! UAGCACCAUCUGAAAUCGGUUA /+4#)"&')#!
,-./012/"*$3! AACUGGCCCUCAAAGUCCCGCU /+4%%%#(*'(!
,-./<;=/(.! UGAGGUAGUAGGUUGUAUAGUU /+4%%#%&*%$!
,-./012/"%"! UAACACUGUCUGGUAAAGAUGG /+4%$+"'(#!
,-./012/"$(! UUAUUGCUUAAGAAUACGCGUAG +4#()("#+'!
,-./012/('*/$7! CUGGGAUCUCCGGGGUCUUGGUU /+4$$($'&&!
,-./012/"#&./&7! UCCCUGAGACCCUUUAACCUGUGA /+4%&'%+('%!
,-./012/"##(! CGUGCCACCCUUUUCCCCAG +4#($'%%%)!
,-./012/('+! CGGCUCUGGGUCUGUGGGGA /+4$+++"%"(!
,-./012/#%! UGGCUCAGUUCAGCAGGAACAG /+4%%"*+$(%!
,-./012/$$.! GUGCAUUGUAGUUGCAUUGCA +4$+'+%'"$!
,-./012/")#! UUUGGCAAUGGUAGAACUCACACU /+4$&%(#'&&!
,-./012/&(%/&7! UGAGUGUGUGUGUGUGAGUGUGU +4'+"$++*!
,-./012/**38! CAAGCUCGUGUCUGUGGGUCCG /+4$(+"%++&!
,-./012/%*%! UGAAACAUACACGGGAAACCUC +4&+)&%'((!
,-./012/%#"! AUCAACAGACAUUAAUUGGGCGC /+4$)$'$+()!
,-./012/'#+! AUGGAGAUAGAUAUAGAAAU +4$%%'&#)'!
,-./012/"##%/&7! GUGAGGACUCGGGAGGUGG /+4#(#'))*!
,-./012/#"! UAGCUUAUCAGACUGAUGUUGA /+4($+$+&*(!
,-./012/$'$8! CGGGUGGAUCACGAUGCAAUUU /+4$'#(*$*!
,-./012/#++9! UAAUACUGCCGGGUAAUGAUGGA /+4&+%%"!
,-./<;=/(38! CUAUACAACCUACUGCCUUCCC +4$"#'*&&!
,-./012/"'! UAGCAGCACGUAAAUAUUGGCG /+4''#+'&(%!
,-./012/#*'/$7! GAGGGUUGGGUGGAGGCUCUCC /+4%#*$$*+)!
,-./012/))&/&7! UCCAUUACACUACCCUGCCUCU +4%+*+&&*)!
 
Table 4.6.7 Table of all differentially regulated microRNAs found after treatment of 
MCF-7 cells with 10-7M PhIP for 12 hours. Values are ratios of vehicle control:PhIP 
treatment after log 2 normalization. 
'()*+,-.!-/'0! '()*+,-.!102304)0! ;+:!$!4+*'/6(107!1)+*0!
,-./012/*#$.! GCAGCAGAGAAUAGGACUACGUC +4*)#*'%!
,-./012/$+9! UGUAAACAUCCUACACUCUCAGC +4'*"%(!
,.-/012/"#$$! UGAGCCCUGUCCUCCCGCAG +4#*+$"'!
,-./012/")&8! AGGGGCUGGCUUUCCUCUGGUC /+4")*++%#$!
,-./012/('(/&7! UGCACCAUGGUUGUCUGAGCAUG /+4#$'**$#!
,-./012/"+'3! UAAAGUGCUGACAGUGCAGAU /+4#((&(!
,-./012/#"! UGUCGGGUAGCUUAUCAGACUGAU /+4&"%&($"(!
,-./012/#(.! UUCACAGUGGCUAAGUUCCGC /+4#)$("(%)!
,-./012/"#&3! UCCCUGAGACCCUAACUUGUGA /+4$+&)*(+$!
,-./012/*$! CAAAGUGCUGUUCGUGCAGGUAG /+4$"$"&!
,-./012/#$3! AUCACAUUGCCAGGGAUUACC /+4$##"$!
,-./012/$+:! UGUAAACAUCCCCGACUGGAAG /+4$'"&'!
,-./012/#'.! UUCAAGUAAUCCAGGAUAGGCU /+4$))(#!
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,-./012/"*$./$7! AACUGGCCUACAAAGUCCCAGU /+4%%)""!
,-./012/*#38!! AGGGACGGGACGCGGUGCAGUG /+4&%&(*!
,-./012/"!! UGGAAUGUAAAGAAGUAUGUAU /+4&*&+*!
,-./012/'$)!! AGGGAUCGCGGGCGGGUGGCGGCCU /+4)")($!
,-./012/''$!! AGGCGGGGCGCCGCGGGACCGC /"4+(*("!
 
Table 4.6.8 Table of all differentially regulated microRNAs found after treatment of 
MCF-7 cells with 10-7M PhIP for 24 hours. Values are ratios of vehicle control:PhIP 
treatment after log 2 normalization. 
 
 
a: MiRBase (version 20) indicates that miR-923 is a fragment of the 28S ribosomal 
RNA and miR-801 is a fragment of the U11 spliceosomal RNA. Hence these 
microRNA were not subsequently considered.  
 
 
 
 
 
'()*+,-.!-/'0! '()*+,-.!102304)0! ;+:!$!4+*'/6(107!1)+*0!=$@9*?!
,-./012/*#$! GCAGCAGAGAAUAGGACUACGUC "4#(#(&!
,-./012/''$! AGGCGGGGCGCCGCGGGACCGC /"4+)+&"'#!
,-./012/'$)! AGGGAUCGCGGGCGGGUGGCGGCCU /"4+%'**!
,-./012/*#38! AGGGACGGGACGCGGUGCAGUG /+4(('"*!
,.-/012/"#$$! UGAGCCCUGUCCUCCCGCAG +4($%$+%!
,-./012/#(.! UUCACAGUGGCUAAGUUCCGC /+4&)%+%!
,-./012/"+'3! UAAAGUGCUGACAGUGCAGAU /+4'"#(#!
,-./012/$+9! UGUAAACAUCCUACACUCUCAGC +4&+)($$!
,-./012/"*$./$7! AACUGGCCUACAAAGUCCCAGU /+4'"$%'!
,-./012/#"! UGUCGGGUAGCUUAUCAGACUGAU /+4'''&(!
,-./012/$+:! UGUAAACAUCCCCGACUGGAAG /+4(&*)'!
,-./012/#'.! UUCAAGUAAUCCAGGAUAGGCU /+4)"%+(!
,-./012/#$3! AUCACAUUGCCAGGGAUUACC /+4&(($(!
,-./012/*$! CAAAGUGCUGUUCGUGCAGGUAG /+4&+##$!
,-./012/$+.8! CUUUCAGUCGGAUGUUUGCAGC /+4%+"#'$)'!
,-./012/"##'8! GUGAGGGCAUGCAGGCCUGGAUGGGG /+4&$())")&!
,-./012/)+".! CAGUAACAAAGAUUCAUCCUUGU /+4'&*$*%*!
,-./012/$$+/&7! UCUCUGGGCCUGUGUCUUAGGC /+4(*'$**"!
,-./012/&(%/&7! UGAGUGUGUGUGUGUGAGUGUGU +4($*"""*!
,-./012/"+'38! CCGCACUGUGGGUACUUGCUGC /+4$"()#)%&!
,-./012/&(#! GUCCGCUCGGCGGUGGCCCA /+4#('$"&(!
,-./012/'#$! AUCCCUUGCAGGGGCUGUUGGGU /+4$*+')*)#!
,-./012/%$$! AUCAUGAUGGGCUCCUCGGUGU /+4&&+"%""!
,-./012/'"&/&7! GGGGGUCCCCGGUGCUCGGAUC /+4'%()$'!
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Table 4.6.9 Table of upregulated microRNAs in published studies. The microRNA 
identity and cell type or tissue where the finding was made and relevant publication 
are presented.  
miRNA Human cell line/tissue miRNA Human cell line/tissue 
let-7 
family 
MCF-7 cells (Paris et al., 2012). miR-203 MCF-7 cells (Klinge, 2009) 
miR-7 MCF-7 cells (Klinge, 2009 and Masuda 
et al, 2012) 
miR-205  ER! stably expressing SW480 colon 
cancer cells (Edvardsson et al., 2013) 
miR-10a 
miR-10b 
ER! stably expressing SW480 colon 
cancer cells (Edvardsson et al., 2013) 
miR-206 ER!-selective agonist in MCF-7 cells 
(Adams et al., 2007) 
miR-15a MCF-7 cells (Klinge, 2009) miR-210 ZR-75-1 cells (Ferraro et al., 2012) 
miR-16-
1* 
ZR-75-1 cells (Ferraro et al., 2012) miR-216a MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
MCF-7 cells stably overexpressing 
inducible ER! or ER# (Paris et al., 2012) 
miR-16-
2* 
T47D cells (Katchy et al., 2012) miR-219-5p MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
miR-17* MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
miR-222 MCF-7 cells (Tilghman et al., 2012) 
miR-17-
3p 
MCF-7 stably transfected to overexpress 
the aromatase gene (MCF-7aro) (Masri 
et al., 2010) 
miR-223 MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
miR-17–
92 
MCF-7 cells (Castellano et al, 2009, 
Masuda et al, 2012 and Wang et al, 2010) 
miR-301b MCF-7 cells (Wang et al., 2010) 
miR-18a ZR-75-1 cells (Ferraro et al., 2012) miR-320 Ishikawa and ECC-1 ER#+ human 
endometrial cancer cells (Zhang et al., 
2012) 
miR-18a* MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
MCF-7 cells stably overexpressing 
inducible ER! or ER# (Paris et al., 2012) 
miR-320a MCF-7 cells (Tilghman et al., 2012) 
miR-18b MCF-7 cells (Ferraro et al., 2012) miR-320c MCF-7 cells (Tilghman et al., 2012) 
miR-19a, 
19b 
MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
MCF-7 cells stably overexpressing 
miR-330-5p MCF-7 cells stably overexpressing 
inducible ER! not ER# (Paris et al., 2012) 
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inducible ER! or ER# (Paris et al., 2012). 
miR-19b-
1 
MCF-7 cells (Ferraro et al., 2012) miR-335 MCF-7 and ZR-75-1 cells, but not at 24!h 
(Ferraro et al., 2012) 
miR-19b MCF-7 cells stably overexpressing 
inducible ER! or ER# (Paris et al., 2012) 
miR-342 MCF-7-HER2 cells, (Cittelly et al., 2010) 
miR-20a* MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
MCF-7 cells stably overexpressing 
inducible ER! or ER# (Paris et al., 2012) 
miR-363 ZR-75-1 cells, (Ferraro et al., 2012) 
miR-22  MCF-7 cells (Huang et al., 2014) miR-365 MCF-7 cells (Klinge, 2009) 
miR-23b* MCF-7 cells stably overexpressing 
inducible ER! but not ER# (Paris et al., 
2012) 
miR-374a* MCF-7 and ZR-75-1 cells, (Ferraro et al., 
2012) 
miR-24 MCF-7 cells (Tilghman et al., 2012) miR-375 ZR-75-1 cells, (Ferraro et al., 2012) 
miR-24-
1* 
MCF-7 cells stably overexpressing 
inducible ER! but not ER# (Paris et al., 
2012) 
miR-376b ZR-75-1 (Ferraro et al., 2012) 
miR-25 MCF-7 cells (Klinge, 2009 and Masuda 
et al, 2012) 
miR-423-5p MCF-7 cells (Tilghman et al., 2012) 
miR-25* MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
miR-424 MCF-7 cells (Cicatiello et al., 2010) 
miR-26a Primary human myometrial smooth muscle 
cells (MSMC) (Pan et al., 2008) 
miR-424* MCF-7 and ZR-75-1 cells, but not at 24!h 
(Ferraro et al., 2012) 
miR-27a 1!&M E2 in Ishikawa and ECC-1 ER#+ 
human endometrial cancer cells (Zhang 
et al., 2012) 
miR-425 Ishikawa and ECC-1 ER#+ human 
endometrial cancer cells (Zhang et al., 
2012) 
MCF-7 cells (Di Leva et al., 2013) 
miR-27b MCF-7 cells (Masuda et al., 2012) miR-449a ZR-75-1 cells (Ferraro et al., 2012) 
miR-29a MCF-7 cells (Masuda et al., 2012) miR-450b-3p,5p MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
miR-29b-
2* 
MCF-7 cells stably overexpressing 
inducible ER! but inhibited by ER# (Paris 
et al., 2012) 
miR-455-5p, 
455-3p 
ZR-75-1 cells (Ferraro et al., 2012) 
miR-29c T47D cells (Katchy et al., 2012) miR-484 MCF-7 cells (Tilghman et al., 2012) 
miR-30b MCF-7 cells (Klinge, 2009) miR-489 MCF-7 and ZR-75-1 cells (Ferraro et al., 
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2012) 
miR-30d 1!&M E2 in Ishikawa ER#+ human 
endometrial cancer cells (Zhang et al., 
2012) 
miR-491-3p ZR-75-1 cells (Ferraro et al., 2012) 
miR-32 MCF-7 cells stably overexpressing 
inducible ER! (Paris et al., 2012) 
miR-499-5p ZR-75-1 cells (Ferraro et al., 2012) 
miR-33a MCF-7 cells (Ferraro et al., 2012) miR-542-5p 10!nM E2 for 72!h in MCF-7 cells (Ferraro 
et al., 2012) 
miR-92 MCF-7 cells (Ferraro et al., 2012) miR-542-3p MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
miR-92a 1 ECC-1 ER#+ human endometrial cancer 
cells (Zhang et al., 2012) 
1! MCF-7 cells (Tilghman et al., 2012) 
miR-548d-3p ZR-75-1 cells (Ferraro et al., 2012) 
MCF-7 cells stably overexpressing 
inducible ER!, but not ER# (Paris et al., 
2012) 
miR-92a-
1* 
MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
miR-548e ZR-75-1 cells (Ferraro et al., 2012) 
miR-92b MCF-7 cells (Tilghman et al., 2012) miR-550 MCF-7 cells (Ferraro et al., 2012) 
miR-93 MCF-10A and T47D cells (Singh et al., 
2013). MCF-7 cells (Tilghman et al., 2012) 
miR-556-5p MCF-7 and ZR-75-1 cells, but not at 24!h 
(Ferraro et al., 2012) 
miR-98 MCF-7 cells (Klinge, 2009) miR-560:9.1 MCF-7 cells (Ferraro et al., 2012) 
miR-99b MCF-7 cells (Tilghman et al., 2012) miR-564 ZR-75-1 cells (Ferraro et al., 2012) 
miR-101 MCF-7 cells (Kim et al., 2013) miR-574-5p Ishikawa ER#+ human endometrial cancer 
cells (Zhang et al., 2012) 
MCF-7 cells (Thesis) 
miR-101* MCF-7 cells stably overexpressing 
inducible ER!  
miR-574-3p MCF-7 cells (Thesis) 
miR-103 MCF-7 cells (Tilghman et al., 2012) miR-579 ZR-75-1 cells (Ferraro et al., 2012) 
miR-122 ZR-75-1 cells (Ferraro et al., 2012) miR-590-3p ZR-75-1 cells (Ferraro et al., 2012) 
miR-124 MCF-7 cells (Masuda et al., 2012) miR-594:9.1 MCF-7 cells (Ferraro et al., 2012) 
miR-130b MCF-7 cells (Wang et al., 2010) miR-615-3p MCF-7 cells (Kim et al., 2013) 
miR-135a 1 MCF-7 cells (Kim et al., 2013) miR-628-5p ZR-75-1 cells (Ferraro et al., 2012) 
miR-135b ZR-75-1 cells (Ferraro et al., 2012) miR-638 MCF-7 cells (Tilghman et al., 2012) 
miR-142-
3p 
MCF-7 cells (Ferraro et al., 2012) miR-643 ZR-75-1 cells (Ferraro et al., 2012) 
miR-148 MCF-7 cells (Masuda et al., 2012) miR-651 ZR-75-1 cells (Ferraro et al., 2012) 
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miR-149 MCF-7 cells (Masuda et al., 2012) miR-652 ZR-75-1 cells, but not at 6 or 12!h (Ferraro 
et al., 2012) 
miR-151-
5p 
MCF-7 cells (Tilghman et al., 2012) miR-653 MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
miR-155 MCF-7 cells (Zhang et al., 2013) miR-653:9.1 MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
miR-181a Ishikawa ER#+ human endometrial cancer 
cells (Zhang et al., 2012) 
miR-660 ZR-75-1 cells (Ferraro et al., 2012) 
miR-181d MCF-7 cells (Masuda et al., 2012) miR-663 MCF-7 cells (Tilghman et al., 2012) 
miR-186 MCF-7 cells (Ferraro et al., 2012). miR-663b ZR-75-1 cells (Ferraro et al., 2012) 
MCF-7 cells stably overexpressing 
inducible ER! or ER# (Paris et al., 2012) 
miR-190 ZR-75-1 cells (Ferraro et al., 2012) miR-708 ZR-75-1 cells (Ferraro et al., 2012) 
miR-190a MCF-7 cells (Chu et al., 2014). miR-720 MCF-7 cells (Tilghman et al., 2012) 
miR-190b MCF-7 cells (Ferraro et al., 2012). miR-760 MCF-7 cells (Cicatiello et al., 2010) 
miR-191 MCF-7 cells (Di Leva et al., 2013) miR-886-3p MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
miR-
193a-5p 
MCF-7 cells (Tilghman et al., 2012) miR-938 MCF-7 cells (Razandi et al., 2000) 
miR-193b MCF-7 cells (Wang et al., 2010) miR-939 MCF-7 cells (Ferraro et al., 2012) 
miR-194 MCF-7 cells (Ferraro et al., 2012) miR-940 MCF-7 cells (Ferraro et al., 2012) 
miR-195 MCF-7 cells (Klinge, 2009) miR-942 MCF-7 and ZR-75-1 cells (Ferraro et al., 
2012) 
miR-195* ZR-75-1 cells  (Ferraro et al., 2012) miR-944 MCF-7 cells (Razandi et al., 2000) 
miR-
196a2* 
MCF-7 cells (Kim et al., 2013) miR-1206 MCF-7 cells (Ferraro et al., 2012) 
miR-198 T47D cells (Katchy et al., 2012) miR-122 MCF-7 cells (Ferraro et al., 2012) 
miR-
199a/b-3p 
ZR-75-1 cells, (Ferraro et al., 2012) miR-1248 MCF-7 cells (Ferraro et al., 2012) 
miR-
199a-5p 
MCF-7 cells stably overexpressing 
inducible ER! or ER# (Paris et al., 2012). 
  
miR-200a MCF-7 cells (Klinge, 2009)   
miR-200c MCF-10A cells Rokavec et al., 2012).   
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Table 4.6.10 Table of downregulated microRNAs in published studies. The 
microRNA identity, cell type or tissue where the finding was made and relevant 
publication are presented.   
miRNA Human cell line/tissue miRNA Human cell line/tissue 
let-7 family MCF-7 cells (Bhat-Nakshatri et al., 2009). 
(Cochrane et al, 2010 and Klinge, 2009) 
miR-222 MCF-7 cells (Tilghman et al., 2012) 
miR-7 MCF-7 cells (Klinge, 2009 and Masuda et al, 
2012) 
miR-223 MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
miR-10a 
miR-10b 
ER! stably expressing SW480 colon cancer cells 
(Edvardsson et al., 2013) 
miR-301b MCF-7 cells (Wang et al., 2010) 
miR-15a MCF-7 cells (Klinge, 2009) miR-320 Ishikawa and ECC-1 ER#+ human endometrial 
cancer cells (Zhang et al., 2012) 
miR-16-1* ZR-75-1 cells (Ferraro et al., 2012) miR-320a MCF-7 cells (Tilghman et al., 2012) 
miR-16-2* T47D cells (Katchy et al., 2012) miR-320c MCF-7 cells (Tilghman et al., 2012) 
miR-17* MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) miR-330-5p MCF-7 cells stably overexpressing inducible 
ER! not ER# (Paris et al., 2012) 
miR-17-3p MCF-7 stably transfected to overexpress the 
aromatase gene (MCF-7aro) (Masri et al., 2010) 
miR-335 MCF-7 and ZR-75-1 cells, but not at 24!h 
(Ferraro et al., 2012) 
miR-17–92 MCF-7 cells (Castellano et al, 2009, Masuda 
et al, 2012 and Wang et al, 2010) 
miR-342 MCF-7-HER2 cells (Cittelly et al., 2010) 
miR-18a ZR-75-1 cells (Ferraro et al., 2012) miR-363 ZR-75-1 cells, (Ferraro et al., 2012) 
miR-18a* MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
MCF-7 cells stably overexpressing inducible ER! 
or ER# (Paris et al., 2012) 
miR-365 MCF-7 cells (Klinge, 2009) 
miR-18b MCF-7 cells (Ferraro et al., 2012) 
MCF-7 cells stably overexpressing inducible ER! 
or ER#-downregulated at 24 and 72!h (Paris et al., 
2012) 
miR-374a* MCF-7 and ZR-75-1 cells, (Ferraro et al., 2012) 
miR-19a, 
19b 
MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) miR-375 ZR-75-1 cells, (Ferraro et al., 2012) 
miR-19b-1 MCF-7 cells (Ferraro et al., 2012) miR-376b ZR-75-1 cells (Ferraro et al., 2012) 
miR-19b MCF-7 cells stably overexpressing inducible ER! 
or ER# (Paris et al., 2012) 
miR-423-5p MCF-7 cells (Tilghman et al., 2012) 
miR-20a* MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
MCF-7 cells stably overexpressing inducible ER! 
miR-424 MCF-7 cells (Cicatiello et al., 2010) 
MCF-7 cells (Ferraro et al., 2012) 
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or ER# (Paris et al., 2012) 
miR-23b* MCF-7 cells stably overexpressing inducible ER! 
but not ER# (Paris et al., 2012) 
miR-424* MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
miR-24 MCF-7 cells (Tilghman et al., 2012) miR-425 Ishikawa and ECC-1 ER#+ human endometrial 
cancer cells (Zhang et al., 2012) 
MCF-7 cells (Di Leva et al., 2013) 
miR-24-1* MCF-7 cells stably overexpressing inducible ER! 
but not ER# (Paris et al., 2012) 
miR-449a ZR-75-1 cells, (Ferraro et al., 2012) 
miR-25 MCF-7 cells (Klinge, 2009 and Masuda et al, 
2012) 
miR-450b-
3p,5p 
MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
miR-25* MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) miR-455-5p, 
455-3p 
ZR-75-1 cells (Ferraro et al., 2012) 
miR-26a Primary human myometrial smooth muscle cells 
(MSMC) (Pan et al., 2008) 
miR-484 MCF-7 cells (Tilghman et al., 2012) 
miR-27a Ishikawa and ECC-1 ER#+ human endometrial 
cancer cells (Zhang et al., 2012) 
miR-489 MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
miR-27b MCF-7 cells (Masuda et al., 2012) miR-491-3p ZR-75-1 cells (Ferraro et al., 2012) 
miR-29a MCF-7 cells (Masuda et al., 2012) miR-499-5p ZR-75-1 cells (Ferraro et al., 2012) 
miR-29b-2* MCF-7 cells stably overexpressing inducible ER! 
but inhibited by ER# (Paris et al., 2012) 
miR-520d MCF-7 cells stably expressing a constitutively 
active AKT (Bhat-Nakshatri et al., 2009) 
miR-29c T47D cells (Katchy et al., 2012) miR-542-5p MCF-7 cells (Ferraro et al., 2012) 
miR-30b MCF-7 cells (Klinge, 2009) miR-542-3p MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
miR-30d Ishikawa ER#+ human endometrial cancer cells 
(Zhang et al., 2012) 
miR-548d-3p ZR-75-1 cells (Ferraro et al., 2012) 
MCF-7 cells stably overexpressing inducible 
ER!, but not ER# (Paris et al., 2012) 
miR-32 MCF-7 cells stably overexpressing inducible ER! 
(Paris et al., 2012) 
miR-548e ZR-75-1 cells (Ferraro et al., 2012) 
miR-33a MCF-7 cells (Ferraro et al., 2012) miR-550 MCF-7 cells (Ferraro et al., 2012) 
miR-92 MCF-7 cells (Ferraro et al., 2012) miR-556-5p MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
MCF-7 cells stably overexpressing inducible 
ER! or ER# (Paris et al., 2012) 
miR-92a ER#+ human endometrial cancer cells (Zhang 
et al., 2012) 
MCF-7 cells (Tilghman et al., 2012) 
miR-560:9.1 MCF-7 cells (Ferraro et al., 2012) 
miR-92a-1* MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) miR-564 ZR-75-1 cells (Ferraro et al., 2012) 
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miR-92b MCF-7 cells (Tilghman et al., 2012) miR-574-5p Ishikawa ER#+ human endometrial cancer cells 
(Zhang et al., 2012) 
MCF-7 cells (Thesis) 
miR-93 MCF-10A and T47D cells (Singh et al., 2013). 
MCF-7 cells (Tilghman et al., 2012) 
miR-574-3p MCF-7 cells (Thesis) 
miR-98 MCF-7 cells (Klinge, 2009) miR-579 ZR-75-1 cells (Ferraro et al., 2012) 
miR-99b MCF-7 cells (Tilghman et al., 2012) miR-590-3p ZR-75-1 cells (Ferraro et al., 2012) 
miR-101 MCF-7 cells (Kim et al., 2013) miR-594:9.1 MCF-7 cells (Ferraro et al., 2012) 
miR-101* MCF-7 cells stably overexpressing inducible ER! 
(72!h) but not ER# (Paris et al., 2012) 
miR-615-3p MCF-7 cells (Kim et al., 2013) 
miR-103 MCF-7 cells (Tilghman et al., 2012) miR-628-5p ZR-75-1 cells (Ferraro et al., 2012) 
miR-122 ZR-75-1 cells (Ferraro et al., 2012) miR-638 MCF-7 cells (Tilghman et al., 2012) 
miR-124 MCF-7 cells (Masuda et al., 2012) miR-643 ZR-75-1 cells (Ferraro et al., 2012) 
miR-130b MCF-7 cells (Wang et al., 2010) miR-651 ZR-75-1 cells (Ferraro et al., 2012) 
miR-135a MCF-7 cells (Kim et al., 2013) 
MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
miR-652 ZR-75-1 cells (Ferraro et al., 2012) 
miR-135b ZR-75-1 cells (Ferraro et al., 2012) miR-653 MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
miR-142-3p MCF-7 cells (Ferraro et al., 2012) miR-653:9.1 MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
miR-148 MCF-7 cells (Masuda et al., 2012) miR-660 10!nM E2 for 6, 12, 24, and 72!h in ZR-75-1 cells 
(Ferraro et al., 2012) 
miR-149 MCF-7 cells (Masuda et al., 2012) miR-663 MCF-7 cells (Tilghman et al., 2012) 
miR-151-5p MCF-7 cells (Tilghman et al., 2012) miR-663b ZR-75-1 cells (Ferraro et al., 2012) 
MCF-7 cells stably overexpressing inducible 
ER! or ER# (Paris et al., 2012) 
miR-155 MCF-7 cells (Zhang et al., 2013) miR-708 ZR-75-1 cells (Ferraro et al., 2012) 
miR-181a Ishikawa ER#+ human endometrial cancer cells 
(Zhang et al., 2012) 
miR-720 MCF-7 cells (Tilghman et al., 2012) 
miR-181d MCF-7 cells (Masuda et al., 2012) miR-760 MCF-7 cells (Cicatiello et al., 2010) 
MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
miR-186 MCF-7 cells (Ferraro et al., 2012). miR-886-3p MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
miR-190 ZR-75-1 cells, (Ferraro et al., 2012) miR-938 MCF-7 cells (Razandi et al., 2000) 
miR-190a MCF-7 cells (Chu et al., 2014). miR-939 MCF-7 cells (Ferraro et al., 2012) 
miR-190b MCF-7 cells (Ferraro et al., 2012). miR-940 MCF-7 cells (Ferraro et al., 2012) 
miR-191 MCF-7 cells (Di Leva et al., 2013) miR-942 ZR-75-1 cells  (Ferraro et al., 2012) 
miR-193a- MCF-7 cells (Tilghman et al., 2012) miR-944 MCF-7 cells (Razandi et al., 2000) 
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5p 
miR-193b MCF-7 cells (Wang et al., 2010) miR-1206 MCF-7 cells (Ferraro et al., 2012) 
miR-194 MCF-7 cells (Ferraro et al., 2012) miR-122 MCF-7 cells (Ferraro et al., 2012) 
miR-195 MCF-7 cells (Klinge, 2009) miR-1248 MCF-7 cells (Ferraro et al., 2012) 
miR-195* ZR-75-1 (Ferraro et al., 2012) miR-1268 MCF-7 cells (Ferraro et al., 2012) 
miR-196a2* MCF-7 cells (Kim et al., 2013) miR-1275 1 MCF-7 cells (Tilghman et al., 2012) 
miR-198 T47D cells (Katchy et al., 2012) miR-1305 MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
miR-199a/b-
3p 
ZR-75-1 cells, (Ferraro et al., 2012) miR-1323 ZR-75-1 cells (Ferraro et al., 2012) 
miR-199a-
5p 
MCF-7 cells stably overexpressing inducible ER! 
or ER# (Paris et al., 2012). 
miR-1826 ZR-75-1 cells (Ferraro et al., 2012) 
miR-200a MCF-7 cells (Klinge, 2009) miR-1915 MCF-7 cells (Tilghman et al., 2012) 
miR-203 MCF-7 cells (Klinge, 2009)   
miR-205 ER! stably expressing SW480 colon cancer cells 
(Edvardsson et al., 2013) 
  
miR-206 ER!-selective agonist in MCF-7 cells (Adams 
et al., 2007) 
  
miR-210 ZR-75-1 cells (Ferraro et al., 2012)   
miR-216a MCF-7 and ZR-75-1 cells (Ferraro et al., 2012) 
MCF-7 cells stably overexpressing inducible ER! 
or ER# (Paris et al., 2012) 
  
miR-219-5p MCF-7 and ZR-75-1 cells (Ferraro et al., 2012)   
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CHAPTER 5: Analysis of cancer related putative targets of miR-663. 
 
5.1 Introduction 
 
 In the emerging field of microRNA-based regulation of gene expression in 
relation to cancer formation and progression, as well as all the physiological functions 
in which microRNAs seem to be involved, the most problematical issue is the 
experimental confirmation of a direct link between a microRNA and one of its 
putative target genes. Confirmation requires initial in silico analysis of the whole 
transcriptome for seed regions within the mRNA sequences that match with the 
sequence of a microRNA. Additionally, these regions must also present a favorable 
thermodynamic profile in the interaction between microRNA and mRNA in order for 
the binding between the two molecules to occur. Most of the microRNA reports to 
date only focus on different levels of expression of certain microRNAs or present 
microRNA expression profiles from probing tumour samples or other biological 
functions and treatments. Comparatively few present a functional link between the 
observed microRNA status and a microRNA target gene that plays a role in the 
investigated process, phenotype or disease. Recently though the number of 
microRNA::mRNA interactions that have been validated, mainly through luciferase 
reporter assays, has increased.  
 
 The results obtained from the array experiment indicated that three 
microRNAs, whose expression was mostly affected by the treatment, were found in 
both treatments with the estrogenic compounds 17-! estradiol and PhIP. However one 
of them is a microRNA star sequence and its role as a regulatory molecule is not 
certain. Nevertheless, in the remaining microRNAs that were both found 
downregulated (miR-663, miR-638), a large number of putative interactions with the 
mRNAs of various genes are predicted (See Section 5.3.1). In exploring this analysis 
and validation I have focussed on the ability to affect promotion of cell proliferation 
or contribution to cancer formation or progression.  
 
 The objective of this investigation was to analyse the in silico putative targets 
of the most deregulated microRNAs and to attempt to confirm a direct link between 
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microRNA levels and protein levels of specific proliferation or cancer related genes. 
This was achieved through initial in silico examination, estimation of potential mRNA 
effects on chosen targets, through semi-quantitiative PCR, and examination of their 
protein levels in a microRNA knockdown experiment in MCF-7 cells. Due to time 
considerations, I concentrated these studies on the most promising microRNA 
candidate, miR-663. 
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5.2 Material and Methods 
 
5.2.1 Materials 
 Primers for semi-quantitative PCR were purchased from Sigma. Primers used 
GAPDH: Forward primer: 5’-GCCTTCCGTGTCCCCACTGC-3’, reverse primer:  
5’- CAATGCCAGCCCCAGCGTCA-3’. ILK-1: Forward primer: 5’ 
GAACGGAGCCAACCCTTGGGGAG, reverse primer:  5’-
TGTTGTCCAGCCACAGGCGAA-3’. 
 
5.2.2 In silico analysis of microRNA::mRNA interactions  
  
 The determination of potential mRNA targets for the microRNAs that were 
differentially expressed after 17-! estradiol and PhIP treatments was achieved through 
the use of specific software tools available on the Internet. The available programs 
that provide information for putative targets of microRNAs are numerous and, more 
importantly, present different results for each microRNA since the principle behind 
their calculations varies from seed sequence complimentarity, thermodynamic 
stability of the microRNA::mRNA interaction as well as statistical models and 
experimentally validated targets. Hence, in order to ensure the widest representation 
of results the MiRWalk web tool (Dweep et al., 2011) was utilised. This programme 
combines and presents all the results from all the aforementioned factors and presents 
the microRNA targets that are predicted in multiple analysis programmes. The 
programmes available for target prediction are: DIANA-microT (Maragkakis et al., 
2009), MiRanda (John et al., 2005), miRDB (Wang, 2008), miRWalk (Dweep et al., 
2011), PICTAR 5 (Chen and Rajewsky, 2006), RNA 22 (Miranda et al., 2006), 
RNAHybrid (Rehmsmeier et al. 2004) and TargetScan (Lewis et al., 2005). The 
combination of different approaches for the detection of putative microRNA::mRNA 
interactions increases the possibility that the precicted interaction does occur. For 
each microRNA, only cancer-related targets were reported. 
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5.2.3 Semi-quantitative polymerase chain reaction  
 
 DNA amplification for semi-quantitative PCR was performed from cDNA 
libraries. The protocol for semi-quantitative PCR amplifications was a 25 µl total 
reaction in a nuclease free PCR tube Eppendorf tube containing 25ng of  DNA 
(ranging from 25-100 ng), 1.5 µl of a 50mM MgCl2 solution, 2.5 µl of 10x PCR 
buffer (supplied from Promega), 0.5 µl of a 10mM dNTP solution containing all four 
dNTPs at that concentration, 0.5 µl each of the two primers at a concentration of 10 
pmol/µl, 0.2 µl of Taq Polymerase (i.e. 1 unit) and nuclease-free deionised water up 
to 25 µl for the total volume of the reaction. The tube was briefly mixed by tapping or 
pipetting and centrifuged. The generic semi-quantitative PCR program on the thermal 
cycler for PCR reaction with Taq DNA polymerase constituted: 95°C for 25 seconds 
(activation step), followed by: differing number of cycles of 95°C for 25 seconds 
(separation of strands), 30 seconds at a temperature 4°C lower than the melting 
temperature of the primer (annealing of primers) and 68°C for 45 seconds 
(elongation) and then finally 68°C for 10 minutes (completion of polymerisation of all 
fragments). The reaction was then cooled down at 4°C ad infinitum, until it was 
removed from the thermal cycler. The amplification of the fragment of interest was 
confirmed by visualisation of the DNA fragment with agarose gel electrophoresis as 
described in Section 2.2.9. The PCR bands were quantified by using a Fujifilm 3000 
Imager! and band intensity was measured using densitometry in the Image J program.  
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5.3 Results  
 
5.3.1 Putative and cancer-related targets of miR-663 
 
 Following the protocols described in Section 5.2.2, the analysis of putative 
microRNA::mRNA interactions includes only those interactions that were present in 6 
or more target prediction programmes. The putative targets were subsequently 
analysed for potential involvement in cancer development, through a literature search.  
 
The analysis of putative miR-663 mRNA targets resulted in a total of 167 
candidate interactions, out of which 159 were predicted in 6 prediction programmes 
and the remaining 8 were found in 7. There was no interaction predicted in 8 or more 
target analysis programmes. All the predictions are presented in the Supplementary 
Data Section. The Entrez/Gene enquiry resulted in a total of 160 putative targets with 
assigned gene functions, whilst 7 were either homologue sequences or open reading 
frames yet to have their gene function discovered.  
 
Out of 160 genes that have a likelihood of being potential targets of miR-663, 
31 were found to be related to processes that might directly lead to the increased 
proliferation profiles observed in the E-Screen and, by extension, to the cell 
proliferating phenotype associated with 17-! estradiol and PhIP treatment. The 
majority of these 31 genes encode proteins that are enzymes involved in signalling 
cascades, such as serine/threonine kinases, phosphatases or their inhibitors, followed 
by genes whose proteins take part in the process of transcription either as transcription 
factors, transcriptional co-activators, repressors or modulators. The remaining few are 
associated with increased proliferation through their association with known 
proliferative signals or with certain increased proliferation cellular contexts, such as 
certain neoplasias.   
 
More specifically, 16 targets fall into the first aforementioned group, with 
targets including such genes as mitogen-activated protein kinase kinase 2 (MAP2K2), 
cyclin dependent kinase inhibitor 2A (an inhibitor of cyclin dependent kinase 4), 
tousled-like kinase 2 (TLK2) and integrin-linked kinase (ILK). Table 5.3.1 below 
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presents all the miR-663 targets that participate in signal transduction in cellular 
processes. 
 
Table 5.3.1 Table of putative in silico predicted miR-663 target genes that are 
involved in cell division-related signal transduction. Gene name, encoded protein and 
relevant cellular function are presented. 
Target gene Target protein Cell related function 
 
PPP5C 
 
Protein phosphatase 5, 
catalytic subunit 
Has been shown to participate in signalling 
pathways in response to hormones or cellular 
stress, and elevated levels of this protein may 
be associated with breast cancer development. 
 
 
CDKN2A 
 
Cyclin-dependent kinase 
inhibitor 2A 
The CDK inhibitor encoded by this gene 
displays functionality in cell cycle G1 control. 
Frequently mutated or deleted in a wide variety 
of tumors. Known to be an important tumor 
suppressor gene. 
 
TLK2 Tousled-like kinase Nuclear serine-threonine kinase potentially 
involved in the regulation of chromatin 
assembly. 
 
DUSP14 
 
Dual specificity 
phosphatase 2 
Type I cysteine-based protein-tyrosine 
phosphatase. Implicated as major modulator of 
critical signalling pathways. 
EPHB2 Ephrin receptor 2 Receptor tyrosine kinase binding ephrin-B. 
Mediates numerous developmental processes. 
FLT4 Fms-related tyrosine kinase 
4 
Tyrosine kinase receptor for vascular 
endothelial growth factors C and D. Protein 
thought to be involved in lymphangiogenesis. 
 
GSK3A 
Glycogen synthase kinase 3 
alpha 
Multifunctional serine-threonine protein kinase 
implicated in the control of several regulatory 
proteins and transcription factors such as JUN. 
Also plays role in the WNT and PI3K 
signalling pathways. 
ILK Integrin-linked kinase Mediates transduction of extracellular matrix 
signals through integrins, acting as a proximal 
receptor kinase regulating integrin mediated 
signal transduction. 
 
ARAF 
v-raf murine sarcoma 3611 
viral oncogene homolog 
Member of the RAF subfamily of serine-
threonine kinases. May be involved in cell 
growth and development. 
 
PRKCG 
 
Protein kinase C 
Serine-threonine kinase activated by calcium 
and diacylglycerol. Known to be involved in 
diverse cellular signalling pathways and also 
serves as major receptors for phorbol esters, a 
class of tumor promoters. 
 
PRKDC 
DNA activated protein 
kinase catalytic polypeptide 
DNA-PK functions with the Ku70/Ku80 
heterodimer protein in DNA double strand 
break repair and recombination.  
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MAP2K2 
Mitogen activated protein 
kinase kinase 2 
Plays a critical role in mitogen growth factor 
signal transduction by phopsphorylating and 
thus activating MAPK1/ERK2 and 
MAPK2/ERK3. 
           SNIP Src kinase signalling 
inhibitor 1 
Inhibitor of Src tyrosine-protein kinase that 
may play a role in cell growth and 
development. 
EHMT1 Euchromatic histone-lysine-
N-methyltransferase 
Part of the E2F6 complex, which represses 
transcription methylates histone H3 for 
transcriptional repression. 
 
LATS1 
Large tumor suppressor 
homolog 1 (Drosophila) 
Putative serine-threonine kinase that localizes 
to the mitotic apparatus and complexes with 
cell cycle controller CDC2 kinase in early 
mitosis, acting a s negative regulator of 
CDC2/cyclinA. 
 
CDC42BPB 
CDC42-binding protein 
kinase beta 
Serine-threonine protein kinase that may act as 
a downstream effector of CDC42 in 
cystoskeletal reorganization. 
 
The next biggest group of targets that fall in the same category are those that 
can potentially drive increased cell proliferation albeit indirectly, by influencing the 
expression of other effector proteins. There are 10 targets that are potentially involved 
in transcription with the greater part being transcription factors. Some of the targets in 
this group include apoptosis antagonising transcription factor (AATF), T-cell 
leukaemia homeobox 3 (TLX3), nuclear factor I/X (NFIX), transcription factor 20 
(AR1) (TCF20) and JunB. All the targets that fall into the aforementioned group of 
transcription factor proteins are subsequently presented in Table 5.3.1.2.  
 
Table 5.3.2 Table of putative in silico predicted target genes of miR-663 with a role 
in transcription. Gene name, encoded protein and role in transcription are presented.  
Target gene Target protein Cancer related function 
 
FOXN4 
 
Forkhead box N4 
Member of the winged-helix/forkhead family 
of transcription factors. Key regulators of 
development and metabolism. 
 
EEF1A2 
 
Eukaryotic translation 
elongation factor 1 alpha 2 
Responsible for the enzymatic delivery of 
aminoacyl tRNAs to the ribosome. May be 
critical in the formation of ovarian cancer. 
 
ZNF385A Zinc finger protein 385A Regulatory protein that acts as a transcription 
factor, binds single-or double-stranded RNA 
orinteracts with proteins. 
 
AATF 
 
Apoptosis antagonising 
transcription factor 
Interacts with MAP3K12/DLK, which is 
known to be involved in the induction of cell 
apoptosis. Shows strong transactivation 
activity when binding to DNA.  
TLX3 T-cell leukaemia 
homeobox-3  
Orphan homeobox gene, encoding DNA-
binding nuclear transcription factor. 
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JUNB JunB proto-oncogene Part of the AP-1 complex of transcription 
factors acting as a tumour suppressor. 
NFIX Nuclear factor I/X CCAAT-binding transcription factor. 
 
TBX2 
 
T-box 2 
Transcription factor involved in the 
regulation of developmental processes. 
Expression studies indicate that this gene may 
have a potential role in tumorigenesisi as an 
immortalising agent.  
TCF20 Transcription factor 20 
(AR1) 
Transcriptional coactivator that enhances the 
activity of transcription factors such as JUN 
and SP1.  
           ZIC2 Zic family member 2 Functions a transcriptional repressor and may 
regulate tissue specific expression of 
dopamine receptor D1. 
 
The remaining 5 putative targets of miR-663 that resulted from the in silico analysis 
are varied in their potential involvement with cell proliferation. Two of them have a 
clear connection, with BBC3 encoding a member of the well-known BCL-2 anti-
apoptotic family and CTAGE5 expressing a protein that is associated with cutaneous 
T-cell lymphoma and several other cancers. The remaining three encode proteins that 
have various functions that could potentially play a role in the distortion of processes, 
which could contribute to increased cell division and potentially cancer. One of the 
targets, Arrestin !2, plays a role in agonist-mediated desensitisation of G-coupled 
receptors, the other (MCM5) contributes to chromosome maintenance and cell cycle 
progression and the last is a major calcium storage protein that modulates regulation 
of gene transcription by nuclear hormone receptors. The genes names, encoded 
proteins and functions of the aforementioned targets are presented in Table 5.3.1.3. 
 
Table 5.3.3 Putative in silico predicted target genes of miR-663 with a role in cell 
proliferation. Gene name, encoded protein and potential role in cell proliferation are 
presented. 
 
Target gene Target protein Cancer related function 
 
BBC3 
 
BCL-2 binding component 
3 
Cooperates with activator proteins to induce 
mitochondrial outer membrane 
permeabilization and apoptosis. Binds anti-
apoptotic Bcl-2 family members to induce 
mitochondrial dysfunction and caspase 
activation 
 
CTAGE5 
Cutaneous T-cell 
lymphoma associated 
antigen 5 
Tumor-associated antigen found in 
cutaneous T-cell lymphoma and several 
other cancers. Autoantibodeis against the 
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encoded protein have been found in some 
cancers. 
 
ARRB2 
 
 
Arrestin beta 2 
Thought to participate in agonist-mediated 
desensitization of G-protein-coupled 
receptors and cause specific dampening of 
cellular responses to stimuli such as 
hormones or sensory signals. 
 
MCM5  
 
Minichromosome 
maintenance complex 
component 5 
Member of the MCM family of chromatin-
binding proteins. Upregulated in the 
transition from the G0 to G1/S phase. May 
actively participate in cell cycle progression. 
 
CALR 
 
Calreticulin 
Binds to and inhibits the transcriptional 
activities of hormone receptors such as 
androgen and retinoic acid receptors. Thus 
acts as an important modulator of the 
regulation of gene transcription.  
  
 Out of the predicted targets analysed, a few are genes that have been the 
subject of extensive interest due to their involvement in increased cell division in the 
context of cancer development. These include targets such as BBC3, better known as 
the pro-apoptotic protein PUMA (p53-upregulated modulator of apoptosis) that plays 
role in the instigation of the mitochondrial apoptotic process (Han et al, 2001) and 
similarly, in the context of functioning as a tumour suppressor, JunB which has been 
shown to induce tumour suppressor genes such as p16 (Passegué and Wagner, 2000) 
and inhibit cyclinD1 (Vartanian et al. 2011) thus inhibiting cell proliferation.  
 
 From the genes that are involved in increased cell proliferation as oncogenes, 
only kinases, phosphatases and some enzyme inhibitors are found among the putative 
in silico targets of miR-663. More specifically, out of the 16 proteins that are listed in 
Table 5.3.1, five constitute major players in the signalling cascades that are involved 
in increased cell proliferation and hence the process of cancer development. These 
proteins can be overexpressed in various types of tumors. Included in these targets is 
the C catalytic subunit of protein phosphatase 5, an enzyme that has been found 
overexpressed in diverse cancers including human breast cancer (Golden et al, 2008) 
and integrin-linked kinase, a protein that has diverse connections with cancer 
progression in a variety of tissues (Cortez et al., 2011, Caccavari et al., 2010, 
McDonald et al., 2008). Moreover, mitogen-activated protein kinase kinase 2, also 
known as MEK2, is another target that plays a major role in many signalling cascades 
and has been found overexpressed in many types of cancers (Neuzillet et al., 2014). 
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Confirmation that these genes are actual targets of miR-663 needs to be 
experimentally confirmed. Unfortunately, there was insufficient time to systematically 
investigate the potential of all these to be targets of miR-663.  
 
 Therefore, a more focussed approach that concentrated on a high probability 
target was chosen. This particular putative target for miR-663 was integrin linked 
kinase (ILK). ILK was chosen on the basis of the favourable target prediction (6 out 
of 8 microRNA target algorithms predicted interaction between miR-663 and ILK), as 
well as its relevance with hormone related signalling and thereby related cancers, such 
as breast, ovary and colon (Cortez et al., 2011). Importantly, ILK has been shown to 
interact with ER# and participate in ER# signalling in breast cancer cells (Acconcia et 
al., 2006). It was shown that exposure of MCF-7 cells to 17-! estradiol results in the 
prevention of ER#-ILK binding which causes an increase in ILK kinase activity 
(Acconcia et al. 2006). Another study indicated that ILK also interacts with PELP1, 
an ER-coregulator protein that is part of the ER# signalosome in the cytoplasm 
(Chakravarty et al., 2010). Therefore, ILK is activated by estrogen signalling, and in 
turn is part of the diverse estrogenic signalling events that promote cell proliferation. 
As such, a mechanism where reduced levels of miR-663 due to estrogenic exposure 
would lead to increased levels of ILK and increased estrogen-related cell proliferation 
can be postulated.  
 
 
5.3.2 Semi-quantitative PCR of integrin-linked kinase in MCF-7 cells treated 
with 17-! estradiol or PhIP 
 
 Semi-quantitative polymerase chain reaction can indicate differences in the 
expression levels of a specific gene at the level of mRNA. I therefore used semi-
quantitative PCR to investigate the expression of potential targets of miR-663. Thus 
examination of changes in the expression levels of the mRNA of integrin-linked 
kinase in the same samples that were used for the microarray experiments was 
undertaken. The gels of the PCR products were assessed quantitatively by 
documenting gels with the Fujifilm 3000 Imager! Analyzer and quantifying the PCR 
bands by using band densitometry in Image J!. The accuracy of this approach is 
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inferior to the more expensive real-time PCR approach, nevertheless a quantitative 
assessment is possible. As can be seen in figure 5.3.2.1 the PCR experiment indicated 
that the levels of the ILK mRNA were upregulated, particularly at the 4 and 24 hour 
timepoints of the treatment, where the change was significant. More specifically, for 
the treatment with 10-8 M 17-! estradiol, mRNA levels were increased by an average 
of 63% at 4 hours, and 58% at 24 hours post treatment with 17-! estradiol. Treatment 
with 10-7 M PhIP also resulted in a relative increase of integrin-linked kinase levels. 
Again the biggest and significant changes were similarly observed at 4 and 24 hours 
post treatment with increases of 66% and 62% respectively. No significant changes 
were found at 8 or 12 hours treatments. The quantitated results of the semi-
quantitative polymerase experiments are summarised in Figure 5.3.2.1 whilst a 
representative agarose gel, along with the GAPDH mRNA for loading normalisation, 
is presented in Figure 5.3.1 
                
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 5.3.1 Quantification of PCR products of intergrin-linked kinase mRNA 
(normalised with GAPDH mRNA) from MCF-7 cells treated with 17-! estradiol (10-8 
M) or PhIP (10-7 M). Values represent means and error bars standard deviations 
(n=3). Stars represent statistical significance (Student’s t-test, p<0.05). 
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5.3.3 Immunoblot analysis of integrin-linked kinase in MCF-7 cells treated with 
17-! estradiol or PhIP 
 
 Following the initial indication that the levels of ILK-1 mRNA were increased 
after treatment with 17-! estradiol or PhIP, the protein levels of the putative target 
were also examined. Any increases in the protein levels of integrin linked kinase, 
would further substantiate the possibility that this enzyme could be a target of miR-
663. The samples used for the detection of the protein levels of ILK-1 were those used 
in the microarray and the semi-quantitative PCR experiments. Strikingly, the results 
of the immuno-blot experiment showed that integrin-linked kinase protein levels are 
also increased following treatment with 17-! estradiol or PhIP. For both treatments a 
significant increase at all the timepoints examined was observed. ILK-1 protein levels 
were almost doubled at 4 and 8 hours treatment with both 17-! estradiol and PhIP, 
whilst 12 and 24 hour treatments indicated a more modest induction compared to 
control. The quantified results can be seen in Figure 5.3.3 and Figure 5.3.4.   
 
Figure 5.3.2 Representative agarose gel electrophoresis of semi-quantitative PCR for 
integrin-linked kinase and GAPDH from cDNA samples isolated from MCF-7 cells 
treated with 17-! estradiol (10-8 M) or PhIP (10-7 M) at 4,8,12 and 24 hour treatments 
 ILK-1 
GAPDH 
250 bp 
400 bp 
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Picture 5.3.4 Representative Immunoblot images for integrin-linked kinase and !-actin 
from protein samples isolated from MCF-7 cells treated with 17-! estradiol (10-8 M) or 
PhIP (10-7 M) at 4,8,12 and 24 hour treatments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 5.3.3 Quantification of Immunoblot analysis of integrin-linked kinase (normalised 
with !-actin) from MCF-7 cells treated with 17-! estradiol (10-8 M) or PhIP (10-7 M). Values 
represent means error bars standard deviations (n=3). Stars represent statistical significance. 
(Student’s t-test , p<0.05) 
 ILK-1 
 !-actin  
*
* * *
* * *
* 
4hr 8hr 12hr 24hr 
Timepoints 
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5.4 Discussion 
 
 One of the main contributors to breast cancer development is sex steroid 
hormones acting through their respective receptors (Osborne et al., 1980). The role of 
the endogenous hormone estrogen in the promotion and development of breast cancer 
is well documented by epidemiological data as well as the now well-established 
therapeutic efficacy of antiestrogen therapy (Jordan, 1992). More direct evidence has 
been obtained from estrogen receptor positive breast cancer cell lines, in which 
estrogens and estrogenic compounds, such as PhIP, have been found to stimulate cell 
proliferation and invasion (Lauber and Gooderham 2011). Epigenetics is one of the 
areas where estrogenic signaling also engenders significant change in the direction of 
developing breast cancer (Hervouet et al., 2013). More specifically, in terms of 
affecting the expression of microRNAs in breast cancer, estrogen has been found to 
drive the aberrant expression of numerous microRNAs in a wide range of breast 
cancer subtypes (reviewed in Klinge, 2015).  
 
 The estrogenic activity of PhIP was established based on the similarities 
between 17-! estradiol and PhIP in the cell growth response curves in the E-Screen 
experiment (Section 3.2.2) and the microRNA deregulation profiles generated by the 
array experiment (Section 4.3.4.4). This supports the already established estrogenic 
activity of PhIP in mammary cell lines (Lauber and Gooderham, 2007, Lauber and 
Gooderham, 2011). Subsequently, it was postulated that PhIP could express 
estrogenic activity by influencing microRNA levels, which in turn affect the levels of 
proteins involved in the promotion of cell proliferation. Furthermore, a demonstration 
of similar protein-level changes of targets of deregulated microRNAs caused by 17-! 
estradiol or PhIP, would further support the estrogenic character of the latter 
compound.  
 
 Consequently, a microRNA that displayed similar deregulation in response to 
the two treatments was selected for analysis. MiR-663 was chosen based on the fact 
that it was the most deregulated microRNA with both treatments. Initially, an in silico 
analysis of the putative targets of miR-663 was conducted. To make the analysis more 
robust and create a collection of putative targets that had a high probability of being 
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targets of miR-663, eight distinct target algorithms were employed within the 
miRWalk 2.0 platform (Dweep et al., 2011), as described in Section 5.2.2. Notably 
the miRDB target prediction program uses free energy requirements for 
miRNA/mRNA interactions as opposed to seed region complimentarity and, as such, 
presented a differential target prediction analysis. The results of the in silico analysis 
indicated numerous potential targets for miR-663 (see Sections 5.3.1 and 
Supplementary Data Section), many of which are established significant contributors 
to cell proliferation and cancer. Examples include MEK2, which is part of the 
mitogen-activated extracellular signal-regulated kinase pathway, one of the best 
characterized kinase cascades in cancer cell biology (Neuzillet et al., 2014), cyclin-
dependent kinase inhibitor 2A, or p16, a well known component of the MAP kinase 
pathway involved in cancer (Rocco and Sidransky, 2001) and protein kinase C, the 
overexpression of which has been shown to cause mammary epithelial cells to acquire 
a malignant phenotype and to become tumorigenic in vivo (Mazzoni et al., 2003). The 
aforementioned putative targets, along with some others, like protein phosphatase 5 
and glycogen synthase kinase 3, make a case for the potential involvement of miR-
663 downregulation in the increased proliferation of immortalized MCF-7 mammary 
cells induced by estrogenic signalling.  
  
 The assessment of the impact of miR-663 downregulation on some of these 
targets was the next step in establishing this microRNA as a contributor to estrogen 
induced proliferative behavior in MCF-7 cells. Unfortunately, validating miR targets 
is a time consuming process and due to time considerations this thesis focussed on a 
putative target that presented a high probability of being involved in estrogen-related 
signalling. The target chosen was integrin-linked kinase (ILK), for which there are 
several lines of evidence linking ILK with estrogen receptor signalling. Firstly, ILK 
has been shown to directly interact with estrogen receptor, thereby activating the 
enzyme and using it as a downstream effector of estrogenic signalling (Chakravarty et 
al., 2010). Furthermore, ILK has been shown to also interact with an estrogen receptor 
co-regulator, PELP1 (Chakravarty et al., 2010). This evidence suggests that 
deregulation of ILK has the potential to promote estrogen-driven increased cell 
proliferation, so increased levels of integrin-linked kinase could be caused by 
alleviation of the repression of ILK expression with miR-663. One more putative 
miR-663 target is also related with 17-! estradiol, with levels of protein phosphatase 5 
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being increased in MCF-7 cells after 17-! estradiol treatment (Urban et al., 2001). 
Moreover, it was shown that the PP5 promoter contains an estrogen responsive 
element that drives the increased expression of the gene, although increased levels of 
the protein could also be attributed to decreased miR-663 levels, assuming protein 
phosphatase 5 is a miR-663 target. 
 
 My data supports an interaction between miR-663 and ILK with the semi-
quantitative PCR analysis. Despite the technique being inferior to the higher 
sensitivity real-time PCR, a quantitative comparison can be made (Ramalho et al., 
2004). Results from the PCR experiment indicated a rapid induction of ILK mRNA 
after the 4 hour treatment with both 17-! estradiol or PhIP. Subsequently, mRNA 
levels at the 8 and 12 hour timepoints were comparable with vehicle control levels 
and were again increased over controls at the 24 hour treatments. Importantly, the 
response observed with the 17-! estradiol treatment was similar to the response 
observed with the PhIP treatment, supporting the estrogenic character of PhIP. 
Collectively my data lead to the suggestion that MCF-7 cells respond to treatment 
with 17-! estradiol or PhIP by decreasing levels of miR-663, which in turn increases 
the levels of integrin-linked kinase that potentially result in increased cell 
proliferation. It can also be suggested that this response is possible linked with the cell 
cycle of MCF-7 cells, which has been determined at 24 hours when cells are 
exponentially growing (Sutherland et al., 1983). Thus, MCF-7 cells are responsive to 
treatment in the initial early timepoint and then again at the point where they initiate 
the next cell cycle. This suggestion is also in agreement with the observations made in 
Chapter 4, where the microRNA response to 17-! estradiol and PhIP was maximal at 
the 24 hour timepoint and less affected at the 12 hour timepoint for the majority of the 
changes observed.  
 
 Following the treatment mediated upregulation of mRNA levels of ILK, the 
potential changes at the protein level was examined. Changes at the protein level 
would make this miR-663 – ILK potential interaction more physiologically relevant, 
as increased ILK kinase protein levels have been shown to be linked with increased 
proliferation (Hannigan et al., 2005). Indeed, when protein levels of ILK were 
investigated with an Immuno-blot experiment, the results indicated a good induction 
of the levels of ILK protein across all timepoints withboth 17-! estradiol and PhIP 
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treatments. This is an indication that the bursts of increased mRNA, detected in the 
semi-quantitative PCR experiment were sufficient to support increased protein 
expression throughout the entire course of the treatments. This is also in line with the 
timeframe of the changes observed at the mRNA and protein levels, as rapid mRNA 
increases resulted in more sustained protein increases. This can be due to the longer 
half-lives of proteins as opposed to mRNAs (Schwanhäusser et al., 2011), where the 
increased protein expression changes due to higher levels of mRNA template at 4 
hours are sustained.    
 
 The data generated in this chapter confirm that MCF-7 responses to PhIP 
treatment are similar to 17-! estradiol responses, thus further substantiating the pro-
estrogenic character of PhIP. These findings compliment previous reports (Lauber et 
al., 2004, Lauber et al., 2007, Lauber and Gooderham, 2011).  In those studies PhIP 
was shown to exert similar effects to 17-! estradiol on cell proliferation proteins such 
as c-Myc and the MAPK pathway (Lauber et al., 2004), the synthesis and secretion of 
prolactin (Lauber and Gooderham 2007) as well as the increase of cathepsin D, 
cyclooxygenase-2 and matrix metalloproteinase activity (Lauber and Gooderham, 
2011). Similarly, the findings of my research show how PhIP induces changes on the 
microRNAome level similar to those observed with 17-! estradiol and these changes 
might promote cell proliferation and potentially promote carcinogenesis.  
 
 Recent discoveries have shown that the miR-663 molecule is a significant 
factor in carcinogenesis. A luciferase reporter assay showed that miR-663 targets the 
JunB and JunD transcription factors, which decrease activator protein -1 activity  (Tili 
et al., 2010). The same group also discovered in another study that miR-663 targets 
tumor growth factor beta (TGF!) (Tili et al. 2010). In addition, miR-663 was also 
demonstrated to target another component of the AP-1 complex, FOSB through a 
correlation of reduced microRNAs and mRNA molecules in an ischeamic breast 
cancer tissue model (Borgan et al., 2011). Therefore, miR-663 is an important factor 
affecting the AP-1 network, which is a central signalling network in many cancers 
(Shaulian, 2010). Furthermore, miR-663 was also shown to target the delta 
phosphatidylinositol-4,5-bisphosphate 3-kinase PIK3CD and to suppress the 
activation of the AKT signalling pathway (Shi et al., 2014). The above data make a 
strong case for miR-663 acting as a tumor suppressor gene. However there is also 
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evidence from one study that shows that miR-663 acts in the opposite direction by 
promoting the proliferation and tumorigenesis of nasopharyngeal carcinoma by 
targeting p21 (Yi et al., 2012).  
5.5 Conclusion 
 
 Collectively, these studies highlight the complex interactions of miRNAs with 
their target mRNAs and emphasise the importance of their dysregulation in the 
development of cancer. My own studies showing the ability of two established 
carcinogens 17B-estradiol and PhIP to affect miR-663 expression, supports this 
complex role of miRNA expression in carcinogenesis.  
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5.6 Supplementary Data 
 
Table 5.5.1 Table of all in silico predicted targets of miR-663, based on the miRWalk 
2.0 algorithm and 6 other prediction algorithms. Green colour indicates interaction 
between microRNA and target, and red no interaction.  Only targets with interaction 
in 6 or more algorithms are shown. Gene function is also presented   
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CHAPTER 6: General Discussion 
 
 Although it had been known for some time that regulation of gene expression 
also depends on processes other than those influenced by sequence-based changes, it 
is now evident that such processes have a central role in gene regulation both during 
the maintenance of homeostasis as well as during disease. This has placed the main 
processes of epigenetic regulation of gene expression, namely DNA methylation, 
regulation of chromatin structure and microRNAs, amongst some of the most well-
studied biology in the field of genetic research. Consideration of the epigenetic 
implications of any process or interaction of a compound with DNA is now necessary 
in order for the full genetic implications of that compound to be understood. 
Consequently for any compound of interest, the implications of its interactions with 
the human genome has to include an understanding of the effects the compound exerts 
on the epigenome. In particular, when compounds are being investigated for their 
carcinogenic properties, the epigenetic effects of that compound can be important and 
key to its carcinogenic activity.  
 
 The heterocyclic amines are formed during the cooking of red meat (Felton et 
al., 1986). They have been established as dietary agents that display significant 
carcinogenic potential, supporting the aetiology of diet-associated neoplasia. One of 
the most abundant of the heterocyclic amines, PhIP, is of particular interest not only 
because of its potent genotoxic properties but also because of the fact that it displays 
structural and biological similarities with estrogens. These similarities were 
discovered previously in our lab and, importantly, were found at concentrations that 
were close to the physiological concentrations of PhIP that occur after consumption of 
Western meat-rich diets (Lauber et al., 2004). Furthermore, these studies showed that 
PhIP has the capacity to bind ER# and to activate it (Lauber et al., 2004). The 
establishment of PhIP as a diet-borne compound that displays estrogenic properties is 
of significant importance as estrogens are a major risk factor for all hormone related 
neoplasias (Di Leo et al., 2001; Bonkoff et al., 2001).    
 
  In view of the estrogenic properties of PhIP, it is important to examine the 
epigenetic activity of the molecule. Epigenetic studies of PhIP would provide more 
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knowledge about the potential carcinogenic effects that this compound possesses. 
Therefore, the novel investigation of the epigenetic effects of PhIP in relation to those 
caused by estrogen were selected as the main investigative area of this project.   
 
 Out of the three aforementioned epigenetic mechanisms of gene regulation, 
microRNAs can be characterized as the most dynamic. In an ever –expanding 
microRNAome, further research reveals multiple layers of regulation for microRNA 
expression and/or interactions with mRNA targets. The research highlights the 
complexity of regulatory networks that are formed between microRNAs, components 
of their biogenesis machinery and their mRNA targets. A characteristic of 
microRNAs that highlights their potential as master regulators of gene expression is 
the interaction between microRNA and target based on the seed region (i.e. the 
canonical interaction), which allows for one microRNA to potentially interact with 
hundreds of targets in the genome. Advances in microarray technology have made the 
investigation of global microRNA population easily accessible and allow 
investigation of interactions between hypothesized differentially regulated 
microRNAs and in silico identified putative targets.  
 
 At the onset of this work, the hypothesis that I proposed was that PhIP elicits a 
estrogenic response on the microRNA level, similar to the one observed on the level 
of cellular signalling or cellular behavior established previously in our lab (Lauber 
and Gooderham, 2007 and Lauber and Gooderham, 2011). In order to establish a 
working cell model, where my hypothesis could be tested, I used previous knowledge 
from research completed in our laboratory and chose to use the MCF-7 cell line.  The 
breast adenocarcinoma cell line MCF-7 is the most commonly used cell system in the 
study of estrogen-related cellular processes (Klinge, 2015). It expresses both ER# and 
ER! receptors, with ER# being expressed higher and they are both functional in 
binding 17-! estradiol (Watanabe et al., 1997). 17-! estradiol was used as a positive 
control to show functional estrogenic signalling and for comparisons of the results 
between E2 and PhIP.  
 
 In the first instance, phenotypic anchoring of the MCF-7 cell model was 
established. Initially, the dose and time parameters of the experiment were 
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investigated through a standard E-Screen with the MCF-7 cell line. This facilitated the 
optimization of the dosage and the temporal aspects of the subsequent microRNA 
expression profiling experiments. The concentration of the chemicals used for 
treatment ranged from comparatively high (10-6 M) to very low (10-11 M) doses, in 
order to establish the dosage at which the growth effects of E2 and PhIP were highest. 
The timeframe for the E-Screen assay was dictated by the requirement to allow 
enough time in order for cell division to take place; therefore the 24, 48 and 72 hour 
post-dosage time frame was chosen. Consequently, the effects of both E2 and PhIP on 
microRNA levels were examined in a day-based time frame. The results of the E-
Screen showed that the MCF-7 cell line was responsive to both E2 and PhIP with a 
dose response curve that was consistent with that previously observed in our lab. The 
results showed that the most responsive dose was 10-8 M for E2 and 10-7 M for PhIP. 
The E-Screen experiment showed that PhIP induced time and dose-dependent 
increased proliferation of MCF-7 cells, confirming the ability of the chemical to act as 
a xenoestrogen. The E-Screen in this thesis also showed for the first time that 
proliferation in response to PhIP stimulation is of a non-monotonic nature (See Figure 
3.2). This non-monotonic response was also observed in the 17-! estradiol treatment 
in the same MCF-7 cell line (See 3.1). Importantly, this non-monotonic response was 
observed for both compounds at all timepoints, which supports the validity of the 
experimental setup for this E-Screen. Non-monotonic responses to hormones and 
endocrine-disrupting chemicals, including 17-! estradiol, are a matter of ongoing 
debate in regards to their validity and relevance (Vandenberg et al., 2012; Rhomberg 
and Goodman, 2012). In this thesis, the mechanistic basis for the observed non-
monotonic response to the two chemicals was not explored, but could include 
activation of distinct ER#-independent signalling pathways as well as negative 
feedback loops that could be linked with the notable decrease of the proliferative 
response at the highest dose for both treatments. An example of an ER# signalling 
pathway that is independent of ligand binding is its translocation to the nucleus 
through its activation form the MAPK pathway (Marino et al., 2006). A negative 
feedback loop that might become activated in the case of increased ER# activity is the 
one between ER#, and secreted frizzled related proteins (SFRPs), which are Wnt 
antagonists, whereby increased ER# activity, increases SFRP levels, which in turn 
reduce ER# levels (Gregory & Schneider).  It is therefore probable that the observed 
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non-monotonic responses to PhIP and E2 share a similar mechanism, based on the 
shape of the dose-response curves. 
 
 Having established the responsiveness of the cell system utilized, further 
validation of the estrogenic relevance of this response was attempted. One of the 
cellular events of genomic estrogen signalling in an estrogen receptor-positive cellular 
context is the upregulation of the levels of progesterone receptor (Lee and Gorski, 
1996). The expression levels of progesterone receptor were analysed using a Western 
blot from the cell lysates of a fraction of the treated cells that were used for the 
microRNA profiling experiment. The estrogenic character of PhIP had previously 
been described in our laboratory based on its ability to upregulate progesterone 
receptor levels in a estrogen-receptor dependent manner (Lauber and Gooderham, 
2007). The successful upregulation of progesterone receptor expression confirmed 
active estrogen signalling from both compounds. The Western blot analysis showed a 
marked increase in the levels of progesterone receptor in both the 17-! estradiol and 
PhIP treatments. This result supports the estrogenic character of PhIP and affirmed 
the activation of the genomic pathway of estrogen-driven gene regulation. This 
activation would allow for the investigation of the potential non-genotoxic epigenetic 
effects of 17-! estradiol and PhIP on the microRNAome and how these might relate 
to the growth-promoting characteristics of both compounds in a hormonally regulated 
cellular context.  
 
 To demonstrate the potential interplay between microRNAs and the estrogenic 
signalling network, the detection of putative estrogen responsive element sequences in 
the genomic regions surrounding transcription start sites of microRNAs was 
examined. The results from upstream and downstream sequences in microRNA genes 
from the Dragon ERE-Finder Web Tool™ indicated that almost a third of all 
microRNAs, based on miRBase 12.1 (Griffith-Jones et al., 2006), contained at least 
one estrogen responsive element within relatively close genomic proximity from their 
transcription start site (TSS). This result further substantiated the postulation that 
estrogen also drives the expression of microRNAs, thereby incorporating them in the 
extensive regulatory network of estrogen signalling. It should however be noted that 
these were putative and not validated functional genomic features around microRNA 
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genes. Further studies need to be conducted in individual microRNA genes to 
establish whether estrogen responsive element can bind liganded estrogen receptor 
dimers and whether microRNA expression is driven from that interaction. This 
finding does however indicate that a relationship exists between estrogen and 
microRNA expression and this needs to be further investigated, especially in the 
context of breast cancer, an estrogen-linked neoplasia.  
 
 The main focus of this study was the estrogenic character of PhIP and whether 
PhIP-mediated miRNA events could contribute to the compounds carcinogenicity and 
molecular events such as those described in previous studies in our lab (Lauber et al., 
2004). The aforementioned findings established an estrogen-responsive cell model, 
reaffirmed the capability of PhIP to mimic estrogen on a molecular level and hinted 
towards the potential interplay between estrogen receptor signalling and microRNA 
expression. The principal hypothesis of this project was investigated through a 
microarray experiment.  Using the phenotypic anchoring approach, I confirmed the 
estrogenic responsiveness of the cell model and proceeded to evaluate the effect of 
treatment with PhIP and E2 on the microRNAome. The total RNA extracts from the 
selected treatments along with the appropriate vehicle and negative controls were 
analysed using the Agilent microarray platform, which only permitted the 
hybridization of mature microRNAs on the chip. This favoured only those 
microRNAs that were regulatory active in the cell, although it should be noted that 
Ago2-bound microRNA molecules are dissociated from the nucleoprotein complex 
based on the RNA isolation protocol. This dissociation leads to their purification and 
subsequent detection, when they were not yet active in the cell, since they were still 
bound by the Ago2 complex at the time of RNA extraction. An interesting approach 
could stem from an RNA extraction protocol that would be able to isolate only those 
RNA molecules that were regulatorily active in the cell, hence already released from 
the Ago2 complex. This method would be one that would not instigate RNA 
dissociation of Ago2 bound microRNAs. Such approach however, was not tested 
during this experiment.  
 
 The hybridisation data was processed using the GeneSpringGX™ software 
(Doan et al., 2013). A 1.3-fold expression change cut-off along with a statistical 
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significance of p<0.1 were applied for the detection of noteworthy increases or 
decreases in microRNA expression. The results of the microarray experiment showed 
numerous microRNAs being differentially regulated in response to both the E2 and 
PhIP treatments with consistent temporal changes observed. The majority of these 
expression changes were downregulated microRNAs in both treatments and along all 
four timepoins. However, the most striking, and at the same time most interesting, 
information obtained from the array experiment was that the four biggest changes in 
the two treatments were the same microRNA molecules. These microRNAs were 
miR-1233 being upregulated and miR-663, miR-638 and miR-92b* that were 
downregulated in both treatments and across all timepoints. These findings support 
the estrogenic character of PhIP, as the treatment with PhIP and E2 seems to be 
having similar effects on the MCF-7 ER positive cells. Strikingly, in the 4 hour 
treatment, almost 75% of the microRNAs that showed changed expression levels with 
the PhIP treatment were also changed similarly with the E2 treatment. This was also 
noted at the 8 hour treatment. Despite the fact that the expression of some microRNA 
molecules that were found differentially regulated in the E2 treatment were not found 
in the PhIP treatment and vice versa, the similarities are a strong indication of the 
estrogenic character of PhIP. The observation that similarities between the effect of 
the two treatments on the miRNAome were observed at earlier timepoints, could be 
attributed to the involvement of other regulatory signals in gene expression that could 
influence the estrogenic pathway, which was mostly active during the initial phase of 
estrogen or PhIP exposure. This thesis is the first that has shown that PhIP exposure 
elicits widespread effects on the microRNAome of a breast cancer cell line. 
Importantly, microRNAs that were responsive to PhIP were also affected by 17-! 
estradiol treatment as aforementioned and presented in Figure 4.3.3.2. The similar 
effects that the two chemicals cause provide grounds for proposing PhIP driving the 
deregulation of microRNAs through the activation of estrogen-receptor alpha. This 
proposition is further supported by the fact that at least one of the commonly affected 
microRNAs, miR-21, has been shown to be transcriptionally regulated by estrogen-
receptor alpha (Wickramasinghe et al., 2009). This proposition however cannot be 
validated based on the available data, as microRNA changes directly mediated by 
estrogen receptor-alpha activity and those driven from secondary events cannot be 
differentiated from these experiments. Chromatin immunoprecipitation, followed by 
sequencing of the precipitated genomic fragments and mining for microRNA 
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sequences would provide the necessary evidence to distinguish between the two 
aforementioned driving forces of microRNA deregulation. Another observation made 
was that the majority of the microRNAs affected by the treatments displayed reduced 
expression. This observation is in agreement with some studies (Maillot et al., 2009; 
Yu and Snyderwine, 2002), but not others (Klinge et al., 2012). An overall repression 
of microRNA expression is however one of the suggested mechanisms for the 
increased proliferation of mammary cells (Maillot et al., 2009;Yu et al. 2012) and our 
microarray results, combined with those from the E-Screen in this thesis, point 
towards a similar conclusion.    
 
 In terms of some of the differences that could be observed between 17-! 
estradiol and PhIP, those could revolve around the DNA adduct forming capabilities 
of the latter (Yadollahi-Farsani M. et al., 1996). The genotoxicity of PhIP in vivo is 
dependent on its metabolism by the CYP1 enzymes (Zhao et al., 1994). The MCF-7 
cell line possesses active CYP1A1 enzymes that can metabolize PhIP to its DNA-
reactive form. However, the doses of PhIP used in this thesis are much lower than the 
micromolar levels that are required for the genotoxic activity of this compound 
(Gooderham et al., 1996). Another indication that suggests PhIP did not cause 
genotoxicity in this thesis is the fact that the microRNAs affected by PhIP in the 
microarray experiments are different to those that have been reported to be affected 
by DNA damage signalling, such as the induction of the miR-34 family of 
microRNAs by p53 (He et al., 2007). In fact, this thesis shows a stronger induction of 
miR-34b for 17-! estradiol treated MCF-7 cells in the 24 hour timepoint compared to 
PhIP treated cells, that could be a result of the upregulation of p53 and Mdm2 by 17- 
! estradiol treatment (Qin et al., 2002). It is likely that the distinct effects of PhIP on 
microRNA expression observed are either due to differential degrees of ER# 
activation or ER-independent effects of the two compounds, rather than the DNA-
adduct forming effects of PhIP.  
 
 The deregulating effect in microRNA levels that PhIP showed in this thesis, 
could be an important mechanism in PhIP-mediated carcinogenesis, given the fact the 
microRNA deregulation can drive breast carcinogenesis (Shimono et al., 2009; Song 
et al., 2013). PhIP treatment has been shown to upregulate the anti-apoptotic BCL-2 
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in mammary tissue of rats (Venugopal et al., 1999) and at the same time BCL-2 
expression has been shown to be downregualted in MCF-7 cells by miR-21 
(Wickramasinghe et al., 2009), miR-16 (Yu et al., 2012) and miR-24 (Srivastava et 
al., 2011). These three microRNAs were downregulated in this thesis, suggesting a 
plausible mechanim, where microRNA deregulation caused by PhIP promotes the 
destabilization of molecular control mechanisms that keep pro-carcinogenic factors 
under control. PhIP has also been shown to affect metastatic potential in vivo (Lauber 
and Gooderham, 2011). In this thesis, PhIP caused a downregulation of miR-200c/141 
that are part of the miR-200 family that is an important regulator of invasiveness and 
metastasis (Burk et al., 2008). Furthermore doses of PhIP that are estimated to be 
within physiologically relevant levels have been reported to activate ER# and induce 
multiple effects that could contribute to carcinogenesis including increased 
proliferation, prolactin secretion, invasiveness (Lauber et al., 2004; Lauber and 
Gooderham, 2007, 2011), and long interspersed element-1 (L1) mediated genomic 
instability (Okudaira et al., 2013). While the former studies investigating the 
hormone-like properties of PhIP, as well as this thesis, were based on cell line models 
(Lauber et al., 2004;Lauber and Gooderham, 2007,2011), importantly, Okudaira et al. 
(2013) used transgenic mice to detect in vivo ER#-dependent genomic instability 
caused by PhIP exposure, supporting the biological relevance of PhIP promoting 
carcinogenesis. All these correlations are significant in highlighting the importance 
that microRNA deregulation might have in the carcinogenic properties of PhIP, 
however whether the discovered microRNA deregulation can be extrapolated to in 
vivo mammary tissue in exposed animals or humans is not clear. Studies in our lab 
show that the effects of xenobiotics, such as PhIP, on microRNA profiles in vivo are 
highly dependent on the dosage and the time of exposure (Koufaris et al., 2013). 
Nevertheless, the findings of this thesis are an indication that microRNA deregulation 
is likely a mechanism that is involved in that carcinogenic properties of estrogenic 
compounds in breast cancer.  
  
 In order to validate the results of the microRNA expression profiling, the 
analysis of the levels of three microRNAs with quantitave real-time PCR was 
conducted. The technique provides the highest possible sensitivity in detecting 
changes. In all three cases examined, the correlation between the qPCR results and the 
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microarray results was confirmed, even with the case of mir-923, which was updated 
to a ribosomal RNA after the release of the newest miRBase version. The correlations 
supported the similarities observed in the expression profiles between E2 and PhIP 
treatments, especially in the two first timepoints used in our study.  
 
 As far as estrogen is concerned there are a few studies that show estrogen 
affecting the expression of microRNAs within the mammary tissue context (Bhat-
Nakshatri et al. 2009; Wickramasinghe et al., 2009; Ferraro et al., 2012; Paris et al., 
2012; Zhang et al., 2012). It is noteworthy that between the studies, results for the 
differentially regulated microRNAs caused by treatment with 17-! estradiol lack 
consistency. These conflicting results can be attributed to different cell lines used or 
different culturing conditions and treatments prior to E2 exposure resulting in altered 
cell phenotype and the activation of different signalling pathways (Holliday and 
Speirs, 2011). For example, the use of epidermal growth factor, a common culture 
media supplement added to luminal epithelial cell lines such as MCF-7, leads to the 
loss of E-cadherin, which is characteristic of the epithelial to mesenchymal transition 
for breast cancer cells (Matthay et al., 1993). Moreover, another factor that could 
potentially contribute to the different results reported in these studies is the circadian 
regulation of estrogen receptor expression that has been shown to fluctuate within the 
cell’s cycle and also be dependent upon the activity of the c-MYB proto-oncogene 
(Vantaggiato et al., 2014). Therefore, the differing cell cycle stages might affect the 
intensity of the estrogenic signal. These findings indicate the importance of defining 
the specific experimental conditions that are used. Other factors that can lead to 
different results in microarray experiments are the procedures used for normalization 
of data (Katchy et al., 2012) as well as use of control genes in the case of qPCR 
(Manavalan et al., 2011). However, in my experiments, the culturing conditions and 
MCF-7 cells used for both treatments were identical.  Thus PhIP shows remarkable 
similarities with 17-! estradiol in the effects on the expression of microRNAs in 
MCF-7 cells.   
 
 The next step in the investigation of the role of microRNAs in the 
carcinogenic character of PhIP was to examine the link between differentially 
regulated microRNAs and their physiological targets. It is generally accepted that 
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microRNAs cause loss of target protein expression, although there are cases where 
mRNA:miRNA complexes have been shown to engender increased gene expression 
(Vasudevan et al., 2007).  The case of miR-663 was chosen for further examination as 
it was the microRNA that showed the highest degree of downregulation in response to 
treatment. The establishment of microRNA:mRNA interactions that lead to decreased 
mRNA and protein levels is the bottleneck of microRNA research, as there are 
hundreds of putative microRNA targets for each microRNA and confirmation of the 
miRNA/mRNA interaction requires experimental proof. This generally involves 
luciferase reporter assays with cloned mRNA sequences in miRNA transfected 
cellular environments or microRNA knock down studies that lead to decreased target 
protein levels. However there are numerous in silico tools that predict mRNA targets 
for specific microRNAs with various degrees of sensitivity and these are primarily 
based on nucleotide base-pairing. Based on an analysis of the putative targets of miR-
663, through the use of the miRWalk web tool that examines several of the available 
microRNA:mRNA predictor programs, 31 genes were noted as potential high 
probability targets. Out of those, a few had a clear role in the development of breast 
cancer as well as other hormonal cancers (Cortez et al., 2011). The best candidates for 
further analysis were MAP2K2, part of the mitogen activated protein kinase cascade 
(Neuzillet et al., 2014), integrin-linked kinase (ILK), which is a mediator of 
extracellular matrix signal transduction (Cortez et al., 2011), the C catalytic subunit of 
protein phosphatase 5 (PPP5C) that has been shown to be upregulated in human 
breast cancer (Golden et al., 2001) and the gamma isoform of protein kinase C that is 
involved in various cancer-related hormone-related signalling cascades (Parker et al., 
2014). ILK has also been shown to interact with estrogen receptor alpha to promote 
cell migration in breast cancer (Acconcia et al., 2006). In light of this, a potential 
positive feedback loop between estrogen-related downregulation of miR-663 that 
leads to increased ILK expression and therefore an increased migratory cellular 
context could exist and was investigated in the experiments conducted in our study.  
 
 Initially, the cellular expression levels of integrin-linked kinase (ILK) were 
probed through a semi-quantitative PCR approach that examined the ratios between 
the signal increases of the samples compared to controls, normalised against the 
expression of the glyceraldehyde 3-phosphate dehydrogenase gene. The results 
indicated an increase of ILK levels only at the 4 and 24 hour timepoints and not at 8 
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and 12 hours post-treatment, with both 17-! estradiol and PhIP causing similar 
changes. Subsequently, the levels of the ILK protein were detected using the extracts 
from the same samples that were utilized for the microarray experiment. The Western 
blot analysis indicated an increase of ILK protein levels both in the E2 and PhIP 
treatments throughout all the four timepoints. The increase was almost two-fold in 
most cases and again the levels of change were very similar between the E2 and PhIP 
treatments. The increased intergrin-linked kinase levels are an indication of a positive-
feedback loop between estrogen treatment and ILK levels, however this cannot be 
fully ascribed to decreased miR-663 levels. Further experiments that look into the 
potential interaction between the two molecules, namely a cloned plasmid approach, 
are warranted. Nevertheless, the indication that estrogen increases the levels of 
intergrin-linked kinase in a positive feedback loop is supported, and the involvement 
of microRNAs, and more specifically miR-663, is hinted at by these findings. 
Furthermore, the fact that ER# has been shown to interact with ILK increases the 
potential for a regulatory loop that involve ER#, mir-663 and ILK. Increased levels of 
ILK, due to lower levels of its suppressor, miR-663 can lead to increased proliferative 
signalling and more invasive cell behavior. Figure 6.1 summarizes this proposed 
interaction that might contribute to the carcinogenic character of PhIP.  
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Figure 6.1 Schematic diagram of PhIP’s downregulation of miR-663, reducing levels 
of integrin-linked kinase, which in turn affects various cancer promoting factors.  
 In summary, the data presented in this thesis provide further evidence that 
PhIP is a non-steroidal environmental estrogen in line with previously established 
experimental evidence produced by our lab (Lauber et al., 2004). Exposure to PhIP at 
levels likely to be achieved in humans through consumption of meat-rich diets could 
lead to epigenetic changes, at the microRNA level, that are akin to those caused by 
estradiol exposure. PhIP in particular, is unique amongst the cooked food-derived 
heterocyclic amines in being causally linked with hormonally responsive tumours 
(breast and prostate) and the findings of this thesis provide additional mechanistic 
evidence for its action. Two published studies present data that question the ability of 
PhIP to induce estrogenic responses in breast cancer cells (Evans et al., 2010; 
Immonen et al., 2009), however numerous observations vary from their conclusions. 
Computational studies of receptor binding predict PhIP fitting into estrogen receptor-
alpha (Bennion et al., 2005; Nettles et al., 2008). Furthermore, estrogenicity of PhIP 
has been shown in various in vitro assays, such as COS-1 cells transiently transfected 
with ER#, activation of luciferase-reporter gene in MELN cells and induction of 
proliferation in MCF-7 cells (Lauber et al., 2004; Lauber and Gooderham, 2007). This 
estrogenicity is also supported by studies of distinct labs (Bennion et al., 2005; 
Okudaira et al., 2013). Critically, blocking of estrogenic signalling disrupts the ability 
of PhIP to induce phenotypic responses (Lauber et al., 2004; Lauber and Gooderham, 
2007, 2011; Okudaira et al., 2013). Thus, it is highly unlikely that the ability of PhIP 
to induce estrogenic-dependent responses identified by our lab and by others is 
artefactual. It is also important to note that the two contradictory studies did not 
attempt to replicate the original findings and varied in experimental conditions such as 
cell type, treatment doses, exposure times, and seeding densities. The results from this 
thesis further support the estrogenic character of PhIP by showing extensive 
similarities between PhIP and 17-! estradiol on the microRNA level. The results 
present new evidence that PhIP has the ability to induce cancer-promoting effects 
through epigenetic estrogenic activity in addition to its well-established genotoxic 
pathway of causing mutations through the formation of DNA adducts.  
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 The fundamental character of the epigenenetic mechanism of microRNAs and 
their potential to alter the expression of numerous genes at once opens up a strong 
basis for further investigations into this mechanistic approach of PhIP carcinogenicity. 
Providing more quantitative PCR results for different microRNAs as well as for 
different time points and concentrations, followed by links between those microRNAs 
and their mRNA targets, would be important to establish. The results presented here  
point towards the  importance of cellular and signalling events caused by this 
environmental carcinogen that are independent of its activity as a genotoxic agent, 
since the exposure levels required for the former are  attainable in the context of 
human diet. The levels of cell exposure that were used during my investigation are at 
levels that are potentially achieved in meat-heavy diets, thereby increasing the 
significance of these findings. However, more studies need to be conducted in order 
to confirm the involvement of PhIP in these epigenetic mechanisms observed in my 
study. The estrogenic character of PhIP is now well supported in light of these 
epigenetic experiments and the previous molecular findings reported by our lab, 
thereby confirming the hypothesis of this thesis.  
Future work  
 This thesis provided further grounds for the estrogenic character of PhIP by 
showing that the microRNA response to PhIP and 17-! estradiol presents some 
distinct similarities. However the extensive interactionist network still remains 
undiscovered and most of the functional links between altered microRNA and their 
potential miRNA::mRNA interactions are yet to be found. These interactions could 
certainly become the next step to take in the line of research that this thesis created. 
Furthermore, however, the notion that an environmental carcinogenic factor induces 
the same response in an epigenetic mechasnim as the endogenous hormonal 
regulation network, creates even more exciting questions. The exploration of the 
interaction between environmental and endogenous factors in the regulation of the 
cell homeostasis, is an entire research field that is getting increasing attention. 
Numerous research applications in the field of microRNAs that can assist in 
delineating the fine balance between genomics and epigenomics could stem from the 
work presented in this thesis.      
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Appendix 2 MicroRNAs and p53’s involvement in glycolysis 
 
2.1 Introduction 
 
The potential involvement of microRNAs in the regulation of CYP1B1, an 
important enzyme in the field of drug metabolism, was examined in this study. 
Specifically it has been shown that CYP1B1 is targeted by the miR-27b (Tsuchiya et 
al., 2006), a microRNA molecule that has also been associated with several types of 
carcinoma such as lung, colon and prostate (Hennessey et al., 2012; Slaby et al., 2013; 
Goto et al., 2014). The 3’ UTR region of human CYP1B1 contains a near perfect 
complementary sequence to the seed region of miR-27b and the interaction between 
the microRNA and that specific region was confirmed through comparative luciferase 
activity assays with the cloned 3’ UTR region of CYP1B1 in mir-27b positive and 
negative cells (MCF-7 and Jurkat cells respectively) by Tsuchiya et al. Additionally 
the functional link between the two biomolecules was reaffirmed with the detection of 
increasing levels of CYP1B1 protein as well as increasing CYP1B1 enzymatic 
activity when an antisense oligonucleotide against miR-27b was transfected in MCF-7 
cells.  
 
  This study also examined the transcriptional involvement of p53 in the 
process of glycolysis. A regulating role of p53 into the process of glycolysis was 
proposed due to the transcriptional link between p53 and two enzymes that take active 
role in the regulation of energy production in cells, Synthesis of Cytochrome c 
Oxidase 2 (SCO2) and TIGAR (Matoba et al., 2006; Bensaad et al., 2006). These 
initial results linking p53 activity and energy production hinted at a more direct 
regulatory role of p53 in glycolysis. The importance of this is the role of glycolysis in 
tumour tissue, the Warburg effect that is a characteristic of all cancer tissue. Further 
support for a role for p53 in the regulation of glycolysis was reported with the 
discovery of the downregulation of phosphoglycerate mutase (PGAM) through p53’s 
downstream effector Mdm2 in mouse embryo fibroblasts (Mikawa et al., 2014). More 
specifically, an increase of PGAM resulted in increased cell proliferation of mouse 
embryo fibroblasts, along with increased glycolytic flux (the Warburg effect).  
Additionally, a publication reported differences in the mRNA levels of three 
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glycolytic enzymes, glucose phosphate isomerase (GPI), glyceraldehyde-3- phosphate 
dehydrogenase (GAPDH) and phosphoglycerate kinase (PGK-1), in comparative 
studies between wild p53 and p53-null mice (Xi et al., 2006). However the study did 
not include comparative studies at the protein level. Bioinformatic analysis of the 
miR27b seed region suggested it might target p53 mRNA. Thus this study attempted 
to examine the hypothesis that miR27b was capable of regulating CYP1B1 and 
potentially p53. 
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2.2 Material and Methods  
 
2.2.1 Materials  
 
A549 cells were obtained from the European Collection of Cell Cultures 
(ECACC; Salisbury, UK). Ham’s F12 media, Minimal Essential Media (MEM), and 
Opti-MEM, fetal calf serum (FCS), L-glutamine, penicillin/streptomycin were 
obtained from Invitrogen (Paisley, UK). SDS PAGE molecular weight standards were 
bought from Bio-Rad (UK). Hybond ECL nitrocellulose membrane, N and Hyperfilm 
ECL autoradiography film were purchased from Amersham Biosciences 
(Buckinghamshire, UK). Lipid based oligonucleotide transfection siPORT were 
purchased from Ambion Inc. (California, US).  siRNA oligonucleotides against miR-
27b and p53 were bought from Dharmacon Inc. (Lafayette, US Rabbit polyclonal 
antibodies were bought from Santa Cruz (California, US). 
 
2.2.2 Oligonucleotide transfection of A549 cells 
 
Cells were trypsinised as described in the General Methods chapter, pelletted 
at 1,000 rpm for 5 minutes and subsequently, cell viability was assessed with Trypan 
Blue exclusion. The transfection agent (SiPORT from Ambion Inc.) and 
oligonucleotides (siRNA anti-p53 oligonucleotide sequence: 5’-p-
UACAGUCAGAGCCAACCUCUU-3’ from Dharmacon Inc. anti-miR-27b 
oligonucleotide sequence: 5’-p-GCAGAACTTAGCCACTGTGAA-3’) were mixed 
into Opti-MEM media and incubated at room temperature for 10 minutes and then 
mixed with each other. 5µl of the transfection complexes were mixed with 100µl of 
Opti-MEM media and applied to each well of a 6-well plate, then covered with 
230,000 cells at a total volume of 2.5ml and incubated at 37°C/5% v/v CO2 for 
various time periods. Each transfection was executed in triplicate and contained 
vehicle controls. 
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2.2.3 Immunoblot detection of p53 and glycolytic enzymes 
 
 The protocol followed for carrying out the detection of the proteins of interest 
is described in Sections 2.24 and 2.2.5 in Chapter 2. The details of the primary and  
secondary antibodies are summarised in Table 7.1.  
 
Table 2.1 List of antibodies used for detection of various protein targets of interests in 
Immunoblot protein detection 
Ab raised against Ab raised in Dilution factor Supplier 
Human p53 Mouse 1:1000 Sigma-Aldrich 
Human PGAM Goat 1:2000 Novus Biologicals 
Human GAPDH Rabbit 1:2000 GenWay 
Human PGK-1 Rabbit 1:500 Abgent 
Human GPI Rabbit 1:2000 Santa Cruz  
Human $-actin Mouse 1:10000 Invitrogen 
Mouse anti-Ig Goat  1:20000 Santa Cruz 
Rabbit anti-Ig Goat  1:5000 Santa Cruz 
Goat anti-Ig Rabbit 1:10000 Santa Cruz 
 
Blots were examined using a digital camera detecting chemiluminescence 
(Fuji 3000 Camera) and pictures were quantified using densitometry (AIDA digital 
image analyser programme).. 
 
2.2.4 Northern Blotting for microRNA detection using biotinylated 
oligonucleotide probes 
 
Total RNA concentration of samples was determined with absorbance at 260 
nm using the Nanodrop ™ specrtophotometer. Total RNA quality was assessed with 
the absorbance ratio of 260 nm to 280 nm (ideal ratio>1.8). Five &g of total RNA 
were used to detect microRNA levels. For the gel electrophoresis the Mini-Protean II 
System by Pierce™ was used. Samples were electrophorised in a 15% w/v 
acrylamide, 10M urea gel [for 15ml: 10.96 ml 30% w/v acrylamide , 1.4 ml of 10x 
TBE buffer, 9.21g of urea, 2.75 ml nuclease free water, 175 &l of 10% v/v APS and 
17.5 &l of TEMED (all from Sigma)]. The gel was allowed to polymerise for 1 hour 
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and pre-run for 30 minutes in 0.5x TBE buffer. Samples were brought to 20 &l with 
nuclease-free water and 20 &l of sample buffer (95% v/v Formamide, 18mM EDTA, 
0.025% w/v SDS, 0.025% w/v Xylene Cyanol, 0.025% w/v Bromophenol Blue from 
Ambion Inc.) added. Samples were heated at 65° C for 5 minutes and were 
subsequently chilled in ice for 1 minute. Just before loading, wells were rinsed and 
samples were electrophorised at 180 Volts until the Bromophenol Blue dye reached 
the bottom of the gel. RNA was then electroblotted on a positively charged nylon 
membrane (N+ from Hybond), soaked previously in Transfer Buffer (0.5x TBE) for 
15 minutes, using a semi-dry transfer procedure for 1 to 1.5 hour at 400 mAmp. 
Following transfer the membrane was washed with 0.5x TBE to remove gel traces and 
UV-crosslinked with 120 mjoules of UV radiation using a StrataGene Stratalinker. 
The membrane was then stained with methylene blue solution (0.3% w/v Methylene 
Blue in 0.3M sodium acetate pH 5.2) to validate transfer of RNA onto the membrane 
and mark the position of the RNA ladder (ds RNA ladder from New England 
Biolabs). For probe hybridisation the membrane was transferred in a 50 ml Falcon 
tube and prehybridised at 65°C for 30 minutes with at least 0.1 ml of hybridisation 
buffer (North-to-South® Hybridisation Kit, Pierce™) per cm2 of membrane with 
continuous rotation. While pre-hybridising, the biotinylated probe was heated at 
100°C for 10 minutes and then placed in ice for 5 minutes. Following pre-
hybridisation, the denatured biotinylated probe (probe sequence: 5’-p-
GCAGAACTTAGCCACTGTGAA-3’ 5’ biotinylated from Exiqon) was added to the 
hybridisation buffer at 30ng of probe per millilitre of hybridisation buffer. The 
membrane was incubated overnight with rotation at 65°C. On the next day, the 
membrane was washed three times with stringency wash buffer (North-to-South® 
Hybridisation Kit, Pierce™ ) (0.2 ml of buffer per cm2 of membrane) at 65°C with 
rotation and then blocked with blocking buffer (North-to-South® Hybridisation Kit, 
Pierce™ ) (0.25 ml of Buffer per cm2 of membrane) for 15 minutes at RT. 
Subsequently the Streptavidin-HRP conjugate was added to a portion of the blocking 
buffer and then to the membrane at a final dilution of 1:300. The membrane was 
incubated for 15 minutes at RT, subsequently washed four times for 5 minutes with 
wash buffer (North-to-South® Hybridisation Kit, Pierce™) at RT with agitation and 
incubated for 5 minutes with substrate equilibration buffer (North-to-South® 
Hybridisation Kit, Pierce™) with agitation. Finally, the ECL substrate working 
solution was prepared by mixing equal volumes of the luminol/enhancer solution and 
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stable peroxide solution (both from the North-to-South® Hybridisation Kit, Pierce™) 
and the membrane was fully covered with at least 0.1 ml per cm2 for 5 minutes. The 
membrane was then placed in between two acetate sheets, placed in a Hypercassette 
and exposed at various times to obtain the optimum signal.  
 
2.2.5 Stripping and reprobing of Northern Blot 
 
 For reprobing the blot for U6 snRNA (probe sequence: 5’-p-
CACGAATTTGCG TGTCATCCTT-3’ 5’ biotinylated from Exiqon), the membrane 
was washed with 0.5x TBE twice for 5 minutes each at RT, in order to remove excess  
ECL Substrate Working Solution. The membrane was subsequently washed with 
0.5% w/v SDS at 65°C with constant rotation. The blot was then washed once with 
wash buffer North-to-South® Hybridisation Kit, Pierce™), followed by pre-
hybridisation for 30 minutes at 65ºC and subsequently hybridisation and detection as 
described in section 1.2.4.     
 
2.2.6 Bioinformatic analysis of genomic sequences for detection of potential 
microRNA-target interactions and structure modelling 
 
For the bioinformatics analysis, the genomic sequences of interest, miR-27b 
and the 3’ UTR sequences of human CYP1B1 and p53 were linked in the 
MicroInspector web tool, an algorithm based program that allows for the detection of 
microRNA binding sites, provides free energy settings for the analysed potential 
binding, (to control the rigidity of the prediction model), as well as a sequence-based 
modelling of the structure that results from the interaction of the two biomolecules. 
The algorithm was designed on the principles used for dynamic hybridisation and 
folding routines for secondary RNA structures outlined in the Vienna RNA Package 
designed by the University of Vienna (Hofacker, 2003). The algorithm takes into 
account a variety of folding routines as well as energy parameters based on  Watson-
Crick complementarity and also the presence of G-U wobble base-pairing (rHofacker, 
2003). The results provide information considering the thermodynamic profile of the 
bonding as well as a two dimensional model of the interaction.  
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2.2.7 Preparation of cell culture media for NMR spectroscopy  
 
 Media that were to be examined with 1H NMR spectroscopy were collected in 
a falcon tube and frozen at -80°C until analysis. The samples were allowed to defrost 
at room temperature and 550 µl were transferred in an Eppendorf tube and 50 µl of 
D2O with 0.2% w/v 3-(Trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TSP), 
acting as a standard for NMR) added. The tube was mixed thoroughly by inverting 
and the sample was then transferred into a 5mm NMR tube and capped.  
 
2.2.8 1H-NMR spectroscopy of cell culture media 
 
 High-resolution, one-dimensional, 1H NMR spectra were acquired at a field 
strength of 14.1 T (600.13 MHz 1H frequency) using a Bruker DRX600 spectrometer 
fitted with a 5mm broadband-inverse tube probehead (Bruker Biospin, Rheinstetten, 
Germany) at 300 K. Samples were introduced to the instrument using a BACS 60 
automated sample changer, and acquisitions controlled using Xwin-NMR and Icon-
NMR (Bruker Biospin). Gradient shimming was used to improve the magnetic field 
homogeneity prior to all acquisitions. One-dimensional 1H spectra were acquired for 
all aqueous samples (media) using the pulse sequence: (RD-90o-t1-90o-tm-90o-AQ). 
The mixing time tm set to 10 ms and t1 was set to 4 us. During the acquisition period 
(AQ, 2.73 s), the free induction decay (FID) was recorded into 64k data-points in the 
time domain, with a spectral width of 20 ppm. Typically, spectra were recorded as the 
sum of 64 transients following eight dummy scans. 
Carr-Purcell-Meiboom-Gill (CPMG) 1H spectra were also acquired for all aqueous 
samples (media) using the pulse sequence (RD-90o-{)-180o-)}n-AQ). The fixed echo 
time, ) was set to 400 us, giving a total spin-echo time of 64 ms. During the 
acquisition period (AQ, 2.73 s), the free induction decay (FID) was recorded into 64k 
data-points in the time domain, with a spectral width of 20 ppm. Typically, spectra 
were recorded as the sum of 128 transients following v16 dummy scans.v In both 
cases, suppression of the water resonance centered at dH = 4.7 ppm was achieved by 
the application of a presaturation pulse during the relaxation delay (RD, 3 s). Samples 
were phased, baseline corrected and calibrated to the internal standard 3-
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(Trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt (TSP), in aqueous samples, 
tetramethylsilane, TMS in organic samples) resonance at %1H = 0.00 ppm. Spectra 
were imported into Matlab (release 2007b, The MathWorks, USA) and interpolated 
into 300 points. The analysis of NMR spectra was conducted with the kind help of Dr. 
Hector Keun.  
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2.3 Results 
 
2.3.1  CYP1B1 and p53 comparative analysis of miR-27b knockdown 
 
 The lung adenocarcinoma A549 cell line was used as it expressed wild type 
p53 as well as CYP1B1 and miR-27b. The miR27b knockdown was performed at 
different concentrations of anti-miR-27b locked nucleis acid (LNA) and examined at 
72 hours post-transfection. MicroRNA levels of miR-27b were successfully knocked 
down in A549 cells at concentrations of 250, 500 and 750 pmol of LNA. Maximal 
knockdown of the microRNA was achieved at 500 pmol of the LNA oligo (Figure 1.1 
A). As it can be seen in Figure 1.1(B), CYP1B1 levels were found to be slightly 
increased when compared with the levels of the protein in the vehicle control (mock 
transfected) cells. In the same samples, p53 levels were not altered in the absence of 
miR-27b (Fig 1.1D), suggesting that the miR-27b was not targeting p53 mRNA at the 
putative miR-27b target site on the 3’UTR. The results were all conducted in triplicate 
in order to ensure for the statistical significance of any observed changes. 
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Figure 2.3.1 miR-27b knockdown and the effect on CYP1B1 and p53 protein levels in 
A549 cells at 72hours post transfection. A) Northern blot of antimiR-27b-LNA 
knockdown. B) and D) Quantification of CYP1B1 (B) and p53 (D) protein levels 
alongside miR-27b dose-dependent knockdowns. Bands represent % of vehicle control 
(mock transfection) and are means from three separate experiments,. C and E: 
Representative immunoblots of CYP1B1 (C) and p53 (E.) 
 
A 
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2.3.2 Bioinformatic analysis of the interaction of miR-27b with CYP1B1 and p53 
 
The coding region of CYP1B1 is highly conserved amongst species, as is the 
miR-27b target site in its 3’ UTR region. It was previously reported that lowering 
levels of miR-27b resulted in increased amounts of CYP1B1 protein (27). 
Additionally miR-27b was hypothesised to be a regulator of p53 protein levels. More 
specifically, a miR-27b target site was found in the 3’ UTR region of p53 with the 
utilisation of the MicroInspector algorithm (30 from MPhil). The binding sites of 
miR-27b on the 3’ UTRs of these two genes are presented in Figure 7.2, along with 
the secondary structures of the mRNA/microRNA complexes. In the structures below, 
the interaction between miR-27b and CYP1B1 appears to be more thermodynamically 
stable than that of the interaction between miR-27b and p53. Whilst CYP1B1 mRNA 
appears complementary to the entire seed region (nucleotides 2-8) of miR27b, the 
interaction with the p53 mRNA sequence is not as convincing.    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.2: Location and secondary structure of miR-27b target sites in 3’ UTR 
regions of p53 (A) and CYP1B1 (B). The targets sites were identified through 
miRBase and secondary structures were identified from the MicroInspector algorithm.  
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2.3.3 Dose-dependent and temporal p53 knockdown in A549 cells 
 
In order to achieve knockdown of p53 protein in A549 cells, a p53-specific 
siRNA oligonucleotide was transiently transfected into the cells. The knockdown was 
carried out using multiple doses and times  to optimise the required conditions . As 
summarised in Figure 1.3.3, p53 was successfully knocked down in these cells. All 
three oligonucleotide concentrations utilised were found to result in a significant 
lowering of p53 protein level, appearing to be maximal at 100nM of siRNA at 48-72 
hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.3. Dose-dependent (48 hour) (A) and temporal aspect (C) of p53 
knockdown. Bars represent averages from at least three separate experiments with 
standard error of mean. B and D: Representative immunoblots. *p significance value 
is less than 0.05 (p<0.05) in ANOVA with a Dunnett post-test. 
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2.3.4 Effect of temporal and dose dependent p53 knockdown on PGAM levels in 
A549 cells  
 
To explore the potential role of p53 in glycolysis, we examined the effect of 
p53 knockdown on PGAM protein levels in A549 cells. As summarised in Figure 
1.3.4, the dose dependent knockdown of p53 resulted in PGAM protein levels that 
only slightly decreased compared to the vehicle control at 48-72 hours post 
transfection. Overall the knockdown of p53 had little effect on the protein levels of 
PGAM in A549 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.4 Effect of p53 knockdown on PGAM.  Effect of p53 siRNA dose  at 48 
hours (A) and temporal aspects (C) in A549 cells. All bars represent averages from at 
least three separate experiments with standard error of mean. Changes are expressed 
as percentage of vehicle control. B and D: Representative immuno blots. !-actin is 
loading control. *p significance values is less than 0.05 (p<0.05) in ANOVA with a 
Dunnett post-test. 
B 
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2.3.5 Effect of temporal and dose dependent p53 knockdown on PGK-1 levels in 
A549 cells  
 
Phosphoglycerate kinase (PGK-1) is a transferase enzyme, catalysing the 
seventh step of glycolysis in which 1,3 biphosphoglycerate loses a phosphate group to 
produce ATP from ADP. It is one of the energy producing steps of glycolysis and 
therefore importantin the Warburg effect since the main source of ATP for cancer 
cells is profoundly shifted towards glycolysis. Protein levels of PGK-1 were found to 
be decreased in p53 knockdowns, however the change was not statistically significant 
(Figure 1.3.5A). The temporal effects of the treatment were also explored, but PGK-1 
protein levels were similar irrespective of time post knockdown of the p53.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.5 Effect of p53 knockdown on PGK-1. Anti-p53 siRNA dose at 48 hours 
(A) and temporal aspect (C) in A549 cells. All bars represent means from three 
separate experiments with bars standard error of the mean. B and D: Representative 
immuno blots. !-actin is loading control. *p significance value is less than 0.05 
(p<0.05) in ANOVA with a Dunnett post-test. 
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2.3.6 Effect of temporal and dose dependent p53 knockdown on GAPDH levels in 
A549 cells 
 
 Glyceraldehyde-phosphate-dehydrogenase (GAPDH) is involved in the 
catalysis of the sixth step of glycolysis in which glyceraldehyde-3-phosphate is 
transformed into D-glycerate 1,3 bisphosphate coupled with the reduction of a 
molecule of NAD+ to NADH. During this step GAPDH utilises both its kinase as well 
as its oxidoreductase molecular functions. A previous study indicated that mRNA 
levels of GAPDH are decreased in the absence of a p53 by a 3.2-fold change (26). 
The results obtained in the present study from knocking down p53 in A549 cells did 
not confirm this reported mRNA observation. Knockdown of p53 at 48 hours had 
little effect on GAPDH protein levels (see Figure 1.3.6A). Examination of the 
temporal aspect of p53 knockdown was also carried out for GAPDH, and at the 24 
hour timepoint a statistically significant reduction of the protein levels was noted. yet 
the 48 hour post-transfected cells shared similar levels to the vehicle control. On the 
other hand, GAPDH levels at 72 hours post transfection were found to be upregulated 
by almost 40% with the change being statistically significant. The results obtained 
indicated a potential connection between p53 knockdown and GAPDH.  
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Figure 2.3.6 Effect of p53 knockdown on GAPDH protein levels. Anti-p53 siRNA 
dose at 48 hours (A) and temporal aspects (C) in A549 cells. All bars represent 
immunoblot average values from three separate experiments with standard error of the 
mean. Changes are expressed as percentage of vehicle control. B and D: 
Representative immuno blots. !-actin is loading control. *p significance value is less 
than 0.05 (p<0.05) in ANOVA with a Dunnett post-test. 
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2.3.7 Effect of temporal and dose dependent p53 knockdown on GPI levels in 
A549 cells 
 
Glucose phosphate isomerase (GPI) catalyses the conversion of glucose-6-
phosphate into fructose-6-phosphate, which is the second step of glycolysis, not 
requiring a coupling with any co-enzyme, and was the third and last candidate from 
the group of glycolytic enzymesthat could potentially have a regulatory interaction 
with p53 at the level of transcription. As with the previous two glycolytic enzymes, 
the absence of p53 (p53 null mice) resulted in a decrease of GPI mRNA (Xi et al., 
2006). However, in the present study using A549 cells, a similar result on the protein 
level was not observed. In the p53 knockdowns, the levels of GPI were virtually 
unchanged at 48 hours post transfection (Figure 1.3.7 A) and increasing amounts of 
oligonucleotide did not change the protein levels of GPI (Figure 1.3.7 A). A similar 
result was also observed in the time-dependent knockdown of p53, with the protein 
levels of GPI found unchanged at 24 and 48 hours post-transfection with the highest 
concentration of oligonucleotide (Figure 1.3.7 C). At 72 hours post transfection the 
levels of GPI were found slightly increased (~20%) although the increase was not 
statistically significant. The results obtained for GPI indicate that this glycolytic 
enzyme appears not to be directly affected from p53 status.  
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Figure 2.3.7 Effect of p53 knockdown on GPT. Anti-p53 siRNA dose at 48 h (A) and 
time-dependent effects (C) in A549 cells. Western Blot analysis of averages of three 
experiments with standard error of mean. Bars represent percentage of vehicle 
control. B and D: Representative Western blot images *p significance value is less 
than 0.05 (p<0.05) in a repeated measures ANOVA with a Dunnett post-test.  
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2.3.8 Investigation of the functional impact of p53 knockdown on glycolysis 
assessed using 1H-NMR spectroscopy 
 
 Regardless of the potential alterations in the levels of the glycolytic enzymes 
that could result from the absence of p53 protein, the most important process that 
needs to be assessed is the balance of the glycolytic flux in the cell’s metabolism. One 
very accurate way of observing this metabolic process is through the comparative 
analysis of the levels of glucose present in the cell media, using NMR. The 
concentration of glucose in cell culture media is very high in order to provide a 
constant supply of energy for the cells. This permits comparisons between cells with 
and without p53 knock down. The levels of glucose were compared by subtracting the 
values found at 24-, 48 and 48-72 hours post treatment. The production of the 
metabolic by-product of glycolysis, lactate is also another way of investigating 
whether glycolysis has increased or decreased. The results summarised in Figure 
7.3.3.6 indicate that, for the most part, no changes were observed in the levels of 
either glucose (Figure 1.3.8 A) or lactate (Figure 1.3.8 B) when the p53 knockdown 
samples were compared with either the vehicle or negative controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.8 Comparative analysis of p53 knockdown in A549 cells on glucose 
uptake (A) and lactate production (B) by 1H-NMR. Bars indicate standard error of the 
mean from three experimental replicates. The location of the glucose and lactate 
peaks in a typical NMR spectrum are also presented (C red arrows). 
B 
C 
A 
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2.4 Discussion 
 
 This study was set up to investigate the hypothesis that miR27b, known to 
regulate CYP1B1, could potentially regulate p53 mRNA expression.  Furthermore, 
the role of p53 in the Warburg effect, where energy requirements are increasingly 
satisfied through glycolysis, was examined. Using anti-miR27b-LNA, I succeeded in 
knocking down miR27b levels in the A549 cell line. This cell line was chosen as 
previous work in our laboratory has confirmed its usefulness in studies of CYP1B1 
knockdown. The changes in the levels of CYP1B1 that were induced by the 
knockdown of miR-27b microRNA molecule, as observed through Northern blotting, 
were not as pronounced as those previously reported (Tsuchiya et al., 2006). However 
the indication of a potential link between CYP1B1 and miRNA27b levels was 
evident, since the levels of the protein were certainly increased in the presence of the 
miR-27b specific oligonucleotide, although the changes in CYP1B1 expression levels 
were not substantial. The utilisation of different cell lines could be a potential reason 
for the difference observed between my results and the published data (Tsychiya et 
al., 2006). The cell line utilised in the reporting paper was the breast adenocarcinoma 
MCF-7 line, whilst the experiments in this study were conducted in the lung 
adenocarcinoma cell line, A549. The fact that breast adenocarcinoma is a 
characteristic estrogen target-tissue and that CYP1B1 is involved in the process of the 
4-hydroxylation of 17beta-estradiol, could point to a more significant role for 
CYP1B1 in these cells compared to the cells originating from a lung adenocarcinoma, 
which is not an estrogen-responsive tissue. 
 
 The analysis of potential targets for miR-27b, through mining for potential 
interaction sequences in the 3’UTR regions of genes through a bioniformatics 
approach, indicated that one the potential targets of miR-27b is the mRNA of p53 
tumour supressor protein. I also used the bioinfomatics tool, MicroInspector, which is 
an algorithm that examines the two-dimensional prediction of the interaction between 
microRNA and target mRNA molecule (Rusinov et al., 2005). However, experimental 
examination of this proposal using immuno blotting did not detect any alteration in 
the levels of p53 protein when miR-27b was knocked down. This is a strong 
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indication that the putative interaction between the two molecules is unlikely to take 
place and the link between the two molecules is not established physiologically.  
   
 The research then went on to examine the potential of a direct involvement of 
p53 in glycolysis through its function as a transcription factor. Since the initial 
implication of p53 in the regulation of energy metabolism in cancer cells (Bensaad et 
al., 2006), the evidence for a much more central role for this multi-functional protein 
in the process of the glycolytic shift of cancer cells is gradually becoming more 
evident. Moreover, the wide variety of functional properties that this protein presents 
seem to also contribute to its involvement in the process of changing the predominant 
energy producing pathway of cancer cells.  Either by utilising its transcriptional 
regulatory property to directly interact with components of the glycolytic process 
(Bensaad et al., 2006; Matoba et al., 2006), or by mediating disruptions in the balance 
between mitochondrial and cytosolic energy production (Ma et al., 2007), p53 seems 
to be actively involved in the implementation of the Warburg effect. The suggestion 
that p53 could be interacting with the glycolytic process with links yet to be 
discovered was further substantiated by the results of a genome-wide comparative 
study between p53 wild type and p53 null setups. More specifically the HCT-116 
colon cancer cell with wild-type p53 was manipulated with both p53 alleles knocked 
out. A genome wide comparative analysis indicated that three glycolytic enzymes, 
glucose phosphate isomerase (GPI), glyceraldehyde-3- phosphate dehydrogenase 
(GAPDH) and phosphoglycerate kinase (PGK-1) displayed increased mRNA 
expression levels in the absence of p53 (Xi et al., 2006). These three targets were 
therefore hypothesized as targets of the tumour suppressor. The established and 
putative interactions of p53 with the process of energy metabolism in the cell and its 
respective components in summarised in Figure 2.4.1.  
 
 
 
 
 
 
 
 
Appendix 2: MicroRNAs and p53’s involvement in glycolysis    
!
!
##(
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4.1  p53 regulation of mitochondrial respiration and glycolysis. Shown are 
the nuclear transactivation of SCO2 (synthesis of cytochrome c oxidase 2) and 
TIGAR (TP53-induced Glycolysis and Apoptosis Regulator) genes by p53. SCO2 is 
targeted to the inner membrane of the mitochondria where it facilitates the assembly 
of the cytochrome c complex. TIGAR influences glycolysis by dephosphorylating 
fructose-2,6-bisphosphate(Fru-2,6-P2), an important allosteric effector (+) of the key 
glycolytic enzyme 6-phosphofructose-1-kinase (PFK-1). In contrast, wild-type p53 
has been shown to decrease (*) phosphoglycerate mutase (PGAM) activity. The 
hypothetical regulation of p53 on glucose phosphate isomerase (GPI), 
glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate kinase (PGK-1) are 
also shown. Other abbreviations:  hexokinase (HK), 6-phosphofructo-2-kinase (PFK-
2), glucose-6-phosphate (Glu-6P), fructose-6-phosphate (Fru-6-P), fructose-1,6-bis 
phosphate (Fru-1.6-P2), glyceraldehyde 3-phosphate (G3P), 1,3-bisphosphoglycerate 
(1,3-P2Gly), 3-phosphoglycerate (3-P-Gly), 2-phosphoglycerate (2-P-Gly). 
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 From the experiments conducted in this study, it seems that in A549 cells p53 
has the property of affecting the protein levels of glycolytic enzymes 
phosphoglycerate kinase and glucose-6-phosphate dehydrogenase but not glucose 
phosphate isomerase. Lowering levels of p53 protein using an siRNA approach 
resulted in an initial reduction of these two enzymes, followed by a subsequent 
increase. In the case of PGK-1 the genome wide array study comparing mRNA levels 
from HCT-116 cells with wild-type p53 and cells with both p53 alleles knocked out, 
indicated a 6.2-fold difference of PGK-1 mRNA and a 3.2-fold difference in GAPDH 
mRNA, with the levels being higher in the wild type p53 expressing cells (Xi et al. 
2006). However, these data are for mRNA levels and in order for such a change to 
have significance the protein levels and their activity have to be altered as well. In my 
experiment, transient change was observed in the protein levels of both PGK-1 and 
GAPDH, suggesting that p53 may be involved in regulating these enzymes. It is 
important to note that there were temporal differences in the protein levels of these 
glycolytic enzymes during p53 knockdown GAPDH was found decreased 24 hours 
post treatment and then gradually increasing through 48 and 72 hours and PGK-1 
levels remained stable at 24 hours post treatment but subsequently decreased and then 
increased in the periods of 48 and 72 hours post treatment respectively. Thus the 
indicated periodicity of the link between p53 and these enzymes could possibly be 
related to their protein turnover characteristics. In the case of GPI, prolonged p53 
downregulation led to a marginal increase of the protein levels of the glycolytic 
enzyme.  
 
The above observations support the potential of p53 being a regulator of these 
enzymes. The glycolytic process is of vital significance to survival, so that a tightly 
controlled and at the same time plastic regulatory mechanism controlling these 
enzymes, is likely to apply. A549 cells express wild type p53, so it would be 
interesting to examine whether a similar effect on these glycolytic enzymes would be 
observed in a cancer cell line that express a mutated form of the protein. In the case of 
the A549 cell, p53’s role in the regulation of glycolysis is biologically plausible. 
  
Regardless of the scale of the changes observed at the protein level, the real 
effect of reducing levels of p53 is to be observed at the potential disruption of the 
balance of the glycolytic flux of the cell. The latter requires a direct calculation of the 
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glucose content, which was achieved through NMR spectroscopy. Glucose displays a 
very distinctive peak in the NMR spectrum and the fact that it is abundant in the cell 
culture media allows for the detection of this energy metabolite. Furthermore, another 
glycolysis-linked metabolite is lactate, a by-product of anaerobic metabolism, also 
readily detectable in NMR. Therefore both these metabolites were detected and 
measured in the different cell media from the cell cultures that were used for the 
protein analysis experiments. 
  
The results from NMR spectroscopy indicated a rather stable glycolytic 
balance of the cells, irrespective of the p53 status. The amounts of glucose uptake and 
lactate production did not seem to alter in cells with different levels of p53 or PGK-1 
and GAPDH. This result highlights the importance of the glycolytic process and the 
preservation of its homeostasis. The fact that neither the disruption of p53 status nor 
the changing levels of the enzymes directly involved in the process resulted in any 
change of the 10-step process, supports the case for a very plastic process of energy 
production that is also characterised by redundancy, at least in the case of total 
enzymatic function.  
 
Another plausible case that can be made for describing the observations made 
is the fact that the cells utilised in this experiment are already an immortalised lung 
adenocarcinoma cell line. Hence, the energy production process for these cells is 
already shifted towards the Warburg effect. Therefore, attempts to further increase the 
glycolytic output of the cell in an already shifted system would result in very little or 
no change.  
 
 
2.5 Conclusion   
 
 These experiments were prompted by the observation that miR27b was 
identified as a regulator of CYP1B1 and that potentially this miR could also target 
p53 mRNA. However, this was not shown to be the case. Therefore the role of p53 in 
manipulating the Warburg effect in cancer cells was examined. However, this 
hypothesis could not be substantiated with experimental results as the case for p53’s 
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direct involvement in glycolysis though its transcriptional interaction with three 
glycolytic enzymes could not be made and further experiments were not carried out in 
this direction of research in this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
